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Information about this conference and other continuing education program s offered by the 
C olle ge  o fV e te rin a ry  M edicine at Cornell University are available by contacting:
Office of Continuing Education 
College of Veterinary Medicine 
S2 113 Schurman Hall, Box 52 
Cornell University 
Ithaca, N Y 14853-6401
Phone 607-253-3200
Fax 607-253-3198
Email amm36@cornell.edu
Website www.vet.cornell.edu/events
Information about the Cornell Feline Health C enter at the College ofV e terina ry  
M edicine at Cornell University contact:
Cornell Feline Health Center 
College of Veterinary Medicine 
Hungerford Hill Road 
Cornell University 
Ithaca, N Y  14853
Phone 607-253-3414
Fax 607-253-3419
Website www.vet.cornell.edu/fhc/

G e n e r a l  I n f o r m a t i o n  a n d  L o g i s t i c s
23rd Annual Fred Scott Feline Symposium 
_________ July 29-31,2011
C o u rs e  O v e rv ie w
This year’s 23rd Annual Fred Scott Feline Symposium will educate and update veterinarians in feline 
oncology, gingivostomatitis, infectious diseases, and behavioral issues.
R A C E  A ccreditation  a nd  C o n tin u in g  E d u ca tio n  C re d it
This program was reviewed and approved by the A A V S B  R A C E  program for 19 hours of continuing 
education in jurisdictions which recognize A A V S B  R A C E  approval. Please contact the A A V S B  R A C E  
program if you have any comments/concerns regarding this program’s validity or relevancy to the 
veterinary profession.
You are asked to sign-in at the registration desk on the first day so that there is evidence of your 
attendance.
For questions about accreditation and continuing education credit please contact:
Office of Continuing Education Phone 607-253-3200
College of Veterinary Medicine Fax 607-253-3198
S2 113 Schurman Hall, Box 52 Email CVM ER M @ cornell.edu
Cornell University Website www.vet.cornell.edu/events
Ithaca, N Y  14853-6401
Evaluation
It is important for the Cornell Office of Continuing Education, faculty, corporate sponsors, and exhibitors to 
receive your feedback. W e ask that you complete the evaluation form and return it to the registration desk 
before you leave the symposium. Th e  information you provide us is essential in the development of future 
educational programs. W e welcome and encourage your comments on all aspects of this symposium.
M eals
Meal tickets are in the back of your nametag for:
Lunch on Friday and Saturday. These lunch meal tickets are to be turned into the cafeteria 
cashier after you select your lunch on Friday and at the cafeteria entrance on Saturday.
Lunch with Dr. Barbara Kitchell on Friday in S1 007 Schurman Hall. If you signed up to have lunch 
with Dr. Kitchell on Friday please turn in your ticket to the staff member at the room entrance.
Lunch with Dr. Ralph Henderson on Saturday in S1 007 Schurman Hall. If you signed up to have 
lunch with Dr. Henderson on Friday please turn in your ticket to the staff member at the room  
entrance.
T o u rs
If you registered to participate in a tour of the college during lunch on Friday you will find an admittance 
ticket in the back of your nametag. Please meet in the Atrium at the beginning of your lunch break.
C o u rs e  M aterials
Th e  course materials that are distributed during this symposium are under the auspices of the Office of 
Continuing Education at the College of Veterinary Medicine at Cornell University. Duplication of these 
materials is prohibited.
D iscla im er
Th e  lectures offered during this symposium will include some discussion of off-label use and commercial 
products and/or services. Th e  opinion and recommendations expressed by the faculty are their own.
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• All lectures will be held in Lecture Hall I in the Veterinary Education Center.
• Continental Breakfasts and breaks will be located in the Hagan Room.
Frid a y, J u ly  29, 2011
7:30-8:00 a.m. Registration and Continental Breakfast
Sponsored by ID EX X  Laboratories
8:00-8:15 a.m. Welcome
8:15-9:05 a.m. Feline Mast Cell Disease
-Barbara Kitchell
9:05-9:20 a.m. Break
9:20-10:10 a.m. Advances in Feline Lymphosarcoma Care
-Barbara Kitchell
10:10-10:25 a.m. Break
10:25-11:15a.m . James R. Richards, Jr. Memorial Feline Lecture
Th e  Difference Between Dogs and Cats with Cancer 
-Barbara Kitchell
11:15-11:30 a.m. Break
11:30 a.m .-12:20 p.m. Multi-modal Therapy for Cancer: Fundamental principles and practice
-Ralph Henderson
12:20-1:30 p.m Lunch
Lunch with Dr. Barbara Kitchell (pre-registration is required)
1:30-2:20 p.m. Surgical Management of Specific Feline Neoplasms
-Ralph Henderson
2:20-2:35 p.m. Break
2:35-3:25 p.m. People-directed Aggression: Making the Diagnosis
-Michelle Bamberger
3:25-3:40 p.m. Break
3:40-4:30 p.m. Elimination Behavior Problems
-Pamela Perry
4:40-5:30 p.m. Inter-cat Aggression and Miscellaneous Behavior Problems
-Pamela Perry
6:30-9:00 p.m. Annual Picnic-Celebrations
7:30-8:00 a.m.
8:00-8:50 a.m.
8:50-9:05 a.m. 
9:05-9:55 a.m.
9:55-10:10 a.m. 
10:10-11:00 a.m.
11:00-11:15a.m . 
11:15a.m .-12:05 p.m.
12:05-1:10 p.m.
1:10-2:00 p.m.
2:00-2:15 p.m. 
2:15-3:05 p.m.
3:05-3:20 p.m. 
3:20-4:10 p.m.
4:10-5:00 p.m.
5:00-6:00 p.m.
S u n d a y , J u ly  31
8:00-8:30 a.m.
8:30-9:50 a.m.
9:50-10:10 a.m. 
10:10-11:30 a.m.
S aturday , Ju ly  30
Continental Breakfast
Sponsored by Fallon Wellness Pharmacy
Injection Site Sarcomas W here Do W e Stand in 2011? 
-Barbara Kitchell
Break
Feline Carcinoma Management 
-Barbara Kitchell
Break
Feline Cutaneous Oncology  
-Barbara Kitchell
Break
Supportive Care for the Feline Patient With Cancer 
-Cheryl Balkman
Lunch -  Sponsored by Intervet Schering-Plough Animal Health 
Lunch with Dr. Ralph Henderson (pre-registration is required)
Feline Juvenile Gingivostomatitis -  An Overlooked Disease 
-Jennifer Rawlinson
Break
Parasites of the Feline Lung 
-Dwight Bowman
Break
The  Intestinal Conundrum  Protozoal Package 
-Dwight Bowman
Tw o  cat killers: Cuterebra and Cytauxzoon  
-Dwight Bowman
Wine and cheese cocktail hour 
Sponsored by ArthroDynam ic Technologies
Continental Breakfast
Sponsored by Fallon Wellness Pharmacy
Feline Pain 
-Andrea Looney
Break
Vet Oncology Assessm ent and Treatment 
-Andrea Looney
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C o r p o r a t e  S p o n s o r s  a n d  E x h i b i t o r s
23rd Annual Fred Scott Feline Symposium 
_______________________  July 29-31,2011
Corporate S p o n s o r s
ArthroDvnamic Technologies
w w w .a rth ro d yn a m ic .co m
A rth ro D yn a m ic  Te c h n o lo g ie s , ba sed  out of Lexington, K e ntu cky, is the m a k er of P olyglyca n, 
A -C Y S T ,  T a n d e m  O ra l, P o ly  C h e w s , and D y n a  Lyte. A - C Y S T  is a patented form ulation  
de signed for te m p o ra ry  replenishm ent of the g lyco sa m ino g lyca n  layer in the  b la dde r and  
contains naturally occurring  c o m p o n e n ts  of the  b ladder epithelium . G A G  deficiency contributes  
to clinical s y m p to m s  in d ise a se s s u ch  a s  feline IC , F L U T D ,  an d  cystitis ca u se  b y  infections, 
traum a, urolithiasis, u rinary retention and neoplasia.
Fallon Wellness Pharmacy
w w w .fa llo npha rm a cy.co m /
P e a ce  of m ind is a precious com m odity, and that’s w h at yo u  can expe ct w h e n  you rely o n  Fallon  
W e lln e ss P h a rm a c y  (o n e  of the ve ry  few  co m p o u nd in g  ph a rm a cie s nationally that h a ve  earned  
Professional C o m p o u n d in g  A ccreditation B o a rd  (P C A B )  accreditation. W e  strive to im prove  
patient o u tco m e s and expe rience s through co m p o u n d in g  and w e llne ss consultations.
ID E X X  Laboratories
w w w .id e x x .co m
T h e  p urp o se  of ID E X X  Laboratories is to be  a great c o m p a n y  that creates exceptional lo ng -term  
value  for o u r custo m e rs, e m p lo ye e s  and sh are h o ld e rs  b y  e n h a n cin g  the health a n d  w e ll-b e in g  of 
pets, people  a nd  livestock.
MERCK Animal Health (formerly Intervet Schering-Plough Animal Health ) 
www.merck.com
A s  an organization, o u r co re  va lu e s are  driven b y  a de sire  to im p ro ve  h u m an life, a ch ie ve  
scientific e xcelle nce , op era te  with the highest sta ndards of integrity, expa nd  a cce s s  to ou r  
products and e m p lo y  a d ive rse  w orkforce that va lue s collaboration.
MERIAL
w w w .m e ria l.co m
M erial is a w o rld -le a d in g  anim al health co m p a n y. W e  a re  a forw ard-looking c o m p a n y  with a 
p roven track record, p roducing  p harm aceutical products a n d  va cc in e s  for livestock, pets and  
wildlife. W e  a re  on the  cutting e d g e  of product d e velo p m e n t and innovation, providing m illions of 
d o se s  w o rld w id e  a n nu a lly  to keep livestock a nd  pets healthy.
J a m e s  R . R ic h a rd s . J r . M em oria l F e lin e  L e c tu re
T h e  Ja m e s  R . R ich a rd s  J r . M em orial Feline  Le ctu re s  w e re  established to h o n o r the outstanding  
contributions that the late Dr. Ja m e s  R . R icha rds J r .,  m a d e  to the field of feline m e dicine  to 
im prove the health and well being of cats e veryw h e re . A  series of state -of th e-art lectures on  
va rio u s a rea s of feline m e dicine  will be  held (1 ) periodically at the C o lle g e  of V e te rin a ry  
M edicine, (2 ) at the  annual N e w  Y o rk  State  V e te rin a ry  C o n fe re nce , and (3 )  at the annu al F re d  
Sco tt Feline  S ym p o s iu m .
D r. R ichards w a s  D irector of the C o rn ell Fe line  H ealth C e n te r (1 9 9 7 -2 0 0 7 ), and P ast P re side nt  
of the A m e rica n  Association  of Fe line  Practitioners. F u n d s  contributed to the Ja m e s  R. 
R ichards, J r . M em orial F u n d  for Feline  H ealth at C ornell U n ive rsity  by his m a n y  friends and  
colle agu es are being p laced in an  e n d o w m e n t fund, and the incom e from  this fund will su pport 
these m em orial lectures in perpetuity.
Annual Picnic
T h e  annual picnic will be  held at the C e le b ra tio n s B a n q u e t Facility, the b a n d  will be  the A g e  
B a r o n s .  W e  will ha ve  a shuttle available  for th o se  that requested it.
Exhibitors
A rth ro D yn a m ic  Te c h n o lo g ie s
C o m p a n io n  T h e ra p y  L a se r b y  L ite C u re
C ornell Fe lin e  H ealth C e n te r
D V M  Solutions
Fallon W e lln e s s  P h a rm a cy
H e sk a  C o rpo ra tio n
Hill’s Pet Nutrition, Inc. 
M E R C K  A nim a l H ealth  
M E R IA L
R x  Vita m ins for Pets  
W ile y  -  Blackw ell
Corporate Sponsors & Exhibitors 2

F a c u l t y
C h e r y l  B a lk m a n . M S .  D V M . D A C V I M
Dr. Cheryl Balkman received her veterinary degree from Cornell University College of Veterinary 
Medicine. She completed an internship at the Animal Medical Center in N Y C  and a residency at 
Cornell University in small animal internal medicine. From there she pursued a two year oncology 
research fellowship and a non-conforming residency in medical oncology. Dr. Balkman has been a 
lecturer in the medical oncology section at Cornell University since 2003. Dr. Balkman is board 
certified in small animal internal medicine.
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M ic h e lle  B a m b e r g e r .  M S .  D V M
Dr. Michelle Bamberger received her DVM  from Cornell University in 1985. Before attending Cornell, 
she earned her masters degree in pharmacology from Hahnemann University Medical College and 
then worked in equine research for two years at N ew  Bolton Center, University of Pennsylvania 
Veterinary School. After graduating from Cornell, Dr. Bamberger studied at Oxford University and 
practiced small animal and exotic medicine and surgery in both Massachusetts and N ew  York. 
Before opening Vet Behavior Consults, Dr. Bamberger returned to Cornell for training in the field of 
behavior medicine as a Visiting Fellow. Dr. Bamberger has a special interest in educating the public 
on veterinary topics. She has taught adult education courses and written two books on the topic of 
first aid. She spends much of her spare time documenting the impacts that hydraulic fracturing for 
extraction of hydrocarbons has on both animal and human health.
D w ig h t  B o w m a n . M S . P H D
As a parasitologist, the focus of Dr. Bowman’s research has been on the biology of parasitic 
infections, testing of various agents for efficacy against parasites, disinfection of parasites in 
manures and sewage sludges, and improved diagnostics. In 2008, he was awarded the 
Distinguished Veterinary Parasitologist Award by the American Association of Veterinary 
Parasitologists. In 2009, he was awarded the Chancellor's Award for Excellence in Teaching from 
the State University of New York. Since 1987, Dr. Bowman has taught veterinary parasitology in the 
College of Veterinary Medicine at Cornell University. He has authored and edited four textbooks on 
the parasites of domestic animals. Dr. Bowman first entered the field of veterinary medicine as a 
postdoctoral student of Dr. Robert Grieve in the Department of Pathobiological Sciences at the 
School of Veterinary Medicine, University of Wisconsin, Madison. At Wisconsin, Dr. Bowman worked 
on improved diagnostics for ocular larva migrans. He received his M S and PhD in parasitology from 
Tulane University in New Orleans, La., in 1976 and1983, respectively. Dr. Bowman focused his 
graduate studies on zoonotic diseases due to ascaridoid nematodes. He then spent four years 
working on a survey of parasites in U .S . domestic sewage sludges in a grant funded by the U .S . 
Environmental Protection Agency. Dr. Bowman earned his bachelor of arts in biology, with honors, 
from Hiram College, Hiram, O H , in 1974.
R a lp h  A .  H e n d e r s o n . D V M .  M S
Dr. Ralph Henderson graduated from the University of Missouri in 1972, and joined the faculty of 
Auburn University College of Veterinary Medicine in the Department of Clinical Sciences as an 
intern. He continued as an instructor earning a masters degree and subsequently moved through the 
academic ranks becoming a professor in 1981. He was board certified by the American College of 
Veterinary Surgeons in 1978 and served various committees of that organization including the
governing Board of Regents. He was granted Charter Diplomate status by the American College of 
Veterinary Internal Medicine, subspecialty Clinical Oncology in 1986.
Dr. Henderson’s clinical activity narrowed from general and orthopedic small animal surgery to focus 
on soft tissue and reconstructive surgery in 1980. His focus further narrowed in 1998 when the 
Department of Clinical Sciences established the Clinical Oncology Service and he assumed the role 
of a dedicated Surgical Oncologist. He has received the Norden Outstanding Teacher Award, 
S C A V M A  Certificate for Teaching Excellence, Alumnus of the Year for the University of Missouri and 
was named the Robert and Charlotte Lowder Distinguished Professor of Clinical Oncology.
Dr. Henderson’s research has involved broad areas of veterinary orthopedic and general surgery, 
critical care, and oncology. Highlights of his research include the original description of the “Tibial 
Compression Mechanism” which is the fundamental principle upon which the T P L O  cruciate 
reconstruction procedure is based; a technique for intestinal tube feedings; an intermediate duration 
tracheostomy technique; a number of surgical oncology reconstructive procedures and in 2005 he 
and a graduate student discovered fundamental healing differences between dogs and cats. Dr. 
Henderson was a charter member of the Veterinary Cooperative Oncology Group and participated in 
a number of collaborative retrospective and prospective studies. In addition, Dr. Henderson has had 
opportunity to contribute directly to human health as an instructor for Basic Life Support, Advanced  
Traum a Life Support, and Laparoscopic and Thoracoscopic Surgery instruction.
He is the co-author of one textbook and author or co-author of 20 book chapters, and 72 scientific 
articles. He has presented 15 scientific presentations or posters and 146 continuing education 
seminars.
B a r b a r a  E .  K itc h e ll. D V M .  P h D .  D A C V I M
Dr. Barbara E. Kitchell graduated from Purdue University School of Veterinary Medicine in 1979. Dr. 
Kitchell completed an internship at the University of Minnesota, then residency in Small Animal 
Medicine at U C  Davis. She started an Oncology referral center at Special Veterinary Services, 
Berkeley, California in 1985. She received a Ph.D. degree (emphasis in Cancer Biology) from the 
Department of Comparative Pathology at U C  Davis in 1994. In addition, Dr. Kitchell completed a 
postdoctoral fellowship in the Department of Comparative Medicine, Stanford Medical School from 
1990-1994. She returned to academic medicine in 1994 as Assistant Professor in the Department of 
Veterinary Clinical Medicine, University of Illinois School of Veterinary Medicine. Dr. Kitchell joined 
the faculty of Michigan State University in 2004, where she is acting as Director of the Center for 
Comparative Oncology. Dr. Kitchell is an A C V IM  Diplomate in the specialties of Internal Medicine 
and Oncology. She has received numerous awards including the National Cancer Institute Physician 
Scientist Award, the Dean's Postdoctoral Fellowship Award at Stanford, and the Gaines Cycle  
"Golden Fido” award for Veterinarian of the Year in 1993. She was a selected participant at 2 
workshops (Molecular Biology of Cancer in 1993 and Methods in Clinical Cancer Research in 1997), 
sponsored by the American Association for Cancer Research and is an active m em ber of that 
organization. She is currently president of the Veterinary Cancer Society. Dr. Kitchell is the author of 
numerous scientific publications and chapters, and keeps busy as a single mom of 5 active 
teenagers and is active in adoption, foster care and Transition to Independence for foster 
adolescents in Lansing, Michigan.
A n d r e a  L o o n e y . D V M . D A C V A
Dr. Looney graduated from the College of Veterinary Medicine at Cornell University in 1989. She  
w as an instructor at Cornell University Hospital for Animals from 1990-1996 in the Departments of 
Anesthesiology and Community Practice Medicine. Following completion of her residency, she 
accepted a position at Angell Animal Medical Center where she worked for 10 years, prior to short 
returns to academia at both Tufts University Cum m ings School of Veterinary Medicine and Cornell 
University. She is currently at Upstate Veterinary Specialties in Albany where she works in 
emergency/ perioperative care, and rehabilitation.
Faculty 2
P a m e la  P e rry . D V M
Dr. Pamela Perry was born and raised in Vermont. She went to Cornell University as an 
undergraduate (B S  in Animal Science) and then continued on in veterinary school. Dr. Perry recently 
defended her PhD thesis at Cornell and graduated in May 2011. Her graduate work evaluated the 
effects of enrichment programs on the behavior, welfare, and adoptability of dogs in an animal 
shelter. Before pursuing graduate work, she was in private practice for 5 years working with both 
small and large animals. In addition, she lectured on behavior and welfare topics for seminars and 
conferences and is a lecturer for an Animal Welfare course at Cornell. Dr. Perry was also the primary 
instructor for a Farm Animal Behavior course in Animal Science for 6 years. She is currently a non- 
conforming behavior resident under Dr. Katherine Houpt, VM D , PhD, D A C V B .
J e n n ife r  R a w lin s o n . D V M .  D A V D C
Dr. Rawlinson graduated from Cornell University Veterinary College in 1998. After working as a 
small animal private practitioner for three years in the southern tier of New York, she returned to 
Cornell as a veterinary educator and course organizer. O ver her next two years at Cornell, her 
interest in dentistry grew, and she accepted a residency position in the Dentistry and Oral Surgery 
section at the University of Pennsylvania. In 2005, she became a Diplomate of the American 
Veterinary Dental College and developed the Dental and Oral Surgery section at Cornell University. 
She has devoted the last 6 years to providing high quality dental service for all species, educating 
veterinary students in both small animal and equine dentistry, and developing a fledgling research 
program.
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Feline  M a st C e ll Disease
Barbara E. Kitchell, DVM, PhD ., DACVIM  
Michigan State University
Normal mast cells are o f  hematopoietic origin and function as mediators o f  IgE specific 
inflammatory and hypersensitivity responses. Granules in the mast cells contain a 
number o f vasoactive substances, including heparin, histamine, and seretonin, which 
induce the typical mast cell degranulation reaction o f  redness, pain, swelling, and itch. 
Malignant transformation o f  mast cells is a rare event in human beings but unfortunately 
a common event in dogs and to a lesser extent cats. Because the species in which the 
molecular pathogenesis o f  cancer is usually studied (humans) is not much affected by this 
disorder, research regarding the underlying cause o f  this disorder is scant. There is 
clearly a breed predisposition in canine mast cell disease, suggesting a genetic 
contribution. Environmental carcinogenesis for mast cell disease has not been well 
studied.
Mast cell tumor (MCT) occurs in the skin and in visceral sites in the cat. Skin tumor 
occurs in older (mean age 9 years) cats, with no observed sex predilection. Siamese cats 
are three times more likely than other breeds to develop cutaneous MCT, which are 
histiocytic in appearance and prone to spontaneous regression. Visceral MCT tumors 
occur in the spleen, mediastinum and nodes. There is no FeLV association. Cats also are 
prone to an aggressive intestinal form o f MCT that is associated with vomition, weight 
loss, diarrhea and anorexia. Tumors in the intestine are composed o f  poorly differentiated 
cells. A  recent report describes a form o f  intestinal MCT in cats that is associated with a 
significant stromal component, in which neoplastic mast cells are admixed with moderate 
to abundant dense stromal collagen (sclerosis). This entity has been named feline 
intestinal sclerosing mast cell tumor, and has a particularly poor prognosis.
Most cutaneous MCT o f cats are well differentiated and benign, but occasionally have 
been reported to metastasize and often appear as multiple lesions in the skin. Mast cell 
infiltration was the most common cause o f  splenomegaly in cats, accounting for 15% o f  
splenomegaly cases in one large retrospective study o f 455 cats. Visceral MCT o f the 
spleen may cause massive splenomegaly and vomiting due to GI ulceration from 
histamine release. When visceral organs such as spleen and liver are involved, 
mastocythemia and bone marrow involvement may be detected on staging evaluation. 
Occasionally cats with visceral MCT will develop multiple metastatic foci in the skin. 
Mediastinal involvement presents like thymic lymphosarcoma, with dyspnea and pleural 
effusion. Cytology o f the pleural fluid reveals mast cells and eosinophils.
Histologic Features and M o le c u la r  Pathogenesis -  Feline cutaneous mast cell tumors 
have been histologically classified as well-differentiated mastocytic types or 
atypical/poorly granulated lesions. Granules in feline mast cell tumors may not be 
evident through the use o f  Diff-Quik or H&E staining and thus additional stains such as 
Giemsa or Toluidine Blue may be required to fully characterize anaplastic mast cell 
tumors from cats. A poorly granulated histiocytic type o f  mast cell tumor has been 
described in young Siamese cats and this disease manifestation may be self-limiting. The
histologic grading system described for canine MCT has been shown in repeated studies 
not to be predictive o f  tumor behavior or o f  clinical outcome in feline MCT. Mitotic rate 
within feline tumors may be correlated with biologic behavior. In general, the prognosis 
in feline MCT patients is more closely tied to visceral involvement than to histologic 
appearance o f  the lesions. Additional prognostic features may be identified through use 
o f  proliferation markers such as mitotic index and Ki-67 are helpful in determining the 
potential for aggressive behavior. Additionally, positive immunohistochemical staining 
for CD117 (the c-kit receptor) as well as telomerase reverse transcriptase in feline mast 
cell tumors has been associated with poor prognosis and aggressive biologic behavior.
C - K it  M u ta tio n  in  Fe lin e  M C T  -The stem cell factor receptor c-kit is mutated by an 
internal tandem duplication mutation in the juxtamembrane domain region o f  exon 11-12 
in a substantial proportion o f  canine MCT cases. In the cat, an internal tandem 
duplication mutation o f  12 base pairs has been identified in the region corresponding to 
exon 8. This mutation results in a 4 amino acid insertion in the immunoglobulin-like 
domain o f  the receptor. Because this apparently activating mutation exists in at least 
some feline MCT cases, the potential for response to specific receptor tyrosine kinase 
inhibitors such as toceranib, masitinib, and imatinib is ongoing in feline oncology.
Staging -It is sometimes difficult to define the best staging procedures to recommend for 
feline mast cell tumor patients. Many cats have solitary or multicentric cutaneous lesions 
that are not systemically involved, although they may be recurrent or new lesions may 
arise over time. When multicentric tumors are discovered, systemic staging is indicated. 
Staging for MCT in cats involves a minimum database and buffy coat evaluation for 
occult mastocythemia, thoracic radiographs and abdominal ultrasound with fine needle 
aspiration o f involved organs, and possibly bone marrow aspiration. Issues that are 
particular to the cat include the observation o f  mastocythemia and eosinophilia associated 
with visceral and intestinal forms o f  the disease. The ultrasonographic appearance o f  
liver and spleen in cats with intestinal mast cell disease may appear to be o f  normal 
echotexture, so when intestinal lesions are discovered it may be prudent to perform fine 
needle aspirations o f  even normal appearing liver and spleen. A  recent report suggests 
that intestinal mast cell tumors in the cat may have eccentric non-obstructive hypoechoic 
areas on the serosal surface o f  the bowel, appearing as dark outpouchings on the serosal 
gut wall. Mast cell tumors may also be a cause o f  intra-abdominal and intrathoracic 
lymphadenopathy in cats as in dogs.
T reatm en t -Treatment o f  dermal MCT is primarily through surgery, which occasionally 
must be multiple due to the tendency o f cats to have multiple solitary tumors over 
extended periods o f  time. Because these tumors are well differentiated in general, surgery 
is curative most often for solitary lesions. Corticosteroids (1 mg/kg/day prednisolone) 
may be helpful. Intralesional triamcinolone injections have been helpful for individual 
solitary or multicentric cutaneous MCT lesions in the cat. A  systemic dose o f  
triamcinolone (1.2 to 1.8 mg/cat) can be administered intralesionally in cats at 2 week 
intervals, appears safe and tolerable, and may even eradicate small lesions.
Visceral MCT in cats is variable in behavior. Cats may present with massive 
splenomegaly, prompting the clinician to render a poor prognosis. However, w e and 
others have observed that even splenectomy alone results in median survival times o f  12 
months for these cases, with some cats reported to live 3 years or more. Prolonged 
survival can be seen with splenectomy even when cats have evidence o f  hepatic mast cell 
infiltration on staging FNA.
Radiation therapy can be useful for non-resectable or invasive tumors. External beam 
irradiation is rarely necessary in cats as these lesions are frequently widespread and 
extensively multicentric and therefore not amenable to such therapy. Topical application 
o f strontium-90 through plesiotherapy has been reported to be very effective in this 
setting. Unfortunately, plesiotherapy applicators are costly and highly regulated so this 
form o f  therapy is limited in availability.
Systemic chemotherapy may be useful for cats with disseminated MCT. Agents such as 
used for canine MCT may be tried. However, limited reports o f  prolonged survival as a 
result o f  chemotherapy are available. Vinblastine at 2.0 mg/kg IV weekly may also be 
helpful for treatment o f  multicentric feline mast cell tumors. We have employed 
lomustine (CCNU) chemotherapy at a dose o f  10 mg capsule per cat Q 21 days with 
some positive responses observed. Rassnick et al reported on the use o f  lomustine at a 
dose o f  50-60 mg/m2 PO in 38 feline cases. The mean number o f  doses administered to 
these cats was 2 (range 1-12 doses) These cats had a response rate o f  50% (7 complete 
and 12 partial responses), for a median response duration o f 168 days (range 25-727 
days). Lomustine therapy was associated with neutropenia and thrombocytopenia in this 
group o f  cats.
Recently, the use o f  specific receptor tyrosine kinase inhibitors has been explored in cats. 
Imatinib mesylate (Gleevec) has been shown to improve outcomes in visceral MCT feline 
cases, at a dose o f  10 mg/kg PO SID. In some cases, cats developed GI signs 
necessitating treated on an every other or every third day basis for quality o f  life 
concerns. Masitinib meylate has been administered to 20 healthy cats at doses o f  50 
mg/cat daily or every other day for 4 weeks. Adverse effects observed in these cats 
included proteinuria in 10% o f cats and neutropenia in 15%. The potential for use o f  this 
drug for treatment o f  feline MCT is being explored but no response or toxicity data is yet 
available. Similarly, toceranib (Palladia) has been administered to 18 healthy cats in an 
exploratory pharmacokinetic study. Doses ranging from 2.5-6.5 mg/kg PO every other 
day for 10 days were associated with varying gastrointestinal signs and anorexia, which 
were reversible on discontinuation o f  the drug in this group o f  cats. One can anticipate 
further reports on the use o f  specific receptor tyrosine kinase inhibitors in feline MCT in 
the near future.
S upportive  C a re  - Gastrointestinal signs and signs o f  systemic degranulation reaction 
are rare in cats, but can occur. Bruising at sites o f  MCT can be associated with heparin 
release, as in the dog. Very rarely cats with MCT can suffer sudden hypotensive crisis 
and death from degranulation after surgical manipulation o f  tumor or even a procedure as 
simple as fine needle aspiration. Normal mast cells in the airway o f cats are associated
with signs o f  bronchoconstriction in feline asthma, and in addition to antihistamine 
administration, antiserotonergics such as cyproheptidine may be helpful adjuncts in feline 
mast cell disease. Interestingly, a recent research paper assessing the effect o f  HI 
receptor antagonists terfenadine and loratadine showed inhibition o f  mast cell growth and 
even apoptosis when the drugs were applied to established cell lines and primary mast 
cell cultures from human and canine patients. However, famotidine, cimetidine, and 
ranitidine did not exert substantial growth- inhibitory effects on mast cells in culture. It is 
not yet known whether this approach would prove to have clinical benefit, and the drugs 
were not explored in feline mast cell tumors in culture. Treatment o f  gastric and duodenal 
ulcers is symptomatic as described in canine MCT, and would typically include the use o f  
H2 blockers such as famotidine, or even sucralfate and omeprazole in severe cases. 
Intestinal MCT carries the poorest prognosis o f  all o f  these presentations. Intestinal MCT 
often is associated with systemic involvement and patients are debilitated from 
malassimilation before diagnosis. If possible, bowel resection with 5-10 cm margins 
should be performed. Corticosteroids may be palliative for these cats, but most with 
intestinal involvement die within 4 months o f  diagnosis.
Notes
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A d vances in  Fe lin e  Lym p h o sarco m a C a re
Barbara E. Kitchell, DVM, Ph.D., DACVIM  
Michigan State University
Ep id em io log y: Among the domestic animal species, the incidence o f  lymphoma is
relatively high in both the dog and cat. The incidence rate and disease presentation o f  
this malignant disease in cats has changed since the advent o f  vaccines and diagnostic 
tests for the management o f  feline leukemia virus. The older literature reported rates o f  
lymphoma in cats to be 200 cases o f  lymphoma or leukemia per 100,000 cats at risk per 
year. While definitive feline epidemiologic studies documenting the change in incidence 
rates o f  lymphoma and FeLV infection have yet to be carried out, it appears that the 
incidence rate o f  lymphoma in cats is around 20-25 cases per 100,000 cats at risk per 
year, which is similar to the rate seen in dogs and humans.
Lymphoma has traditionally been the most common malignancy o f  cats. Before vaccines 
for FeLV, approximately 50-70% o f  cats with lymphoma were FeLV positive. Recent 
studies o f  feline lymphoma patients in the 1990's suggest that only 8-14% o f  lymphoma 
cats are FeLV positive. There is also a relationship o f  the feline immunodeficiency virus 
with lymphoma in cats. The relative risks for developing leukemia/lymphoma were 5.6, 
62.1, and 77.3 times greater in cats infected with FIV, FeLV, or with both infections, as 
compared to uninfected control cats. The average age at onset o f  lymphoma has been 
reported to be 5-6 years in cats, but this number may be misleading due to the biphasic 
peak in the age o f  incidence. Co-infected or FIV positive cats with lymphoma were 
significantly older than FeLV infected cats. In most recent clinical studies, the median 
age o f  lymphoma cats is 9-11 years, with the majority o f  cats having alimentary site 
lymphoma.
L y m p h o m a  C lassification : Lymphoma is classified based on essentially 4 criteria:
histologic type, anatomic location, cytologic appearance, and immunologic type o f  
lymphocyte affected. In many cases, the anatomic location and cytologic appearance are 
used to establish the working diagnosis for treating cats affected with this disease. 
Cytologically, tumors have been classified in the older literature as stem cell, 
lymphoblastic, prolymphocytic, histiocytic and lymphohistiocytic types. Anatomic 
locations o f  this disorder in cats include alimentary, anterior mediastinal (thymic), 
multicentric, leukemic, and miscellaneous types (renal, ocular, neurologic, dermatologic, 
nasal, and various other less commonly seen locations).
The immunophenotype o f  feline lymphomas is rarely determined clinically. However, 
because FeLV attacks T lymphocytes, T cell tumors have been reported in the anterior 
mediastinal (thymic) and multicentric forms in about 80% o f  cases so tested. Proviral 
DNA has recently been discovered by nested PCR reaction in up ot 80% o f T cell and 
60% o f  B cell feline lymphomas, although antigen was only noted in 21% o f  T cell and 
11% o f  B cell lymphomas. The presence o f  proviral DNA may be attributed to 
endogenous retroviral elements in the cat genome, while actual expression o f  these 
proviral elements to create detectable antigen is rare, as is naturally acquired FeLV 
infection. Differentiation between inflammatory bowel disease with lymphocyte
infiltration and true intestinal lymphoma can be difficult in cats. There is some debate as 
to the cell o f  origin o f  alimentary LSA in cats; current literature indicates a T cell 
predominance over B cell disease in cats with alimentary LSA, which is typically not 
associated with FeLV infection. However, in the case o f  gastric lymphoma in cats, B cell 
disease predominates almost exclusively. (Moore, Vet Path 2011 -  epub; Vet Path 46(2): 
259-68.) Nasal lymphomas have been reported to be more likely B immunophenotype. 
Cats are also known to suffer from large granular lymphocyte (LGL) lymphoma, which is 
notable for the presence o f  pink granules in the cytoplasm o f  the lymphocytes. These 
lymphocytes may be natural killer cells, or may be a subset o f  cytotoxic T lymphocytes. 
As they have different lineage ontogeny, they have a dichotomous behavior in that some 
o f  these lesions are indolent and while they do not respond well to therapy, they are slow  
to progress. Other o f  the LGL lymphomas o f cats are rapidly progressive and fatal 
despite chemotherapy, with a median survival time reported to be 57 days (Vet Comp 
Oncol 6(2): 102-10).
C lin ic a l Signs and  D iagnostic  Testing: Clinical signs are variable and depend on tumor 
location, stage, and paraneoplastic effects. Definitive diagnosis o f  lymphoma requires 
cytology or preferably histology. Laboratory abnormalities are also variable in cats 
affected with LSA depending upon the stage o f  disease, anatomic site, and FeLV status o f  
the patient. FeLV status should be determined by ELISA testing o f  blood or serum, or by 
immunofluorescence testing o f  blood smears. Normal hemograms are most often 
encountered, but atypical lymphocytes may be seen on careful examination in up to 62% 
o f  cats with LSA. Bone marrow aspiration for cytology or bone marrow biopsy is useful 
in staging and evaluating feline patients with LSA. In some studies, approximately 50% 
o f  cats with LSA are reported to have some marrow infiltration with malignant cells. 
Also, cats with FeLV infection may have myelosuppression and with anemia, 
granulocytopenia, thrombocytopenia, or immune mediated disease. However, bone 
marrow evaluation may not change the recommended therapy for cats with LSA.
Staging: The role o f  staging in clinical oncology is to define the extent o f  tumor in any 
given patient. Staging is accomplished through evaluation o f  the physical examination, 
radiographs, changes in laboratory values, and bone marrow cytology or biopsy findings. 
Staging is necessary for therapeutic decision-making in some types o f  cancer (for 
example, tumors which are localized require only local treatment, whereas cancer that is 
metastatic requires a systemic approach to therapy). We typically stage lymphoma cats 
by performing a CBC with careful cytologic evaluation for occult leukemia, a serum 
chemistry panel, urinalysis, thoracic radiographs and abdominal ultrasound evaluation. 
Intestinal and renal lymphoma will often be more apparent with abdominal ultrasound, 
which reveals loss o f  layering o f  changes in intestinal wall thickness, presence o f  
mesenteric lymphadenopathy in GI lymphoma, or hypoechoic subcasular renal thickening 
as a fairly reliable indicator o f  renal lymphoma. Many cats have evidence o f  bone 
marrow disorders (lymphoma infiltration, retroviral illness, or the anemia o f  chronic 
disease), which must be evaluated in order to develop an appropriate and safe therapeutic 
course. Diagnosis o f  alimentary or abdominal site lymphoma in cats requires evaluation 
o f  the gastrointestinal tract either by ultrasound guided fine needle aspiration, endoscopy 
or by surgical exploratory for full thickness biopsy.
T h e ra p y : The goal o f  therapy in LSA is palliation o f  symptoms by inducing remission, 
thereby improving the quality o f  the patient's life and prolonging the animal's life in 
comfort. Cure is sometimes achieved in LSA in cats, particularly in cases o f  localized 
disease such as in the case o f  intranasal lymphoma or renal lymphoma. In other cases 
with indolent or low-grade disease, long-term survival in cats is possible. O f course, high 
grade lymphoma or lymphoma associated with retroviral disease often has a rapidly 
progressive course and may only respond transiently to therapy. Type o f  therapy chosen 
depends largely on the presentation seen, and will be discussed in the context o f  region o f  
involvement.
Local therapy may be used in patients with Stage I disease (localized to one site) with the 
potential to be curative. Radiation therapy to the local site or surgical resection may be 
helpful. The cases for which the tumor is locally confined to a single site are rare, 
however, nasal lymphoma in cats treated with radiation with or without chemotherapy 
have been reported to have very long survival times. In a paper from UC Davis, cats with 
intranasal lymphoma treated with 22-48 gy o f  radiation (median 42 gy) plus 6 months o f  
chemotherapy had a progression free survival duration o f 945 days, with approximately 
60% o f the cats alive and disease free beyond that point. O f the 19 cats treated in this 
report, 4 (23%) had local recurrence, while 17% had distant metastasis at some time. 
Involvement o f  the cribriform plate was found to be a negative prognostic factor (Vet 
Rad Ultra 2007 48(4):388 -  93).
Systemic therapy is the most important part o f  the therapy for LSA in cats. Several 
chemotherapy protocols have been published, with most reporting approximately 60 - 
80% o f cats obtaining a durable remission o f lasting a median o f  7-8 months. 
Approximately 20-30% o f  cats can be expected to live beyond one year. FeLV positive 
cats tend to be more sensitive to the myelosuppressive side effects.
Alimentary lymphoma is becoming the most common presentation seen in older cats. 
The intestines are reported to be involved in 70% o f  cases reviewed at Tufts University. 
Signs include vomiting, diarrhea, and anorexia with weight loss. O f 28 cats reported in 
the Tufts study to be treated with COP chemotherapy, 9 had complete response, 2 had 
partial remission, and 16 failed to respond to therapy. Median remission time for the 11 
cats that responded to therapy was 213 days, but the overall median survival duration 
with chemotherapy was 50 days. Thus, most cats that failed to respond to therapy had 
extremely short survivals. However, 5 cats in the study lived beyond one year. More 
recently, as study from Cornell (JAVMA 2008 232(3):405-10) reported the use o f  oral 
prednisone and chlorambucil in 41 cats with low grade lymphocytic lymphoma, 
predominately o f  the gut. O f these cases, 56% achieved a complete response and 39% a 
partial response to treatment. Cats that achieved a complete response had a median 
remission duration o f 897 days, while those with a partial response had a median 
remission duration o f  428 days. All had improved clinical signs on therapy. Overall 
median survival time for the entire group was 704 days. Nutritional support becomes 
very critical for these cats, as gut involvement often is associated with malassimilation o f  
some degree. Low serum cobalamin is frequently seen, as is anemia.
For cats with large cell high-grade lymphoma o f the gastrointestinal tract, we institute 
therapy with prednisolone and 1-asparaginase for 1-3 weeks in these cats, along with 
metronidazole therapy for bacterial overgrowth disease and intense nutritional support, 
before adding cyclophosphamide and vincristine, in an effort to minimize effects on gut 
mucosa or motility. Anecdotally, we have had several cats that were intolerant to 
cyclophosphamide but tolerant o f  chlorambucil in their induction protocol. Others have 
reported that mitoxantrone in cat lymphoma is without effect, but we have managed 
several cats with alimentary lymphoma on mitoxantrone (5.5 mg/M2 IV infusion over 1 
hour) and prednisone therapy with success for several months. Doxorubicin therapy for 
high-grade disease may also be very helpful. While it seems contraindicated to apply 
radiotherapy to the feline intestine, we have successfully rescued out o f  remission GI 
lymphoma cats with focal irradiation to the intestine, using 4 gy/fraction dosing on two 
consecutive days.
Mediastinal lymphoma is becoming more rare in clinical practice due to the efficacy o f  
FeLV vaccines. This form occurs most often in young cats and those that are FeLV 
positive. These cats have fairly good responses to combination chemotherapy with COP 
(79% complete remission rates with a median remission duration o f  150 days, as reported 
by Cotter in 1983.) However, the cat with a mediastinal mass presented today is more 
rare, often older, and frequently is found to have a thymoma rather than a thymic 
lymphosarcoma. Accurate diagnosis is critical, as thymoma may not respond to therapy 
for lymphoma. Typical recommendation for true mediastinal lymphoma remains the use 
o f combination chemotherapy, such as is detailed below, COP therapy, and also 
radiotherapy for local control.
Renal lymphoma has a variable biologic behavior. Those cats that present with solitary 
kidney involvement have better outcomes in response to treatment than those with 
bilateral disease, severe azotemia, or other sites o f  involvement in the abdomen. 
Association with spinal lymphoma has been noted for renal primary disease. Renal 
lymphoma cats with FeLV positive status have shorter survival duration also. In one 
study, 61% o f  renal cats had a complete response to chemotherapy with median remission 
duration o f  127 days (range 20-2,542 days - or cure). These cats are treated with 
aggressive fluid and red cell support and must receive chemotherapy that does not require 
renal elimination initially until renal function is improved. Again, we generally 
administer prednisone or dexamethasone, 1-asparginase, and vincristine to these patients. 
Cyclophosphamide and doxorubicin can be added when renal function is improved. 
Some o f  the longest survivors o f  feline lymphoma have renal lymphoma, with some cats 
surviving up to 4 years from diagnosis.
Spinal lymphoma often presents as posterior paresis in these patients. Severe pain is 
often a feature as well. The majority are FeLV positive and have concurrent bone 
marrow involvement. Chemotherapy with focal radiation therapy is the treatment o f  
choice for these cats. Occasionally cats are diagnosed at surgical decompression and are 
found to have focal lesions. Decompression may be helpful to stabilize neurologic 
function in addition to appropriate anticancer therapy.
Table 1 -Feline Lymphoma Staging!
Stage I Single tumor (extranodal) or single lymphoid tissue including
anterior mediastinum
Stage II A single tumor (extranodal) with regional lymph node
involvement; Two or more nodal areas or extranodal 
tumors on the same side o f  the diaphragm; a resectable 
primary GI tract tumor, with or without involvement o f  
associated lymph nodes 
Stage III Two or more nodal areas or extranodal tumors above and
below the diaphragm; all unresectable intra-abdominal 
disease; all paraspinal or epidural tumors 
Stage IV Liver and/or spleen involvement, with or without the above
Stage V Stages I-IV with involvement o f  the bone marrow, CNS, or
both
i-Mooney S., et al: Renal lymphoma in cats: 28 cases (1977-1984) JAVMA 191:1473, 
1987.
T a b le  2 - D iagnosis &  Staging Tests fo r  Fe lin e  L y m p h o m a
□ Minimum data base including CBC, serum chemistry panel, UA, FeLV and FIV tests; 
confirm FIV ELISA + test by immunoblot
□ T: palpation, measurement, radiographs i f  anterior mediastinal location, cytology, 
biopsy
□ N: palpation, FNA, biopsy
□ M: thoracic radiographs 3 views, abdominal ultrasound. If patient is cytopenic, has 
circulating blast cells, or is feline retroviral positive, bone marrow aspiration should 
be performed
C h em o th erap y  protocols fo r  cats w ith  lym ph om a
Cats are most often 0.25 mg/m2 body surface area, therefore, doses o f  chemotherapy 
drugs given below are based on this calculation.
Low Grade Lymphoma protocol:
Prednisolone 5 mg PO BID initially, then EOD. Chlorambucil (Leukeran) 2 mg tablet 
twice weekly. Monitor the CBC on a monthly basis for myelosuppression, particularly 
increasing anemia or thrombocytopenia long term.
Cyclophosphamide 25mg tablet, PO, twice weekly for 42 days (6 weeks)
Vincristine (Oncovin) 0.1 mg, IV, q 7 days for 42 days (6 weeks)
Prednisone 5 mg, PO, sid for 1 week; then 5mg, PO, eod until relapse or adverse steroid 
effects in which case taper dose and discontinue 
C B C ’s and lymph node/mass measurements w ill be obtained weekly, in order to modify 
treatment i f  deemed necessary.
Fe lin e  version  o f  the U n iversity  o f  W isco n sin -M ad iso n  lym phom a protocol: 
T re a tm e n t „  . „  Treatm en t
COP protocol
W e e k
D ru g , Dosage, and  Route
W e e k D ru g , Dosage, and Route
1 Vincristine, 0.5-0.7 mg/m2, IV 11
L-asparaginase, 400 Units/kg, SQ 
Prednisone, 2 mg/kg, PO 
Cyclophosphamide 200 mg/m2, IV 13
Lasix 3 mg/kg, IV 
Prednisone, 2 mg/kg, PO 
Vincristine, 0.5-0.7 mg/m2, IV 15
Prednisone, 1 mg/kg, PO
Vincristine, 0.5-0.7 mg/m2, IV
Cyclophosphamide 200 mg/m' 
Lasix 3 mg/kg, IV
Vincristine, 0.5-0.7 mg/m2, IV
Doxorubicin, 25 mg/m2, IV 
Prednisone, 1.0 mg/kg, POa
17 Doxorubicin, 25 mg/m2, IV
Vincristine, 0.5-0.7 mg/m2, IV 19 Vincristine, 0.5-0.7 mg/m2, IV
Cyclophosphamide 200 mg/m2, IV 
Lasix 3 mg/kg, IV
21 Cyclophosphamide 200 mg/m‘ 
Lasix 3 mg/kg, IV
Vincristine, 0.5-0.7 mg/m2, IV 23 Vincristine, 0.5-0.7 mg/m2, IV
Doxorubicin, 25 mg/m , IV 25 Doxorubicin, 25 mg/m2, IV
aPrednisone is continued (1 mg/kg, PO) every other day from this point on.
COPLA protocol
Cyclophosphamide 25 mg tablet, PO, twice weekly for 42 days (6 weeks)
Vincristine (Oncovin) 0.1 mg, IV, starting day 1, q 7 days for 42 days (6 weeks) 
Prednisone 5 mg, PO, sid for 7 days; then 5mg, PO, eod until relapse or adverse steroid 
effects in which case taper dose and discontinue 
L-asparaginase 400 U/kg, SC, on days 1 and 8
2
Doxorubicin (Adriamycin) 20-25 mg/m , IV, weeks 6, 9, and 12
C B C ’s and lymph node measurements should be obtained weekly beginning on day 8, in 
order to modify treatment i f  deem ed necessary.
COAP protocol:
Cyclophosphamide 25 mg tablet/cat PO twice weekly for 42 days (6 weeks) 
Vincristine (Oncovin) 0.1 mg/cat, IV, q 7 days for 42 days (6 weeks)
Cytosine Arabinoside 25 mg/cat SC, divided tid for 2 days 
Prednisone 5 mg, PO, SID for 7 days; then 5mg, PO, eod until relapse or 
adverse steroid effects in which case taper dose and discontinue 
NOTE: Cats with acute life threatening lymphoma (anterior mediastinal with respiratory 
compromise, or central nervous system disease) may be additionally treated with:
•  Radiation therapy o f  affected area.
F o r  cats w ith  C N S  L y m p h o m a  o r  L y m p h o m a  w ith  C N S  signs:
Cyclophosphamide 25mg, tablet PO, twice weekly for 42 days (6 weeks)
Vincristine (Oncovin) 0.1 mg, IV, q 7 days for 42 days (6 weeks)
Cytosine Arabinoside 25 mg/cat/day, continuous IV infusion for 2 days.
Prednisone 5 mg, PO, q 12 hours for 7 days; then 5mg, PO, q 24 hours until relapse or 
adverse steroid effects in which case taper dose and discontinue.
FELINE LYMPHOMA RESCUE THERAPY
Doxorubicin (Adriamycin) 20 - 25 mg/m , (or 1 mg/kg) IV, every 21-28 days 
OR
2
Mitoxantrone 5.5 mg/m , IV, q 21 days 
OR
CCNU (Lomustine) 10 mg/cat, PO, q21 -28 days for 4 cycles; alternately, can 
reformulate CCNU capsules to a dose o f  60 mg/m2 and administer every 21-28 days 
depending on appetite and myelosuppression for intertreatment interval.
OR
The feline version o f  the MOPP protocol:
MOPP stands for:
Mustargen 3 mg/m2 IV in 10 ml NaCl
0 -W--W
Oncovin (Vincristine) 0.6 mg/m IV
Procarbazine (Matulane) 10 mg PO once daily
Prednisolone 5 mg orally twice daily
Protocol Schedule:
■ Day 1: Mustargen + Vincristine IV
Day 7: Mustargen + Vincristine IV
■ Day 1 through 14: Matulane + Prednisolone PO
■ Day 15 through 18: Rest
Patients are rechecked on day 28 and the cycle is started again.
OR
DOMAC protocol
(C ycle  is repeated every 21 days)
NOTE: This is a dose intense protocol; monitor closely for adverse GI or bone marrow 
side effects.
Dexamethasone 1 mg/kg, PO or SC, days 1, 8, and 15
2
Vincristine (Oncovin) 0.5 mg/m , IV, days 8 and 15
2
Mitoxantrone 4 to 5 mg/m , IV infusion (over 3 to 4 hours) day 1
2
Cytosine Arabinoside 150 - 200 mg/m , SC, divided tid, days 8 and 15 
Cyclophosphamide 200 mg/m^, PO, day 10
Other agents that have been useful in treatment o f  cat lymphoma include 
doxorubicin, idarubicin, and mitoxantrone. In 36 cats with lymphoma treated with COP 
therapy, eighteen achieved CR. Those that continued on COP therapy had a median 
remission duration o f  83 days, while those that were given doxorubicin therapy for 6 
months had a median remission duration o f  259 days, according to Moore at Tufts. 
Idarubicin is an oral anthracycline that has been reported in cats, again by Tony Moore. 
Median remission o f  cats maintained with idarubicin (2 mg/day PO for 3 consecutive 
days every 21 days) after COP induction therapy and CR was 183 days (range 30-825 
days). The idarubicin was associated with leukopenia and anorexia, but the drug is less 
cardiotoxic than doxorubicin. Idarubicin is as yet not commercially available in the US.
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Barbara E. Kitchell, DVM, PhD ., DACVIM
Like all other eukaryotes, the feline species is subject to development o f  a variety 
o f  malignancies. Despite being declared the most popular companion animals in 
the United States and in fact worldwide, feline cancer therapy and research has 
lagged behind that o f  the dog. As the old adage states, “cats are not small dogs,” 
and perhaps this is nowhere better evident than in the cancers that arise in the cat, 
the biologic behavior o f  those tumors, and the peculiarities o f  feline metabolism 
as regards cancer therapies. Cats may have less or more aggressive malignancies 
o f organ or tissue sites when compared to dogs, and individualization o f  feline 
care is important to successful outcomes.
The feline species is believed to have been domesticated as long at 10,000 years ago, 
from a potential list o f  5 progenitor feline types. As phenotypic variation through 
selective breeding has not been particularly striking in domestic cats, the exact point o f  
domestication o f  Felis catus is in some doubt. It is believed that the originating species 
include small wild felids, the African wild cat {Felis sylvestri lybica), the European wild 
cat (Felis sylvestri). It is believed that the original domestication event occurred in the 
Fertile Crescent in the Near East. The earliest known archeological record o f  human and 
cat cohabitation was found in a burial site in Cyprus, dated 9,500 years ago. In this site, 
there was evidence o f  funerary rites for a cat buried alongside a human. Egyptians are 
known to have mummified cats to accompany them to the afterlife as early as 2500 BC. 
Cats were likely less easy to domesticate than dogs, as cats do not have a hierarchical 
social structure that would adapt well to a human alpha. Thus, cats likely joined humans 
in a mutually beneficial symbiotic relationship based on the prevalence o f  rodent 
infestation in early agrarian societies. Humans have long manipulated the canine genome 
through artificial selection in breeding to result in the modem dog, which has the highest 
morphologic variance o f  any species on the planet. Cats overall display less physical and 
behavioral phenotypic diversity than do dogs. The feline genome consists o f  38 
chromosomes and roughly 20,000 genes, although the feline genome project has thus far 
published approximately 65% coverage o f  the sequence o f  an Abyssinian cat named 
Cinnamon in 2007.
Feline cancer research has lagged behind canine research due to the paucity o f  genomic 
data, lack o f  availability o f  feline specific antibodies for investigation, and a general 
perception that the domestic cat is less useful as a translational model species for research 
than is the dog. The unique aspects o f  feline hepatic metabolism have rendered them 
particularly challenging for pharmaceutical research as well. Cats are unable to mobilize 
lipid stores rapidly through liver metabolism, resulting in a tendency toward hepatic 
lipidosis in times o f  inanition. Cats have a relative deficiency in glucuronyl transferase 
activity, making them vulnerable to toxicity from specific drugs and toxins. Cats are 
unable to synthesize arginine, which make them susceptible to hyperammonemia during 
times o f  anorexia. Cats are particularly vulnerable to potentially lethal toxicities from 
several chemotherapy agents, including 5-fluorouracil and its oral analog capecitabine,
The Difference Between Dogs and Cats with Cancer
cisplatin, and temozolomide.
D iffe re n t T u m o r  B eh a v io r
Some o f  the tumors that arise in the cat are more likely malignant than benign 
when compared to the histologic counterpart diseases in dogs, as is true for 
masses that arise in the skin and mammary gland. Itis also true that the biologic 
behaviour o f  certain o f  the malignancies that arise in the feline species have 
apparently differing clinical courses than counterpart histologies in dogs or 
humans. Coupled with different underlying carcinogenic responses and biologic 
behaviors in cat tumors is the unique pharmacologic responses o f  the cat's 
metabolism and excretion o f  many drugs important in cancer chemotherapy. 
Feline oncology thus presents additional challenges in veterinary medicine. 
Because cats are so common as companion animals, veterinary oncologists must 
constantly evaluate novel drugs and strategies to improve outcomes for cats 
afflicted with malignant disease.
Examples o f  tumors with more aggressive biologic behaviors in cats that in dogs 
include skin tumors in general, which are reportedly malignant in 60% o f  cats 
compared to 30% o f  dogs, and feline mammary tumors are 90% likely to be 
malignant as compared to 50% o f  canine mammary tumors. Oral tumors in cats 
are generally malignant, with a reported rate o f  95%, while 70% o f  similar oral 
tumors in dogs are malignant. While dogs are most commonly affected by oral 
melanoma, which carries a poor prognosis due to metastasis, cats rarely 
experience oral melanomas. Instead, the most common oral malignancy in cats is 
the squamous cell carcinoma, which has a low  metastatic rate but is highly 
invasive into bone and generally detected too late in the course o f  disease to 
allow for complete resection. Oral squamous cell carcinoma lesions in dogs are 
rarely metastatic also, and may be surgically cured if  rostrally located and 
detected early. Also, cats are unfortunately susceptible to formation o f  sarcomas 
at sites o f  tissue wounding and inflammation, such as the uvea after ocular injury 
or the development o f  injection site sarcomas. These inflammatory and wound 
healing associated tumors are rarely encountered in the dog.
Conversely, hemangiosarcomas in cats may be actinic and non-metastatic in 
behavior, although the rare visceral hemangiosarcoma lesion o f  the cat is highly 
metastatic. Appedicular osteosarcomas o f  cats, on the other hand, tend to have 
much lower rates o f  metastasis (10%) than do the same lesions o f  dogs, where 
metastasis is expected in greater than 90% o f  cases. Similarly, melanocytic 
lesions o f  cats are more rare, and cutaneous melanomas in cats are largely benign, 
although uveal and oral lesions can have malignant behavior. Pulmonary 
carcinomas o f  cats may have an unusual metastatic pattern o f  behavior, with cats 
sometimes presented for swelling o f  the distal digits and nail bed or digital 
metastasis being the primary presenting complaint while the primary pulmonary 
tumor may be an incidental finding on thoracic radiographs.
Lymphoma in the cat can have disparate forms, ranging from the aggressive high
grade multicentric and thymic diseases that arise spontaneously or as a 
consequence o f  retroviral infection, to the more indolent GI lymphoma forms.
Dogs have not been discovered to have a retroviral causation for lymphoma.
Before vaccines for FeLV, approximately 50-70% o f cats with lymphoma were 
FeLV positive. Studies o f  feline lymphoma patients in the 1990's suggest that 
only 8-14% o f  lymphoma cats are FeLV positive. In the past, FeLV infection 
occurred in the young adult feline population, with onset o f  lymphomas 
displaying a biphasic peak at 2 and then 5-6 years o f  age. Now, the median age o f  
lymphoma cats was 11 years, with the majority o f  cats having alimentary site 
lymphoma. Alimentary lymphoma is very rare as a primary tumor o f  dogs.
Feline GI lymphoma is often o f  low grade, but in dogs lymphoma is largely a 
high-grade disease.
Feline  Paraneoplastic Syndrom es are  D ifferent
Hypercalcemia o f  malignancy is the most common paraneoplastic syndrome seen in the 
dog, and is commonly associated with lymphoma, anal sac adenocarcinoma, mammary 
carcinoma, and other less common neoplasms. Hypercalceima o f  malignancy is much 
more rare in cats and is seen in cases o f  oral squamous cell carcinoma, lymphoma, and 
rarely in other neoplastic syndromes. A  very rare and unusual paraneoplastic cutaneous 
disorder is seen in cats that are affected by pancreatic and bile duct carcinomas. 
Bilaterally symmetrical alopecia o f  the ventral abdomen and medial limbs has a unique, 
shiny skin appearance with easily epilated fur. Lameness due to footpad lesions was also 
noted in some cases. Exfoliative dermatitis lesions may also be noted in cases o f  feline 
thymoma, particularly affecting the head, pinnea and ear canals. A brown waxy 
discharge is reported to occur in the feet as well as in the ear canals. Paraneoplastic 
syndromes are mitigated by resolution o f  the underlying neoplastic disease process in 
cats, as in other species.
D ifference in  C h em oth erapy To le ra n ce
It has been well established that a handful o f  chemotherapy agents are not safe for 
use in cats. Among these are cisplatin, which causes a potentially fatal 
pulmonary edema syndrome o f  undetermined origin. Cats are apparently 
deficient in dihydropyrimidine dehydrogenase, which makes them vulnerable to 
potentially lethal neurotoxicity from 5-fluoruracil and its oral analog 
capecitabine. Even exposure to 5% 5-fluoruracil topical cream has been reported 
to cause seizures and death in one cat.
Doxorubicin has been reported to induce renal toxicity in cats, although there is debate 
about the significance o f  this assertion. The original report was based on 30 mg/m2 IV 
dosing o f  doxorubicin, which is likely an overdose. Since anorexia and gastrointestinal 
signs are prominent with high dose doxorubicin therapy, and since many cats with cancer 
are geriatric, it is conceivable that the renal toxicity that was observed could be attributed 
to acute-on-chronic renal insufficiency brought on by dehydration in cats with renal 
compromise. Adequate hydration and dosing at 1 mg/kg doxorubicin, with careful 
attention to renal status, means that many cats with marginal renal function may safely 
receive this important antineoplastic agent.
Cats overall appear to tolerate alkylating agents very well. Lomustine (CCNU) 
has been used to treat cats with a variety o f  malignancies. The dose range for this 
agent is reported to be either 60 mg/m2 or 10 mg/cat for cats between 3.5 and 7 
kg body weight. Responses have been noted with this agent in a variety o f  tumor 
settings. The drug dacarbazine is a non-traditional alkylating agent that binds 
primarily to the 06 position o f  guanine to cause DNA injury. This drug has not 
been explored for use in the cat because it is a prodrug that requires hepatic 
microsomal activity to activate the primary cytotoxic effect. Because o f  the 
relatively unexplored states o f  hepatic cytochrome P450 activation in cats, it is 
generally thought that there might be pharmacogenomic issues with either 
overactivation o f  dacarbazine with excess toxicity, or insufficient activation that 
would limit the drugs efficacy. Recently, an oral analog o f  dacarbazine called 
temozolomide has been introduced to veterinary oncology. This new drug has the 
advantage o f  being an already activated form o f  dacarbazine with high 
bioavailability and volume o f  distribution, including crossing the blood-brain 
barrier. However, we have discovered a subset o f  cats that develop pleural and 
pericardial effusion when treated with temozolomide either as a single agent or in 
combination with an anthracycline agent such as doxorubicin. This effect was 
seen in 3 o f  13 cats, which resulted in early closure o f  the clinical trial. Until the 
exact mechanism for this effect is determined, we advocate caution in treating 
cats with this agent.
Several new drugs and protocols have become available to treat cats with non- 
resectable or metastatic solid tumors. Cats with injection site sarcomas, mammary 
tumors, and a variety o f  carcinomas have been managed with varying degrees o f  
success using traditional chemotherapy agents as well as with drugs that are 
relatively new to veterinary medicine. The standard broad-spectrum 
chemotherapeutics in feline oncology include doxorubicin, which is typically 
administered at a dose o f  1 mg/kg IV over 20-30 minutes in cats on a 21-28 day 
basis. Mitoxantrone may also be substituted for doxorubicin when there is 
concern for cardiac or renal compromise in the cat. Carboplatin is used 
exclusively in cats as cisplatin causes potentially lethal pulmonary toxicity. 
Carboplatin has some level o f  efficacy against a variety o f  neoplasm in the cat. 
The dose we use at MSU ranges from 180-240 mg/m2 IV bolus on a 21 day basis. 
We have also evaluated a combination doublet therapy with gemcitabine and 
carboplatin in the cat. The protocol is administered as follows: Day 1- 
Gemcitabine 2 mg/kg IV over 20 minutes, followed by a 4 hour period to allow  
for prodrug activation, then carboplatin at 10 mg/kg IV bolus Day 8 - 
Gemcitabine 2 mg/kg IV over 20 minutes Day 15 -CBC only; Day 21 - I f  CBC is 
recovered, administer the next cycle o f  the protocol. We have seen a modest 
response rate with this protocol, including complete remission o f  a biopsy 
confirmed pancreatic adenocarcinoma in a 10 year old that that has remained 
durable over 15 months.
Ifosfamide is a third generation alkylating agent that is similar to 
cyclophosphamide. This agent has been efficacious in some cats with metastatic
carcinomas and sarcomas in our hands. This drug is somewhat unique in the cat, 
in the while the canine dose is 375 mg/m2, the feline dose is 900 mg/m2. Itis 
unclear why the maximally tolerated dose is so high in the feline species. It may 
be due to the relative inefficiency o f activation o f  the prodrug in the cat as 
compared to humans and dogs. The drug is both nephrotoxic and a potent 
inducer o f  sterile hemorrhagic cystitis. Thus, it must be given with extensive fluid 
diuresis and with the drug MESNA administered as a urothelial protectant. The 
protocol is as follows:
Normal (0.9%) saline IV diuresis at a fluid rate o f  6 times maintenance over 30 
minutes (18.5 ml/kg/hr)
Ifosfamide diluted to 20 mg/ml or less over 20 minutes 
Normal saline IV diuresis at 6X maintenance over 5 hours 
MESNA urothelial protectant at 1/5 the patient's calculated mg dose at time 0 
(immediately before ifosfamide administration), and repeated 2 and 5 hours after 
ifosfamide administration.
This therapy may be repeated on a 21 day basis.
A new version o f  vinca alkaloid called vinorelbine (Navelbine) has been used in 
the cat for the treatment o f  a variety o f  malignancies. Doses have ranged from 7.5 
to 9.0 mg/m2 administered as a rapid intravenous bolus, on a 5 weeks on, one 
week o ff schedule o f  administration.
Paclitaxel (Taxol) has been used successfully in the cat particularly in the setting 
o f metastatic mammary carcinoma. The dose that has been recommended for cats 
is 80 mg/m2 as a slow IV infusion, with careful attention paid to the potential for 
anaphylactoid reaction to occur. This agent is anaphylactogenic, although, in our 
hands, it appears to induce this response less frequently in the cat than in dogs. It 
is therefore recommended that the premedication protocol used in dogs be applied 
to cats, as follows: For 5 days preceding the anticipated date o f  paclitaxel 
administration, administer prednisolone (5 mg/cat SID PO), Diphenhydramine 1 
mg/kg PO BID, and famotidine 0.5 mg/kg PO SID. Immediately prior to 
instituting the paclitaxel infusion, dexamethasone sodium phosphate is given as a 
2 mg/kg IV bolus, as is famotidine (1 mg/kg IV) and diphenhydramine (4 mg/kg 
1M). Anaphylactoid response should result in transient discontinuation o f  the 
infusion, followed by additional premedications as determined by the clinician, 
and reinstitution o f  the infusion at a slower rate. However, the longer the duration 
o f the infusion, the greater the likelihood o f increased GI and myelosuppressive 
toxicity.
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S U R G E R Y  IN  M U L T I - M O D A L  C A N C E R  T H E R A P Y
Objective: Description interaction o f  surgery, radiation, chemoimmunotherapy and alternative 
therapy in multimodal therapy. Unless otherwise noted, the only disease considered is malignant 
neoplasia; however, these principles may also overlap with specialty care o f  other diseases.
P rincip les
First Treatment. The first treatment is the one that has the greatest opportunity for success. It 
must be implemented as early as possible and must accomplish certain necessary minimum 
criteria for success. Intentional delay o f  diagnosics or treatment is considered to be the first 
treatment. When there is uncertainty o f  appropriate course, obtain consultation or refer.
Diagnosis and Staging. Definitive cancer treatment(s) must be preceded by sufficient effort to 
make a diagnosis, obtain a pathological grade and define the extent o f  disease (stage and 
volume).
Goals. Once an owner is advised o f  diagnosis, stage, treatment options and response possibilities, 
goals are mutually established. Though definitive treatment (maximal response sometimes called 
curative intent) is always desirable; however, based on the stage o f  disease, patient health or 
owner ability and wishes, it may not be possible. The alternatives are palliation when the patient 
is suffering or attempting to alter the rate o f  progression o f disease.
Failure. Treatment should only be undertaken when its objective is clear. The objectives o f  
surgery toward cancer management are: Diagnosis, Cure, Palliation, Adjuvant Care and, perhaps, 
Prophylaxis. (These objectives will be further defined later.) In the process o f  treatment, new 
findings can cause goals to be modified, but the new goal should still remain clear. Whenever the 
goal o f  treatment is not achieved, the treatment has failed. The author believes that high surgical 
standards (and planning) result in fewer failures. Whenever surgery that is intended to achieve a 
cure leaves cancer cells in the tissue, the surgeon has failed. And, when the harvest o f  tissue is 
intended to assist in diagnosis, but renders none, the surgeon has failed and, worse, treatment is 
delayed.
Owner Consent. Informed consent should include at minimum a description o f  the diagnostic or 
therapeutic procedures to be performed, prognosis, aftercare required, estimate o f  cost, and 
manner and timing o f  communication.
Planned Surgery. Surgery for the treatment o f  cancer has been defined as “planned” or 
“unplanned”. Planned surgery is based upon knowledge o f  tumor microscopic examination 
(cytology or histopathology) and, as appropriate, imaging o f  the surgical field which assist in 
determining the volume o f normal tissue to remove as a margin. Procedures that do not have the 
guidance o f  microscopy are defined as unplanned.
Surgical Margin. The quantity o f  margin obtained is important in 
describing the efficacy o f  excision. Because o f  tissue elasticity and the 
dehydrating effect o f  tissue processing, margins measured at surgery will 
be larger than the margins measured by the pathologist. How pathologists 
"India ink Mai%in define and report margins vary, but some o f  the following terms are
with scored Neopiam common: Marginal or “capsular” (dissection was at the tumor-normal
tissue interface), “Narrow” (implies several mm), and “Wide” (implies 1 
to several cm). To aid the pathologist, the surgical margin should be distinguished from trimmed 
or artifactual cuts by marking the surgical borders (India ink or Davidson's System) and tagging 
important foci by suture(s) with description for the pathologist. Depending upon the particular 
neoplasm, a narrow margin composed o f  dense muscle fascia may be equal to a wide margin o f  
fatty subcutis so the surgeon must consider the imperviousness o f  the planned margin when 
considering the pathologist’s findings. It is important to remember that a layer o f  muscle fascia 
(fasciectomy/ myofasciectomy) is usually a barrier for mast cell tumor, but not for feline 
injection-site sarcoma. Whenever neoplasms are intentionally invaded for diagnostic purposes, 
placement o f  the incisions (and any other intentional wounds such as drains) must be placed to 
facilitate future treatments including surgery and radiation.
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Malignant Development. Malignancy culminates from unregulated, rapidly dividing cells, 
characterized by a gradually diverging genotype expressed phenotypically within limits that are 
based on the cell o f  origin. Neoplastic transformation and early growth may depend upon escape 
o f  the neoplasm from detection until the size o f  the neoplasm results in autonomy. During early 
development, most cells in the neoplasm are dividing and the growth rate (doubling time, DT, 
growth fraction, GF) is rapid as expressed in the Gompertzian growth curve diagrammed in this 
section. This may be noted in the pathologist’s 
interpretation by reporting the number o f  
mitoses (number o f  mitoses per field(s)). As a 
neoplasm enlarges, the blood supply is often 
compromised and the neoplasm core becomes 
ischemic or necrotic. Many cells enter resting 
state (GO). The principle growth fraction is the 
portion at the surface o f  the neoplasm.
Differential oxygen content and vascularity 
reduce the proportion o f  cells dividing thus, 
lowering the growth fraction. This status also 
influences the efficacy and distribution o f
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therapy. Contrasted imaging and biopsy would confirm ischemia. The earliest visible neoplasm  
by routine detection mechanisms (inspection, sonography, radiography) will have undergone 
between 20 and 30 doublings (106 to 108 cells). The sequence o f  neoplasm development is 
important clinically because volume, vitality and growth rate influence the outcomes o f  various 
treatments.
Multi-modal Treatment. Although chemotherapy and immunotherapy are occasionally used for 
local treatment, most commonly, they are used for systemic therapy. Conversely, although 
radiation has been used for whole body treatments, it is most commonly employed for local 
treatment. Surgery is also aimed primarily at localized neoplasia. The efficacy o f  each o f  these 
treatments can be compromised (limited) by the aforementioned volume, vitality, and growth 
rate as well as location. Each o f these treatments often have limitations that can be mitigated by 
combining them in specific sequences. These strategic sequential interventions with multiple 
treatments are termed multi-modal therapy.
In multi-modal treatment, one treatment modality usually has a dominant role and it is the 
“primary” treatment. It could be looked at as the key treatment needed for cure (even though 
cure may not be believed to be possible apart from an extraordinary response -  and these do 
occur). Treatments that make the “primary” treatment more effective are adjuvant (helper) 
treatments and may be given neoadjuvant (Greek neo = before) or following the primary 
treatment. Based on treatment response, the relative roles o f  treatments may change from 
adjuvant to primary.
Surgery is most effective when precise neoplastic margins are palpable and when a margin o f  
normal tissue taken with the neoplasm will not jeopardize important structures. Surgery is 
especially capable o f  “curative” treatment o f  localized neoplasia. In otherwise optimum clinical 
presentations, causes o f  failure include undetected metastasis and the more commonly 
encountered iatrogenic failures o f  too conservative margins (fear), contamination o f the surgical 
wound (contamination o f gloves and instruments by ulcerated neoplasms or cut neoplasms) and 
hydraulic propulsion by proximate injection o f  local anesthesia. For the surgeon, the most 
effective chemotherapeutic agent is 10% buffered formalin.
Irradiation is most effective for well-vascularized, oxygenated neoplasias and is advantageous in 
that important structures can often be included in the radiation field. Specifically, with most 
neoplasms, irradiation targets cellular DNA by direct damage or by free oxygen radical 
formation so that a cell may die acutely or when it tries to divide. By comparison, radiation is 
more time consuming (multiple treatments) and expensive than surgery. Radiation kills 
logarithmically. For example, even when radiation kills 99.99% o f a neoplasm, a half kilogram 
neoplasm (500,000,000,000 cells) is reduced to 50,000,000 cells which is still far above the level 
o f autonomy. Large volume neoplasias are more likely to exhibit the natural resistance factors o f  
hypoxia and cell-cycle arrest (G-0 stage) which renders them more resistant to irradiation.
In general chemotherapy and immunotherapy are more effective for highly sensitive, small 
volume neoplasia with high growth fractions and good circulation. Similar to radiation therapy, 
the efficacy o f  chemotherapy and immunotherapy o f  large volume disease is limited to log-kill.
S u rg ica l Scenarios fo r M u lt i-m o d a l T h e ra p y
Multi-modal planning acknowledges that no single therapy will be effective alone and the best 
results for the patient will be achieved with multiple treatment modalities. All o f  the following 
scenarios accept that curative intent surgery w ill be ineffective or less effective. In the real 
world, not only are knowledge o f  diagnosis and stage important, but the “want to” and “financial 
ability to” o f  the client must be considered in addition to the systemic health o f  the animal. The 
veterinarian serves as a broker between these three diagnostic areas (disease, vital reserves, 
owner) attempting to achieve the best outcome after a thorough discussion o f  the options.
In each o f  the following scenarios, the treatment will be built around the most important or 
“primary” treatment for stage and disease and other treatments will serve as adjuvant therapy. 
Palliation is not a goal o f  these scenarios.
Primary Surgery (Reoperation) with Adjuvants if  needed. Most surgical failures result from 
unplanned operations, iatrogenic contamination (inoculation o f the wound with exfoliated cancer 
cells), and undetected dirty margin. Such surgical failures are realized through histopathologic 
may be detected by margin examination or by recurrence. At the time o f  consultation, there may 
or may not be an apparent mass, the type and intent o f  the previous surgery may or may not be 
known, and the opinion o f  the surgeon may not be available. The best treatment for failed 
surgery is often a planned re-operation guided by diagnosis and imaging, but there are 
alternatives that must be considered based on completed histopathology ( if  tissues were 
processed), metastatic risk, and whether clear margins can be obtained:
•  Planned reoperation -  Best used when effective margins seem possible with a reoperation
•  Add adjuvant (radiation, chemotherapy, immunotherapy) -  i f  second surgery fails or is 
not possible
•  Adjuvant(s) only -  sensitive low  volume neoplasia o f  moderate to high grade
•  Surveillance only -  low  /no volume with low grade; negative cytology; owner reluctance
Neoadiuvant Surgery plus Irradiation: Some neoplasia is radiation sensitive and an owner might 
prefer to spare tissue. Surgery can be intentionally planned for the purpose o f  rending irradiation 
more effective by cytoreduction o f  the cells that are necrotic, hypoxic, or in resting stage -  
typically the center o f  the neoplasm. It is worth mentioning that through ctyoreduction, 
oxygenation improved, toxins o f  necrotic tissue are removed and residual GO cells may shift to 
active status rendering them more sensitive to radiation.
•  Teletherapy (beam irradiation) with photons (gamma or x-rays) and electrons are the 
most common treatments. Photons (linear, through-and-through, full-thickness 
penetration) are highly effective for neoplasms surrounded by intermediate (vascular 
endothelium) to non-mitotic tissue (muscle, nerve, bone). The surgical goals are 
cytoreduction and primary wound healing with no more than a 2 to 3 week healing delay. 
The internal margins o f  the surgical field are marked with skin staples or vascular clips to 
show extent o f  dissection margins.
•  High-energy electrons are used when highly mitotic tissue (sensitive, Gl-tract, lung) is 
beneath and in-line with the field containing the neoplasm. The depth o f  penetration o f  
electrons can be pre-determined. Because the tissues absorb the electrons, dosimetry is 
complicated by inhomogenity (variation o f  geometry, thickness or density) o f  the surgical
wound. When electron-based neoadjuvant irradiation is anticipated, the surgical goals are 
1) uniform final wound thickness, 2) compactness o f  the wound, and 3) avoidance o f  
wounds passage around a body curvature, and 4) Marking clips should be limited to the 
four internal comers o f  the wound because stainless steel can protect neoplastic cells by 
blocking electrons.
Neoadiuvant Surgery plus Chemotherapy or Immunotherapy: When animals with large volume 
and high grade neoplasms that have metastasized are considered for treatment, chemotherapy (or 
immunotherapy) will be the cornerstone o f  efficacy or the “primary” treatment. Surgical 
cytoreduction can benefit treatment by removing less sensitive necrotic, hypoxic, and resting 
stage cells that usually occupy the center o f  the neoplasm. Cytoreduction should be aimed at 
proximate and rapid wound healing with minimization o f  factors that could contribute to 
infection and chemotherapy induced sepsis. Similarly, when planned with metronomic 
chemotherapy (anti-angiogenic therapy), rapid healing should be a goal as metronomics pose a 
problem for surgical healing and should not be instituted until healing is complete.
Neoadiuvant Therapy plus Surgery: Some neoplasms might be judged as too advanced for 
surgical care because the margins required would result in wounds that are too large to 
reconstruct or tissues that are vital for function would need to be removed to achieve curative 
intent. The goal o f  treatment is to render the neoplasm operable through an appropriate 
neoadjuvant to achieve tumor consolidation (compaction and reduction o f size). When effective, 
the surgical excision will be easier. To what extent a surgical margin might be reduced is 
controversial. One argument is that a lesser margin is needed; however, the controversy is that 
even though many cells have been killed by the neoadjuvant, there may be sufficient remnant 
cells that would remain outside the lesser margin to repopulate the neoplasm.
•  Chemotherapy can be employed when the primary neoplasm is known to be sensitive. 
Such treatment might be considered for an otherwise inoperable feline mammary 
carcinoma. Owners may be unable to afford radiation therapy and chemotherapy 
sensitivity may be unknown. It is possible to initiate a regimen o f  chemotherapy to 
evaluate for neoplasm responsiveness and to reduce local margin involvement prior to 
surgery. Injection-site sarcoma or mast cell tumor may be considered for such treatment 
because it also affords the opportunity to evaluate for potential chemotherapeutic efficacy 
prior to excision o f the neoplasm and as an alternative to more expensive irradiation.
•  Radiation might also consolidate a neoplasm prior to surgical excision and can be 
combined with chemotherapy. In this setting surgery is still considered the primary 
treatment. This approach might be effective for injection-site sarcoma, invasive thyroid 
and certain oral neoplasms, etc. The risk o f  a lessened surgical margin remains a 
consideration and a new risk imposed is that surgery within irradiated fields is more 
difficult resulting in a 30% to 50% complication rate o f  healing and secondary infection. 
This is the reason many surgeons, the author included, try to avoid operating in irradiated 
tissues.
S u rg ica l Technique
Most veterinarians operate as well as they can, never considering how the mix o f their personal 
fundamentals can influence the outcome o f  their procedures. After years o f  observing novice and 
experienced surgeons (as well as some personal floundering), several transferrable technical
principles have emerged that might benefit you. Many o f  these suggestions relate to improved 
visualization - i f  you can see better, you will operate better. Some suggestions are unique to 
surgical oncology; however, most are o f  more general nature. O f special importance are the 
principles o f  dissection -  the main operation. Admittedly some o f  these are very simple, but even 
Coach Lombardi started the Packers with the famous, “Gentleman this is a football.”
Planning:
• Visualization
o Both direct and indirect lighting will influence visualization. A means to 
aseptically change the light position is helpful, 
o If you have a magnifying loupe, use it. The use o f  a surgical operating loupe o f  
about 2.5x will initially drive you crazy, but gradually you w ill recognize 
structures you have never seen before. Ideally, the focal length will match your 
comfort (usually 20 to 25 cm; a dental loupe focal length may only be 10 to 15 
cm).
o Transilluminate. Light transmitted from the trans (far) side o f  a structure
(mesentery or fascia) can illuminate in silhouette vascular and neural structures
•  Reconstruction -  Double-mindedness during excision leads to failure. Dirty margins are 
most likely to occur because o f  fear o f  inability to close a wound. When considering 
repair/ reconstruction, plan for 2 options
o The first based on the “what you think may transpire -  what is the needed 
margin?”
o The second based on the “worst case scenario” (grafts, more complex flaps) 
o Then concentrate on the excision rather than question the possibility o f  closure 
o It may be fun, but adventure is not the main goal -  so use the simplest closure 
with the greatest safety
•  Positioning:
o Protect the spine (when rolling) and joints (over flexion/ extension) o f  old animals 
under anesthesia/ sedation during movement or positioning. Old patients are 
unable to protect themselves by muscle control and may suffer fractures o f  
arthritic joint or spondolytic bridging when the spine receives torque, and 
postoperative discomfort if  the joints are stressed while anesthetized, 
o The operative field should usually be at the surgeon’s elbow height 
o The surgical site should be the highest point when positioning the patient. Roll a 
towel as needed to improve access
•  Local Anesthesia:
o Effective for analgesia, remain distant from the mass 
o  Fluid dynamics may push neoplastic cells away from the excision field
Incision:
•  Cover ulcerated tissue -  Fear may be the foremost cause o f  recurrence through 
conservative dirty margins and the second is transplantation o f  exfoliated neoplastic cells 
from ulcerated neoplasms or neoplasms cut during surgery (curiosity, accidental)
•  Draw/ Plan on the skin with skin marker or Sharpie
o First mark the border o f  the neoplasm 
o Second mark a reasonable surgical border for clear margins
o Third, mark the line(s) o f  excision
•  Suggested Margins
o Benign (rare in cats) -  at margin or few mm
o In Situ -  0.5 to 1.0 cm
o Malignancies 1.0 to 2.0 cm
o Injection Sarcoma 5.0 cm
• Tense skin for incision
o Follow the marked line for excision.
o If it is curved, use a pencil grip with minimum scalpel surface contact (15 blade) 
for curved incisions.
• Linear Incisions
o The minimum skin incision should be 1.5 times mass for linear incisions;
o Incisions can be shortened by using curvilinear incision flaps to increase exposure
(incision length remains approximately the same)
Dissection:
•  Wound Retraction
o Primary wound retraction improves visualization
o Simple instruments (Gelpi, Weitlaner, Sutures, Allis tissue or Towel forceps)
• Tissue division
o Sharp scalpel, scissor, electrosection, laser, blunt fracture 
o Avoid incision o f  neoplasm (another source o f  exfoliant cells)
•  Hemostasis -  visualization
o Electrosurgery/ laser 
o Exsanguinating tourniquet 
o Ligate drainage as early as possible
•  Traction with counter-traction (assistant or pt weight) -
o Develops tissue plane
o Gentle manipulation o f neoplasm (tumor embolization)
•  Don't “undercut” -  avoids accidents
o Mistaken incision o f  structures/ tumor 
o “Roll” neoplasm o ff as possible
Closure:
•  Confirm adequacy o f hemostasis,
•  Determine need for drain (IPFs, unsuturable deadspace, drains are negatives in oncology 
wound closure).
•  As needed, use buried tension (pulley) sutures while obliterating dead space.
Evaluating a Previous Surgery:
•  Compare opinion o f  the surgeon and pathologist on thoroughness o f  excision
•  Scar becomes softer and flatter over time. Proliferative scar is rare in dogs and cats.
•  When a mass is present, any re-excision should include all coadjacent tissue wounded in 
the previous surgery if  it was within 3 months
Contrast imaging reveals vascular leakage/ abnormality, but neoplastic infiltration may 
extend beyond imaging changes by several mm or more.

Ralph A  Henderson, DVM, MS 
Diplomate ACVS, ACVIM Clinical Oncology 
Auburn University, AL 
hendera@aubum.edu
SURGICAL MANAGEMENT OF SPECIFIC FELINE NEOPLASMS
Objective: Several elements offeline surgical oncology are different from  the dog. Using the tool 
o f  critical thinking, this lecture will emphasize the unique needs o f  the feline surgical patient: 
Wound healing, maxillofacial surgery, injection site sarcoma, and unique situations in feline
surgery.
Critical Thinking: Critical thinking is a 1980s concept to explain some o f the ills o f  the American 
education experience. Educational curricula had become inflexible and bloated by an over­
emphasis on teaching factual knowledge. Educators from the counter-culture o f  critical thinking 
emphasized that students should be taught the understanding o f  processes, concepts and methods 
while encouraging learning through curiosity, self-expression and creativity. This new method o f  
analysis called critical thinking has been defined by Webster as the mental process o f  actively 
a n d  skillfully conceptualizing, applying, analyzing, synthesizing, and evaluating information to 
reach an answer or conclusion. This method began to penetrate veterinary medicine as a sub­
component o f  the 1989 Pew Report. Some veterinary curricula which were new at this time were 
dramatically different from traditional curricula and even traditional curricula began a gradual 
modification, but not without resistance. Some educators maintained that knowledge could be 
“possessed”, and graduation and the passage o f  national board examination was the “license to 
practice”. Those o f  the counter-culture however emphasized “possessed knowledge” was already 
outdated and that “lifetime learning” was the future o f  education.
Critical-thinking coincided with the beginning o f  the information age. Through the early days 
(ARPANET, FreeNet) to the present (WWW), the quantity and quality o f  information available 
increases daily and has far surpassed the ability o f  individuals to acquire, filter, process and use. 
As advancements in technology improve information processing, newer advancements provide 
even more information. Critical analysis has vastly improved some areas o f  our lives such as 
weather forecasting, information sorting (web searches), shopping. Society-wide, critical 
thinking has become synonymous with the kind o f  thinking that strategists in business, finance, 
industry and medicine use to “see the future”. At its core, it is the kind o f  thinking that separates 
factual elements from assumptions, randomness, and rationalizations while accommodating 
important feelings and beliefs that would influence the use o f  those facts. Critical thinking does 
not depend on technology; however, in medicine, the concept o f  evidence-based practice fits 
definition. And veterinarians use it daily to plan diagnostics, treatments and prognoses while 
accommodating clients’ concerns and financial abilities.
Critical Thinking in Feline Wounds. The seminal publication o f  feline wound healing as 
compared to the dog (Bohling, Vet Surg 35;2006:3) reported that cats healed differently than 
dogs. At 21 days, the wounds were similar, but along the way, they were not. Because this was a 
new area o f  research, the most important events o f  feline wound healing were unknown. The 
major finding was that cats depended more on the integrity o f  subcutaneous tissues than did the 
dog. If subcutis was removed from cat wounds, the wound healed slower than in dogs. In the 
presence o f  subcutaneous tissue, epithelial migration occurred, but suffered a lag time awaiting 
granulation. The feline granulating wound differed from the dog as well. Granulation in the cat 
began at the edges and grew centripetally, whereas the caning granulation seemed to be produced 
across the wound at a near equal rate. So cat open wound contraction began slower and gradually 
sped up catching up with the dog at about 3 weeks. Cats also have a propensity to 
“pseudohealing” which is defined as healing o f  the skin to skin but not having reattachment o f  
the skin to the underlying tissues.
Chronic wounds in the cat are among the most difficult to manage. If subcutaneous tissue is 
absent, granulation is slow to occur and is thin -  often effecting little to no benefit. Experience 
teaches that it is better to avoid chronic wounds in cats. With dogs, we often manage a wound on 
the basis o f  delayed closure, knowing that a canine wound cared for properly will granulate and 
readily accept closure by wound contracture and epithelialization, or surgical skin advancement, 
flaps and grafts. Cat wounds must also be managed openly sometimes, but experience has also 
taught that extensive debridement is likely to promote a slow to non-healing wound. When this 
occurs, it is often necessary to shift a complex myocutaneous flap so that a defect is filled with 
vascularized muscle, subcutis and skin simultaneously. In some body sites, this is far more 
difficult than others.
A  second feline wound healing paper paper (Mitsui, AJVR 70;2009:532) reported enhancement 
o f  granulation in feline wounds i f  the muscle fasica was incised (fasciotomy) or removed 
(fasciectomy) but not so with simple abrasion o f  the fascia. The control time to development o f  
robust granulation was 18.5 days, but the treated groups were shortened to 9.6 days. Simple 
abrasion developed similar granulation in 16.7 days.
So based on present knowledge, critical thinking suggests incorporation o f  all o f  these elements 
as the wound might dictate. Initial judicious debridement, accurate closure, consideration o f  
fasciotomy or fasciectomy i f  subcutis is absent, consideration o f  subcutaneous suction drains or 
walking-type sutures to improve contact o f  the skin to underlying tissue to help re-establish 
continuity and prevent pseudohealing, consideration o f  complex flap closures for difficult 
wounds and, finally, despite even the advanced care o f  referral centers some wounds are not 
going to heal. This latter group may be benefitted by growth promoting factors, but this is still 
unknown.
Interestingly cat skin seems resistant to the acute effects o f  radiation. Few cats suffer acute 
irradiation inflammatory change; however, irradiated cat skin that is wounded can be more 
difficult to heal. When irradiation is planned, we have often performed tumor excision followed
immediately (same day) with irradiation and linear wounds seem to heal normally. However the 
healing o f  complex reconstructions may be compromised by irradiation and are allowed to heal 
two to three weeks before irradiation.
Critical Thinking in Feline Maxillofacial Surgery. Maxillofacial surgery began to advance 
rapidly in the early 1980s and surgeons were often amazed at the resilience o f  dogs to major 
reconstructive procedures. In 2006 the complications o f  mandibular surgery were reported for 42 
cats (Northrup, JAAHA 42;2006:350). This seminal paper mostly affirmed the experience o f  
those o f  our profession who had been performing oral surgery on cats - it was understood that 
feline oral surgery was often more challenging than for dogs -  and most veterinary surgeons 
were much more reserved about performing oral surgery in cats compared to dogs. Several 
factors contributed to this problem: Cats hid their disease better than dogs so they ovften 
presented with more advanced disease, the differentials were fewer, but equally malignant 
(mostly squamous cell carcinoma -50%  to 75%, fibrosarcoma, and osteosarcoma), the site o f  
origin was often in the bone rather than on the bone, less labial tissue was available in the cat for 
reconstruction, and sharp canine teeth that became malaligned as a result o f  surgery caused 
trauma and pain. Postoperative contrasts were dramatic. Dogs usually only missed the meal 
withheld for surgery as they readily ate postoperatively; whereas, cats were not likely to eat 
postoperatively, sometimes for a week which posed risks for other metabolic problems and the 
need for alimentary support. Earlier reports that included dogs and cats had far fewer cats in the 
studies and the results for the feline portion were often overshadowed by the number o f  dogs.
The recurrence rates for dogs were lower than for cats
How does critical thinking fit this clinical scenario? Veterinarians learn surgery by rote: Step 1, 
Step 2, etc. Reconstructive surgery and surgical oncology don’t fit this model well. A  standard 
operation is often changed completely by changing the depth o f  the lesion or moving the wound 
or the neoplasm 2 inches in any direction. Instead these types o f  surgery are taught by teaching 
concepts built on “standard” surgical procedures: Create a margin o f  normal tissue, don’t cut into 
the neoplasm, don’t manipulate roughly, ligate vessels early, irrigate frequently, don’t 
contaminate gloves with cancer cells, avoid exfoliant cells, mark the internal extent with 
stainless clips AND don’t leave clips in the wound, remove a layer o f  fascia, remove a layer o f  
muscle with fascia, remove the full thickness o f  the body wall, accommodate wound tension, 
close the wound, delay closure o f  the wound, avoid a biological tourniquet during closure, place 
sutures in or otherwise mark sites o f  interest for the pathologist -  all o f  these principles are not 
useful in every procedure and some countermand the others -  the ones incorporated are those 
which indicated. It is the surgeon’s job to coordinate based on importance and other treatments 
preceding or to follow. It requires an analysis o f  the peculiarities o f  a specific operation -  critical 
thinking. To make it even more complicated no one even knows if  the successful critical thinkers 
do it the same way.
One way to discover how to do things better is to study what went wrong. The chief problems 
reposted by Northrup in the 38 cats followed long term were dysphagia or inappetance 16,
ptyalism 9, mandibular drift 14, tongue protrusion 11, pain 0, difficulty grooming 7, dehiscence 
0, malocclusion with palate injury 7 (only criteria that increased from acute to long term), 
temporomandibular joint crepitus 1, death 2. Only 9 cats has no long term complications. The 
results were still encouraging: Despite acute morbidity o f  98% and 76% long term morbidity, 
83% o f  the owners were satisfied with the outcome o f  mandibulectomy. O f greatest concern was 
the 12% o f cats that never regained the ability to eat.
The critically thinking surgeon would evaluate these findings and structure the surgery to 
minimize potential morbidity. It is not always possible to prevent some problems such as 
ptyalism or tongue protrusion with rostral mandibulectomy, but a feeding tube should be 
considered for cats with anticipated eating problems or cats that already exhibit reluctance to eat. 
For unilateral mandibulectomy, plan for amputation with vital pulpotomy or extraction o f the 
contralateral canine teeth that are likely to cause pressure problems. Unilateral mandibulectomy 
should be accompanied by cheilorraphy o f  the upper and lower lip to the level o f  the first 
premolar to reduce tongue lolling and ptyalism.
Critical thinking analysis o f  operative complications can often be used to design an operation to 
minimize the occurrence o f  complications -  o f  course these are the complications that have been 
reported or experiences. There w ill always be newly experienced complications -  may we think 
critically enough to avoid them a second time.
A  S ho rt G lo ssa ry  —  What are we talking about anyway?
Names for the Disease Process -  These are commonly misused/ confused, 
o Neoplasm -  Unregulated tissue growth Malignant or Benign 
o -om a -  “swelling” a suffix indicating a neoplasm o f  benign character
o -sarcoma -  “fleshy” a suffix indicating a mesenchymal neoplasm o f
malignant character
o -carcinoma -  “hard” a suffix indicating an epithelial neoplasm o f  malignant 
character 
o Cancer -  A malignant neoplasm
o Invasion -  A  mode o f  growth in which malignancy grows into adjacent tissue;
sometimes referred to as “local metastasis” 
o Malignant -  Capable o f  spread or o f  causing death
o Metastasis -  Malignancy that has spread by blood, lymph, airway, or via body 
cavity to a distant site and by direct invasion to an adjacent organ. Retrograde, 
intransit, inflammatory are other descriptors, 
o Benign -  Usually incapable o f  causing death. Site dependent
o Mass -  An undiagnosed swelling o f  /on the body
o Tumor -  An undiagnosed swelling o f  /on the body
o Paraneoplastic - A “side-effect” o f  neoplasia usually caused by the biochemical
action o f  a protein, protein class, cytokine, chemokine, hormone or hormone-like 
substance
Nomenclature for Outcome Analysis -  Accepted abbreviations
o Average -  The sum o f  outcomes divided by the number o f  outcomes 
o Median -  The middle animal in a population
o Disease Free Interval (DFI) -  Normally reported as a median, it is the time from 
treatment to recurrence 
o Median Survival Time (MST) -  Reported as a median, it is the time from 
treatment to death
Multi-modal - Using more than one treatment to attack the disease at several levels. The 
toxicity should not generally be overlapping/ cumulative
Neoadjuvant -  From the Greek “before” rather than the Latin “new”, this is adjuvant care 
given before the primary care rather than after as is more common 
Margin - The edge o f  a neoplasm or tumor submission.
o Clean margin -  absence o f  neoplastic cells at the edge
o Dirty margin - Tumor cells are at the edge o f  the section
o Margin composed o f  normal tissue - clean margin
o Tumor cells abut the margin - dirty martin
o Wide margin -  larger than 1 to 3 cm. May still be dirty if  the primary neoplasm
was large (sampling error).
Metaplasia -  Abnormal transformation o f  one type o f  cell into another usually due to 
tissue chemical mediators or changing genotype.
* Mitoses - cells caught by fixation in the process o f  dividing. Except for certain germinal 
tissues, this is a very unusual finding in normal tissue
•  Mitotic index - the number o f  mitoses seen in a section o f  tissue usually expressed per 10 
high power fields (400x), but is subject to pathologist variation (per field; per 600x field, 
etc.)
•  Pathologist’s Terms -  Commonly encountered terms from pathology that are used to 
interpret the pathology report and to assist in making a prognosis)
o  * Anaplastic - poorly developed cellular differentiation
o  * Anisocytosis -  Differently sized cells/ within a specimen
o  * Anisokaryosis -  Differently sized nuclei within a specimen
o  Atypia -  Cell variation beyond normal. Occ. very early precursor o f  neoplasia
o *Desmoplastic - Containing abundant fibrous connective tissue (see scirrous)
o Dysplasia -  Cells that exhibit evidence o f  stress or other phenotypic alteration
o f abnormal development, but not (yet) neoplastic 
o Grade -  Terminology to define the relative malignancy o f  a neoplasm
o *High grade - Malignant neoplasm that is associated with rapid cell division and
likely to metastasize early 
o Low grade - Usually well-differentiated neoplasm that is associated with
somewhat slower progression or risk 
o Intermediate grade - O f intermediate differentiation and risk
o  Hyperplasia -  Increase in the number o f  cells
o Hypertrophy -  Increase in the size o f  cells
o In situ -  Growing above the basement membrane (not yet invasive)
•  *Pleomorphism -  the occurrence o f  multiple shapes and forms o f  cells usually indicative 
o f unregulated differentiation during neoplasia
•  Prophylaxis - The treatment should reduce the risk o f  neoplasia
•  Rescue - Treatment o f  a neoplasm that has come out o f  remission
•  Rescue (alternate use) - Administration o f  an intentionally lethal overdose o f  
chemotherapy with the intent o f  following with a reversal agent such as methotrexate 
followed by calcium leukovorin
•  * Scirrous -  Inducing or containing abundant fibrous connective tissue
•  Surveillance -  Observation for a specific event with a planned action
•  Treatment Intent -  Goals o f  therapy (plus above terms to describe treatment response)
o Adjuvant - a means o f  assisting another form o f  treatment
o Control - Achieving Remission, Partial Remission or Progression
o Curative - Elimination o f  all neoplastic disease
o Palliation - R elief o f  pain or secondary signs
o Cytoreduction - Reduction o f  neoplasm volume to benefit another treatment
o Debulking - Cytoreduction
•  Treatment Response- Terms used to describe treatment response
o Cure - Elimination o f  all neoplastic disease
o Remission - N o detectable neoplasm; Apparent complete resolution o f  neoplasm
o Partial Remission - Reduction o f  greater that 50% neoplasm volume
o Progression - More than 25% increase in neoplasm volume
o Stable Disease - Less than 50% decrease in neoplasm volume
•  Tumor emboli - malignancy has invaded blood or lymphatic vessels
*Terms that relate to malignancy. Increasing expression o f  these changes usually indicate 
relatively increasing malignancy.
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PEOPLE DIRECTED AGGRESSION: MAKING THE DIAGNOSIS
MICHELLE BAMBERGER, MS, DVM 
Vet Behavior Consults
1. Medical and Nutritional Rule Outs
A. Pain
B. CNS
C. Sensory decline
D. Endocrine imbalances
E. Cognitive dysfunction
F. Drug-related
G. Diet
2. Making the Diagnosis
3. Types of Aggression
A. Aggression as a result of lack of socialization
B. Pain-induced
C. Irritable
D. Petting-induced
E. Play
F. Predatory
G. Maternal
H. Fear
I. Status
J. Territorial 
K. Pathophysiological 
L. Idiopathic 
M. Learned 
N. Redirected
4. Case Discussion
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Feline Elimination
Pamela J. Perry, DVM, PhD 
pjp22@cornell.edu
Feline Elimination Problems
• House soiling
-  Urinating or defecating on horizontal surfaces 
outside the litter box
• Urine marking
-  Usually manifested as spraying
-  Some cats mark on horizontal surfaces
-  Middening = fecal marking (rare)
Determine What the Cat is Doing
• Urination or defecation or both
• Surface where urine is found 
-Vertical versus horizontal
• Posture
-  Standing with tail twitching = spraying
-  Squatting = elimination or marking
• Volume of urine
-  Usually smaller amount voided with spraying
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Identifying the Perpetrator
• Direct observation
• Videotaping
History
• When and where problem began
• Changes in cat’s environment
• Urine and/or feces
• Surfaces soiled
• Frequency of house soiling
• Other behavior changes
• Solutions attempted
Determine Scene of the Crime
• Have owners draw a map of the house 
-S ite of soiling
-  Site of litter box
-  Favorite resting spot of 
each cat
-  Windows, doors, beds, 
couches, etc. indicated
-  Feeding stations
Feline House Soiling
• Eliminating outside the litter box
• Males = females
• Random, or a specific location or 
substrate
• Risk factors
- History of previous urinary tract infection
- Use of scented litter
• Long-haired cats may be predisposed to fecal 
soiling
Feline House Soiling Differentials
• Medical
• Litter box aversions
• Substrate aversions / preferences
• Location aversions / preferences
• Accessibility
• Geriatric issues
Feline House Soiling Differentials
• Anxiety -  social interactions
-  Ambush by other cat
-  New pet, new person, new baby
-  Passive or active 
inter-cat aggression
-  Change in owner's 
schedule or long 
absence
Litter Box Aversions
• If cat urinates AND defecates outside litter 
box, often a problem with the box
• Hygiene
-Odor: waste, disinfectants
• Type / size of box
• Negative experience 
associated with box
Substrate Aversion
• Type of litter
-Clumping vs. non-clumping
-  Scented vs. unscented
-  Plastic “pearls”
-  Texture -  size of granules
• Depth of litter
-  Deeper usually better
Preferred Litters
• Ever Clean®
• World’s Best Cat Litter™
• Swheat Scoop®
• Fresh Step® with Carbon
• Agway’s Clumping Litter
Location Aversions
• Environment near litter pan
• Traffic or noise
• Other animals
• Negative association
-  Pain while in box
-  Medicated in box
• Accessibility
Preferences
• Surface preference
• Location preference
• If only defecates outside box 
-  Rule out medical issues
• Constipation or colitis
Substrate Preference
• Carpet
• Bed or couches
• Clothes or shoes
• Plastic bags
• Soil in house plant
• Hard surfaces -  porcelain
Weather
• Outdoor cat forced to be indoor cat
• Outdoor cat doesn’t want to go outdoors
Feline House Soiling
• Eliminating on horizontal surfaces can be 
marking behavior
-High cat density
-  Stress/anxiety -  investigate other changes in 
cat's behavior
Treatment
• Rule out medical issues
• Remove the cause
• Re-establish litter box use
• Prevent access to soiled areas
Rule Out Medical Problems
• Urinalysis
• Culture
• Radiograph or ultrasound
• Endoscopy
» Assess water intake and urine frequency
• Dysuria
• Stool evaluation -  diarrhea, blood/mucus, 
hard stools, constipation
Remove the Cause
• Treat medical condition
• DO N O T PUNISH!
• Treat underlying anxiety / social issues 
-  Keep cat’s environment consistent
and predictable 
-Schedule daily interaction time
Re-establish Litter Box Use
• Add litter boxes 
- 1  box per cat plus 1 
-  Bigger is better
• Litter cafeteria to determine 
preference
Re-establish Litter Box Use
• Don’t use liners
• Litter box hygiene
-Scoop 1-2xdaily (discard non-clumping daily)
-W ash pans weekly with mild detergent/ 
replace litter
Prevent Access to Soiled Areas
• Change behavioral function of previously 
soiled areas
-  Place food bowls, bedding, toys in area
Prevent Access to Soiled Areas
• Make areas undesirable
-  Scat mat
-  Plastic carpet runner, nubby side up
-  Foil, plastic, or double-sided sticky tape
Prevent Access to Soiled Areas
• Make areas inaccessible
-  Barriers 
-W ater in bathtub
-  Place litter box over soiled area
Treatment
• Confine cat to small area temporarily
-  Reinforces habit of using litter box
-  Let cat out to socialize and play, but must be 
supervised 100%
-  Reward for using box
• Large cage with perch or shelf
-  Cover floor with litter
-  Gradually introduce litter box
Cleaning Soiled Areas
• Bacteria / enzyme combinations
-  Anti-lcky-Poo 
-OutrightVeterinary Strength 
-K O E
-  Feline Odor Neutralizer
-  Planet Urine
-  Zero Odor
Urine Spraying
• Urine sprayed on vertical surfaces
-  Some mark on horizontal surfaces
• Sexually dimorphic behavior
-  Males > females
-  Intact > neutered
• Related to number of cats in the home
Who Sprays?
• 100% intact males
• Intact females in heat
• 10% of castrated males
• 5% of spayed females
Why Do Cats Spray?
• Sexual -  hormonal
• Outside cats
-  Odor 
-Sight
• Multiple cat household -  high population 
density
• Anxiety -  usually social issues
-  Coping mechanism or sign of stress?
Why Do Cats Spray?
• Environmental stimuli
-  Changes in household, new person, novel 
objects
• Relationship with owner 
-Changes in schedule/interactions
-  Punishment
Treatment of Spraying
• Identify and remove triggers
• Neuter
• Deter outside cats from visiting
• Cover windows
• Separate household cats
• Indoor/outdoor access
• Cat diapers
Treatment of Spraying
• Decrease cat population
• Litter box hygiene
• L-shaped boxes or spray panel
• Medication -  CBC/chem panel first
-  SSRl
-  TCA
• Feliway™ as adjunct
-  Cat unlikely to spray over cheek gland secretions

Inter-Cat Aggression
Pamela J. Perry, DVM 
pjp22@cornell.edu
Feline Social Structure
• Highly variable
• Adults solitary when hunting for prey
• Can adapt to living in large groups where 
food is readily available
• Hierarchy in feral cats 
determined by body size in 
females and age in males
Why are Cats Social?
• Temperature regulation
• Kitten care
• Mutual defense
Territories
• Male has larger territory
-  Spray urine to mark territory
• Females have smaller territories -  usually 
encompassed by dominant male’s
• Cats may sleep together, but are active 
alone
• Female groups are stable, but strangers 
are rejected
Inter-Cat Aggression
• Status
• Territorial
• Re-directed
• Fear
Status Aggression
• Cats that bite or attack owners or other 
cats in order to control a situation or 
resource
• Controls access to furniture or other 
resource
• Assertive, pushy behavior
• May bite when petted too long
Territorial Aggression
• Attacks visitors or other cats to expel them 
from their territory
• Seeks out victim
Re-directed Aggression
• Occurs when the cat is 
aroused and cannot reach 
the intended target
• An innocent bystander 
(another cat) becomes 
the victim
• Very acute, intense, and uninhibited
Fear Aggression
• Cat perceives someone or something as a 
threat
• Can quickly escalate to aggression if cat is 
unable to escape
• Can occur in victim cat -  perpetuates 
aggression cycle
Fear Aggression
Treatment of Acute, Serious Feline 
Aggression
• Isolate cat
• Keep in quiet, darkened room
• Assess every few hours; bring tasty food
• To take cat to veterinarian, put cardboard box 
over cat and slide cookie sheet under cat
• Protect victim
-  File can ines
-  O nychectom y
Treatment of Inter-Cat Aggression
• Separate
• Medicate -  if necessary
-  Buspirone for victim
-  SSRI or TCA for aggressor
• Odor exchange
-  Feliway -  the cat cheek gland pheromone
-  Rub each cat with same towel
• Re-introduce slow ly
• Give aggressor smaller or less desirable 
place of confinement
• Give victim larger, more desirable place
Treatment of Inter-Cat Aggression
Reintroduction
• At least one week of total separation
• Feed meals, not free choice
• Reintroduce only at mealtime (continue to 
separate otherwise)
• Have cats on opposite ends of room; both 
cats or only aggressor in carrier or 
tethered
Reintroduction (continued)
• If cats eat with no sign of aggression -  
growl, hiss, caterwaul, etc. -  feed an inch 
closer
• Continue until cats can eat right next to 
one another
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Reintroduction (continued)
• Repeat three times •
1. Aggressor in carrier
2. Aggressor wearing harness and tethered
3. Aggressor wearing harness, but not tethered
• Gradually increase time that cats are 
together after meals
Treatment of Inter-Cat Aggression
• Instruct owners on feline threats
-  Stares
-  Posture
• Interrupt threats
• Bell aggressor as warning to 
victim
Pica
• I ngestion of non-food items
-  Wool or other fabric
-  Plastic
-  Cords 
-Wood
Pica
• Relation to early weaning
«
Plants
• Cats may eat plants 
-  Make sure it is a safe 
plant
Treatment of Pica
• Clomipramine
• Cat garden
• Bones
• Kangaroo meat
Cat Gardens
• Edible grasses
• Available from most pet stores
Geriatric Issues
• House soiling
• Excessive vocalization -  esp. at night
• Wandering aimlessly
• Sleeping
• Purring
• Demanding attention
• Increased affection
• Decreased activity
Possible Medical Causes
• CNS disease • Pain
• Orthopedic issues; • Gl issues
• Dental disease • Endocrinopathies
• Renal disease • Sensory loss
• Hepatic disease • Cognitive decline
Behavior and Health
• Behavior problem remains after medical 
condition is treated
• Learned associations
-  E.g., litter box aversion after UTI
• Behavior modification may be more 
difficult
Incidence from Vet Behavior 
Practices
• Cats
-  73% house soiling
-  6% aggression, vocalization, restlessness
Senior Pet Visit
• 7+ years
• Minimum database
-  Complete blood count
-  Serum chemistry
-  Thyroid values if physical or behavior signs
-  Urinalysis if physical or behavior signs
• Questionnaire -  have owner fill out every 
year
-  Best method to detect minor aging changes
Brain Aging Basics
• Brain function declines with age 
-  Cognitive abilities worsen
• Decline in brain function is associated with 
tissue and behavioral changes
• Underlying cause of these changes may 
be related to oxidative damage from toxic 
free radicals
Hypothesis for Brain Aging
• Free radical theory of aging
-  Reactive oxygen species (ROS) cause 
cumulative damage with age
-  Protein: Impaired metabolism and function 
-Fats: Decreased membrane fluidity 
-DNA: Increased mutations
-  Carbohydrates: Decreased cellular function
Mitochondria, ROS, and Aging
• Produces energy
• Generate free radicals 
as by-products
• Anti-oxidant defenses
- Decrease with age
• Aged mitochondria
- Less efficient
- Produce even more 
free radicals
- Eventual cell death
House Soiling
• VERY common in older cats
• Look for patterns in certain locations
• Stranguria, pollakiuria, hematuria, PU/PD 
-  Medical workup
• Cognitive dysfunction
House Soiling
• Treat underlying medical conditions
• Management
-  More litter boxes
-  Easier access
-  Low sides
-  Confine to smaller area
-Address any inter-cat conflict
Vocalization
• Excessive night-time vocalization common 
in older cats
• Pain, discomfort
• Sensory impairment
• Response to outside stimuli
• Owner response -  reward or punishment
• Daytime stimulation, medications
References
• Landsberg, G., Hunthausen, W., Ackerman, L., 2003, 
Handbook of Behavior Problems of the Dog and Cat. 
Saunders. St. Louis.
• Luescher, A U ., 2003. Diagnosis and management of 
compulsive disorders in dogs and cats. Veterinary 
Clinics of North America: Small Animal Practice 33, 253- 
267.
• Neilson, J.C ., 2003. Feline house soiling: elimination and 
marking behaviors. Veterinary Clinics of North America: 
Small Animal Practice 33, 287-301.
• Virga, V., 2003. Behavioral dermatology. Veterinary 
Clinics of North America: Small Animal Practice 33, 231- 
251.
<0 O 
Q. ~
n <5
« ro
w o)
3
3 Sro a
O  0 ) 
->■ (A
Feline Injection Site Sarcomas -  Where Do We Stand in 2011?
Barbara E. Kite hell, DVM, Ph.D., DACVIM  
Michigan State University
Historical Background: Feline injection site sarcomas (FIS S ) were originally 
referred to as vaccine-associated sarcomas (V A S ). An increase in observed incidence o f 
feline soft tissue fibrosarcomas was first noted by veterinary pathologists Hendrick and 
Goldschm idt at the University o f Pennsylvania in the late 1980's. This increased 
incidence paralleled two tem porally- related events. First, in 1985, was the introduction 
and widespread use o f two killed adjuvanted vaccines that had not been previously 
approved for use in cats. These vaccines were a subcutaneously administered, aluminum- 
adjuvanted killed rabies virus vaccine and an aluminum-adjuvanted killed feline leukem ia 
virus vaccine. Second, in 1987 the State o f Pennsylvania enacted a law  requiring rabies 
vaccination for cats. This effectively increased the number of cats at risk for 
development o f FISS due to an increase in number o f cats vaccinated.
Public concern and rumors o f law suits prompted the C alifornia Veterinary 
M edical Association to bring together a panel o f experts to address the issue o f feline 
FISS in August 1996. In  November 1996, an organization was formed to promote 
research and educational efforts for this emerging disease problem. Charter organizations 
which supported the formation o f what is now known as the Vaccine-Associated Feline 
Sarcoma Task Force (V A FSTF) include the Am erican Veterinary M edical Association, 
the Am erican Anim al Hospital Association, the Am erican Association o f Feline 
Practitioners, Cornell Feline Health Center, and the Veterinary Cancer Society. The 
V A FSTF has since sponsored many research projects to explore the etiology, 
pathogenesis, diagnosis and treatment o f this disease. The V A FSTF has worked towards 
development o f recommendations regarding vaccination protocols and education o f 
veterinarians and the public with regard to vaccine-site reactions and tumors that form at 
sites o f vaccination.
Epidemiology: Investigations have led to a better understanding o f the physical, 
biological, and histological characteristics o f these tumors. Estim ation o f the frequency 
o f feline FISS varies between retrospective studies, and ranges from 1 case/10,000 
vaccinates to 1.3cases/l,000 vaccinates. The interval between vaccination and the 
development o f tumors is highly variable. Tumor latency intervals have been reported to 
be as short as one month and as long as 10 years from vaccination (M cEntee, 2001). 
Kass et al. showed a causal and temporal association between feline sarcomas and use o f 
rabies and feline leukemia vaccines. Kass' study also revealed an increased risk of 
fibrosarcom a development with increased number o f vaccines administered. In  fact, the 
risk o f developing a fibrosarcoma from a single injection in the cervical/intrascapular 
region was close to 50% higher than that o f nonvaccinates. R isk escalated to 127%  when 
2 vaccines were administered and clim bed to 175%  when 3 or 4 concurrent vaccinations 
were given in the same anatomic site. Kass also observed that vaccines with adjuvants 
other than aluminum as w ell as vaccines without adjuvants, were associated with 
fibrosarcom a development. Epidem iologic studies have im plicated an association with 
feline leukemia (FeLV ), rabies, and feline viral rhinotracheitis/calicivirus/panleukopenia 
virus (FV R C P ) vaccines, with monovalent and polyvalent vaccines, and with non-
adjuvanted as w ell as adjuvanted types. (Kass, 1993) These tumors are now called 
injection site sarcomas because they have also been reported in association with long 
acting antibiotics and corticosteroid injections, a lufenuron injection, non-absorbable 
suture m aterial, and also at sites o f m icrochip implantation. (Hendrick, 2011). Thus these 
lesions are presumed to be due to chronic inflamm ation and tissue wound healing 
responses gone awry, rather than to the specific injected m aterial. They are also 
associated with the specific reactions seen w ithin individual cats in  response to these 
tissue wounding factors. (M artano, 2011)
Hendrick et al. follow ed their original observation with a study that compared 
fibrosarcom as that developed at vaccination sites with those arising at nonvaccination 
sites. This retrospective analysis revealed an association o f sarcomas at rabies, FV R C P, 
and FeLV  vaccination sites. These authors hypothesize that normal resident feline 
fibroblasts and m yofibroblasts are induced to proliferate in response to injected adjuvants 
or other vaccine components. M yofibroblasts are believed to represent a transitional 
stage through which fibroblasts and macrophages pass during the process o f wound 
healing. (Martano, 2011) In  some cats, these cells ultim ately undergo neoplastic 
transformation.
Histologic and Biologic Behavior: Through histologic evaluation o f feline FISS 
tumor specimens, Hendrick recognized a characteristic inflam m atory component 
associated with these sarcomas that was sim ilar to the granulomatous and lym phoid 
infiltrates seen in non-malignant injection-site reactions. M any FISS  tumors contain 
spindle cells and m ultinucleated giant cells with a high degree o f nuclear pleomorphism 
and cellular atypia. Pathology studies what were then called comparing vaccine- 4
associated sarcomas (V A S ) and non-vaccine associated sarcomas (N V A S ) reveal that 
VA S lesions exhibit histological features consistent with more aggressive behavior than 
do their N VAS counterparts. Characteristics such as intratumoral necrosis, m itotic 
activity, and cellular pleomorphism have been shown to be more pronounced in  FISS 
than in N FISS.
Retrospective histologic evaluation o f a number o f tumor samples revealed a 
shiny, amorphous, grey-brown m aterial present in  the central necrotic zones and w ithin 
macrophage cytoplasm in 40% o f specimens examined. Electron-probe analysis 
identified this foreign m aterial to be alum inum , a common adjuvant o f vaccines.
Im m unohistochemical analysis is generally positive for im m unoreactive vim entin, 
the mesenchymal cell intermediate filam ent, and smooth m uscle actin. This 
immunohistochemical profile supports a fibroblastic or m yofibroblastic origin for FISS. 
H istologically, FISS tumor types include fibrosarcom as, malignant fibrous histiocytom as, 
rhabdomyosarcomas, soft tissue osteosarcomas, and chondrosarcomas.
These FISS tumors are grossly characterized as well-dem arcated, pseudo­
encapsulated masses. The biologic behavior o f FISS is  consistent w ith local 
aggressiveness and a high incidence o f local recurrence. Furthermore, metastasis is seen 
in 10-25% o f patients. It is observed that FISS is more likely to become metastatic than 
non-FISS sarcomas.
Pathogenesis: Research studies supported by the V A FS TF and also by the
M orris Anim al Foundation have been directed toward understanding the etiology o f this <
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form o f cancer. Retroviral elements, either endogenous or exogenous, do not appear to 
be associated with FISS. E llis  et al. investigated 130 suspected FISS from cats. In  this 
population, a ll 130 suspected FISS were negative for the intratumoral FeLV  gp 70 
antigen on the basis o f immunohistochemistry. One hundred FISS were also examined 
using polymerase chain reaction and were negative for the FeLV long term inal repeat 
region. This study decreased the concerns o f a retroviral etiology for FISS.
Many groups have explored possible growth factors and oncogenes involved in 
the pathogenesis o f FISS tumor development. Nambier et al. evaluated 40 FISS for 
expression o f nuclear p53 protein by immunohistochemistry (IH C ) to detect any 
correlative association o f the p53 tumor suppressor gene in FISS. In  42.5%  (17/40), 
tumor cell nuclei were stained darkly; in 20.0% (8/40), tumor nuclei were stained palely; 
and in 37.5%  (15/40), tumor nuclei were unstained by IH C . This suggests mutations of 
the p53 gene may play a role in the pathogenesis o f these tumors. Further investigation 
by the U niversity o f Minnesota found point mutations in p53 to be relatively rare in FISS 
and only one o f the 20 tumors examined actually harbored the mutation. When these 
researchers compared matched sets o f tumors and blood samples by automated DNA 
sequence analysis, they demonstrated a loss o f heterozygosity at p53 in 39% o f cases. 
This loss had a significant association with increased tumor size. (B aneiji, 2006). 
Research at the U niversity o f Pennsylvania revealed that FISS exhibit a m ild to strong 
positive staining for platelet-derived growth factor (PD G F), whereas N FISS have a 
negative or faint positive reaction. Further, lymphocytes in FISS were positive for PDGF 
but lymphocytes in normal lymph nodes and Peyer's patches were negative. 
Macrophages in the area stained positive for PDGF receptor. Hendrick et al. surmised 
that lymphocytes in vaccine-associated lesions may secrete PDGF to recruit 
macrophages, and thereby cause fibroblast proliferation as a collateral effect. 
Researchers at the U niversity o f Pennsylvania also identified overexpression o f c-jun, a 
proto-oncogene. This gene codes for the transcriptional protein A P-1, w hich is critical to 
cellular proliferation. Further investigation is ongoing to characterize the resident 
intratumoral and peritumoral leukocyte population including lineage (T  or B ) and subset 
(CD4 vs. CD8, T hI v s . Th2). Wound healing cytokines such as transforming growth 
factor- beta and acidic fibroblast growth factor and basis fibroblast growth factor are 
released by the inflammatory cells and are involved in excessive wound healing response. 
(Martano, 2011) A lso, the c-K it receptor has been identified to be upregulated in FISS. 
(Smith, 2009)
The concept o f tumor development secondary to inflammation and wounding is 
not new. In  fact, many such examples can be found in the human literature including 
tumors associated with m etallic im plants, soft tissue sarcomas associated with aluminum 
oxide hip implants, and angiosarcomas associated with foreign body material. The 
veterinary literature also provides examples, including esophageal sarcomas associated 
with Spirocerca lupi in  dogs, post-traumatic ocular sarcomas in cats which are 
histologically sim ilar to FIS S , fracture associated sarcomas, and radiation-induced 
osteosarcomas. Solitary case reports include a liposarcoma associated with a glass 
foreign body and an osteosarcoma associated with total hip arthroplasty.
Another focus o f research has been in the prevention o f FISS tumor development. 
W ork done in chickens infected with the Rous Sarcoma virus indicated that if  the post- 
wounding inflammation was inhibited, tumor development was also inhibited.
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Investigators concluded that inflamm atory mediators play a critical role in providing the 
ideal environment for oncogene integration and activation that leads to tumor 
development.
Diagnostic and Therapeutic Considerations: M any investigators have focused 
on the diagnostic and therapeutic aspects o f this tumor. Veterinarians at the U niversity o f 
Califom ia-D avis set out to assess the use o f advanced im aging in diagnosis and treatment 
planning. This group used computed tomography (C T ) to evaluate cats with presumed 
FISS prior to treatment. These C T scans revealed a larger area o f involvem ent detected 
by contrast-enhanced C T as compared to the pre-contrast images. These investigators 
surmised that FISS are highly aggressive from the onset, are not impeded by fascial 
planes, and affect m ultiple muscle groups at the time o f diagnosis (M cEntee, M , personal 
communication, V CS 19th Annual Conference, 1999). This study supports the 
importance o f advanced im aging to determine the extent o f surgery and/or the size o f the 
radiation field needed for optimal treatment.
Optimum treatment for FISS  is still under investigation. We now know that 
aggressive first surgical excision provides the best chance for a cure. Hershey et al 
(2000) examined 61 FIS S  cases treated with surgical excision alone and learned that 
radical first excision yielded significantly longer median time to first recurrence (325 
days) than did m arginal first excision (79 days). This study also concluded that cats with 
tumors located on the lim bs had a longer median time to first recurrence (325 days) than 
cats with tumors located at other sites (66 days). W hile it is  important to note these 
differences, it is also vital to realize that only 13.8%  o f these cats had longer than 2-year 
survival. This study therefore emphasizes the need for effective adjunctive therapy.
The importance o f adjunctive therapy such as radiation and chemotherapy has 
also been evaluated. Cronin et a l (1998) examined 33 cases treated with radiation 
therapy follow ed by surgery. This retrospective analysis found the only variable that 
influenced treatment success was the presence o f tumor cells at the m argin o f resected 
tissue. Kobayashi et al reported on 92 cats treated with preoperative radiation therapy for 
FISS at N CSU. Cats received 48 Gy RTH  in  a total o f 16 radiation fractions, with the 
intended target volum e being the entire gross tumor plus a 3 cm margin o f normal tissue 
in a ll planes. Tumors were excised 2-4 weeks after radiation therapy was completed. 
The median time to first event (M TFE -  defined as local recurrence or metastasis) for this 
patient cohort was 587 days, and if  the surgical m argins were declared free o f tumor cells 
the M TFE was 986 days vs. 292 days if  m argins were dirty. M etastasis occurred in 
21.7%  and treatment with a com bination o f R T and carboplatin chemotherapy resulted in 
a M TFE o f >986 days. This study confirm s the benefit o f combined m odality therapy for 
FISS. (Kobayashi, 2002)
Cytotoxic chemotherapy agents, including carboplatin, doxorubicin, 
mitoxantrone, cyclophospham ide, ifosfam ide, CCN U , vincristine, and immunotherapy 
with interferon omega have been evaluated by various groups. (Cohen, 2001, Rassnick 
2006, Hampel, 2007, Poirier, 2002) Although sarcomas in cats are not very chemo- 
responsive in general, both partial and complete responses have been seen in FISS. 
Because growth factor signaling pathways through platelet-derived growth factor appear 
to be upregulated in  FIS S , interest in  using specific receptor tyrosine kinase inhibitors is
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being followed with clin ical studies. A study from UW -M adison successfully utilized 
imatanib mesylate (Gleevec) to inhibit PDGF in FISS cell lines in  vitro. Thus far it 
appears that cats can take Gleevec with m inimal adverse consequences, as compared to 
dogs that have potentially lethal hepatotoxicity with the drug. However, no clin ical 
responses have been reported in  FISS. (Katayama, 2004) Other new R T K I agents such as
m asitinib and toceranib may also prove useful.
Unfortunately, complete cures remain unpredictable even with the use o f 
aggressive m ultiple modality treatment. It seems that the best method o f treatment o f 
FISS is prevention by avoiding unnecessary vaccination, and prompt aggressive surgical 
resection o f early lesions. (Martano, 2011)
Prevention and Early Intervention: Current recommendations for vaccination 
may necessitate a change in our thought processes and practice habits. Veterinarians 
have come to appreciate the need for more rational vaccination guidelines and practices. 
The V A FSTF and other organizations such as The Am erican Association o f Feline 
Practitioners and Academy o f Feline M edicine A dvisory Panel on Feline Vaccines have 
advocated proactive changes in standard vaccination protocols. First, no vaccination 
should be given in the interscapular space. Instead, rabies vaccines should be 
administered in the distal aspect of the right hind lim b, the FeLV vaccine should be 
administered in  the distal aspect o f the left hind lim b, and all other vaccines should be 
administered distally in the right shoulder region. These recommendations were made to 
increase the potential for complete resection by lim b amputation. A ll vaccines should be 
administered subcutaneously, as this allow s earlier detection of these growths. (A V M A  
guidelines 2009 http://www.avm a.org/vafstf) Use o f these new injection site guidelines 
has resulted in a shift from forequarter tumor predominance to more distribution over the 
rear legs, which has the potential to allow  for curative intent surgery through amputation.
(Shaw, 2009) .
Another critical question is the appropriate approach to postvaccination masses,
which are most likely  benign. Some types o f rabies and FeLV vaccines have been 
associated with postvaccinal reaction masses in 100% o f vaccinated cases. Fortunately, 
most o f these masses resolve by two to three months postvaccination. The current 
recommendation, developed by the V A FSTF, for dealing with vaccination site reactions 
is to record the anatomic location, shape, and size o f a ll masses that occur at the site o f an 
injection. The group also recommends that a ll masses that develop in an injection site be 
managed as if  malignant until proven otherwise. A  diagnostic biopsy should be 
performed if  the lesion persists for longer than 3 months post-injection, is larger than 2 
cm in diameter, or is increasing in size beyond one month post-injection. A ll biopsies 
should be performed in such a way that subsequent surgical removal o f the biopsy site 
and tract w ill not be hindered. (V A FSTS Roundtable, JA V M A  2005) Once a FISS has 
been confirm ed, a consultation with an oncologist for current treatment recommendations 
is critical to optim ize treatment planning. Adequate diagnostic assessment combined 
with m ultiple m odality therapy currently provides optimum chance for cure or long-term 
rem ission o f these difficult and life  threatening tumors (Table 1 and Table 2).
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Table 1: Current guidelines for the diagnosis o f suspected sarcomas.8
Diagnosis
1. Accurately record location, shape, and size o f a ll masses that occur at injection sites.
2. Assume a ll masses that occur at injection sites are malignant until proven otherwise. 
Further diagnostics and management are indicated if:
• The mass persists for more than 3 months follow ing injection.
• The mass is greater than 2cm in diameter.
• The mass is increasing in size beyond one month post-injection.
3. If  a mass displays any one o f the criteria listed above, a diagnostic biopsy should be
performed without com promising future definitive therapy. Fine needle aspiration 
cytology is  considered unreliable in  the diagnosis o f FISS.________________________
a This inform ation is adapted from the current recommendations o f the Vaccine 
Associated Feline Sarcoma Task Force Guidelines.
Table 2: Current guidelines for the treatment of suspected sarcomas.b
T re a tm e n t
1. Complete staging including pre-operative lab tests and thoracic radiographs should be 
performed.
2. For optimal outcome, FISS should have advanced im aging such as computed 
tomography (C T ) or magnetic resonance im aging (M R I) performed for therapeutic 
planning.
3. Never “shell out” a sarcoma. Incom plete surgical rem oval can result in  treatment 
failure.
4. Consultation with an oncologist w ill aid in the initiation o f optimal treatment 
planning, which may include m ulti-m odality therapy.
5. Submit the entire specimen for histopathology.
6. Report a ll histologically confirm ed FISS  to the manufacturer and to U .S. 
Pharmacopeia Veterianry Practitioners’ Reporting Program. (1-800-487-7776)______
b This inform ation is adapted from the current recommendations o f the Vaccine 
Associated Feline Sarcoma Task Force G uidelines.
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Managing Feline Carcinomas
Barbara E. Kitchell, DVM, P hD ., DACVIM
Carcinom as arise in cells o f ectodermal and endodermal embryonic origin. These cells 
have the propensity to malignant transformation because they contain cells with high 
replicative rates throughout the lifetim e o f the anim al, and also because these cells are on 
the “front line” o f environmental carcinogen exposure. Epithelial cells are protected 
against malignant transformation by a lifestyle that include the capacity for transformed 
cells to slough away under physiologic conditions. However, when carcinogenic hits 
occur to progenitor cells in the basal layers o f skin, gut, airway, or urinary system, cells 
may proliferate inappropriately to form a carcinoma. Carcinom as are known to undergo 
successive m olecular injuries to progress from induced cells with a prim ary carcinogenic 
injury, to adenomas to carcinomas in situ and ultim ately to invasive and metastatic 
carcinoma. These m alignancies are relatively common in  cats.
Feline mammary tumors - Mammary tumors represent the third most common feline 
tumor, after lesions o f the skin and lymphomas. Mammary tumors are seen in both 
female and male cats. Progesterone may play a larger role in mammary carcinogenesis in 
cats than in the dog, as cats are known to develop carcinomas o f mammary tissue after 
exposure to pharmaceutical forms o f progestational agents administered for estrus control 
or behavioral issues. In  queens, cats ovariectom ized at 6 months to one year o f age were 
up to seven times less likely to develop mammary carcinomas than cats that were 
unspayed. Mammary tumors in cats with an overall more aggressive biologic behavior 
than the disease seen in dogs. When a mammary mass develops in a feline patient, it is 
80-90% lik e ly  to be malignant, with the m ajority o f these tumors being adenocarcinomas. 
Feline mammary tumors are characterized as being tubular, papillary, solid or cribriform  
types. Other histologies are more rare. Inflam m atory carcinoma, though rare, can occur 
in cats and carry an extremely grave prognosis. Median age at onset is 10-12 years, and 
Siamese cats have an increased risk o f mammary tumor development, with an earlier age 
at onset than other breeds. Mammary carcinom a cells from cats are more likely  to express 
progesterone receptors than are dogs or humans. Most feline mammary cancers are 
locally invasive and have lymphatic infiltration and ulceration may be a feature o f these 
tumors. Size o f tumor is prognostic, in that cats w ith sm aller tumors have longer disease- 
free intervals and survival times.
In  cats, surgical excision is the treatment o f choice for local control. U ni- or bilateral 
radical mastectomy has been demonstrated to lead to longer disease-free intervals but not 
necessarily longer overall survival times. Cats frequently develop local recurrence after 
mastectomy; it is not uncommon to manage these by m ultiple surgeries before eventual 
metastasis.
D oxorubicin and cyclophosphamide have been demonstrated to be effective as an 
adjuvant therapy to palliate advanced mammary carcinoma in one third to one h a lf o f 
treated cats. One study reported a M edian survival time o f 448 days and 1 and 2 year 
survival rates o f approxim ately 60 and 38% , respectively, in 67 cats treated with 1 mg/kg 
doxorubicin every 21 days for 5 treatments. We have found roughly equivalent rates o f
disease regression for cats treated with mitoxantrone or carboplatin for mammary tumors. 
Note that fluorouracil is contraindicated for use in cats because of fatal 
neurotoxicity; the FA C protocol is indicated for canine use only.
Oral Tumors In  the cat, the oral location accounts for 3%  to 10% o f a ll cancers. In  the 
dog, malignant melanoma and squamous cell carcinoma o f the mouth are the most 
common presentations. In  cats, 75%  o f feline oral neoplasias are squamous cell 
carcinoma. Lingual tumors are most lik e ly  squamous cell carcinom a in the cat. 
Fibrosarcom as are the next most common, accounting for roughly 20% o f m alignancies. 
Other oral malignant tumors seen in cats include adenocarcinomas, fibrosarcom as, 
hemangiosarcomas, lymphomas, and melanoma. Odontogenic tumors are rare in the cat, 
but have been seen. Benign inflam m atory lesions such as polyps may be confused with 
neoplastic lesions, so biopsy is essential for accurate diagnosis. The most obvious rule- 
outs for oral sw elling are tumor or infection.
Although the etiology o f oral tumors rem ains largely unknown, several risk  factors have 
been identified in  the cat. R isk factors include use o f flea control collars, diet, and 
potentially exposure to environmental tobacco smoke. In  fact the latter may associated 
w ith p53 mutations and over-expression o f the mutated form o f the gene. C lin ica l signs 
associated with oral tumors include inappetance, difficulty in prehending or m asticating 
food, dysphagia, ptyalism , halitosis, nasal discharge or oral hemorrhage. Unfortunately, 
anim als often hide their signs and may be diagnosed with oral tumors when they are in an 
advanced state. Careful oral exam ination might reveal a mass, but occasionally incidental 
tumors are noted in the course o f routine dentistry. Diagnostic radiographs should be 
taken under anesthesia, to determine the extent o f boney involvem ent and the potential 
for resectability. Fine detail dental radiographs are helpful for lesion on the rostral 
mandible or m axilla, but more caudal and m axillary tumors are best imaged with 
computed tomography or magnetic resonance images. A  biopsy is in order, because o f 
the potential for radical therapy w ith surgery or radiation therapy for cancer vs. long-term 
antibiotic or antifungal therapy for osteom yelitis o f the mandible. W ithrow recommends 
a large incisional biopsy because o f the potential for m isdiagnosis. Most oral masses are 
infected, inflam ed, or necrotic. Scalpel biopsy instead o f electrocautery is recommended 
because the potential for distortion o f the sample by electrocautery. Specimens should be 
taken from the center and the edges o f the mass to increase diagnostic yield. The biopsy 
site should be situated such that the tract can be removed at the time o f definitive surgery. 
A s a general rule, the biopsy should be obtained through the labial mucosa and not 
through the skin, in order to preserve the latter for facial reconstruction. Culture for 
bacterial organisms may not be fruitfu l, as the oral cavity is a contaminated site. Careful 
examination and palpation o f regional nodes and tonsils is important for staging. Fine 
needle aspirates o f nodes for cytology, or node excision for biopsy should be considered 
in the case o f enlarged nodes that may be infiltrated with cancer cells or m erely reactive, 
inflamm atory nodes because o f a necrotic and infected oral mass. Thoracic radiographs 
for detecting metastatic disease in the lungs is appropriate, but the potential for system ic 
dissem ination o f oral squamous cell carcinom a is very low.
Treatment options -Most oral tumors are treated by a local form o f therapy, such as
surgical excision, radiation therapy or cryosurgery. Radical surgeries, such as 
mandibulectomy, are the most economical, fastest and potentially most curative 
m odalities. Unfortunately, for most malignant SCC lesions the 2-3 cm margins o f normal 
tissue recommended to prevent local recurrence is d ifficult if  not im possible to attain. 
W ithrow, in his chapter on oral neoplasia in Withrow and MacEwen, recommends the 
widest possible margins for feline squamous cell carcinoma, because o f the extremely 
high local recurrence rate. Thus, many feline squamous cell lesions are non-resectable. 
Radiation therapy may be useful for at least palliating non-resectable tumors, or for 
elim inating residual disease when the tumors have been incom pletely resected. Radiation 
therapy is rarely curative alone. Hyperfractionation or accelerated fractionation schemes 
for the delivery o f radiation therapy to these tumors is currently being investigated. 
Hypo-fractionated radiation therapy has shown lim ited efficacy in feline oral tumors, 
inducing non-durable responses. Systemic chemotherapy has not been effective in local 
control o f oral m alignancy. Piroxicam  may be used in SCCs as a single agent, providing 
symptomatic treatment and potentially partial rem issions. Gemcitabine or carboplatin 
may be added as radiosensitizers. Most recently aminobisphosphonates such as 
pamidronate 2 mg/kg IV in a 2-hour saline infusion every 28 days, have been applied to 
feline oral tumor patients to mitigate the bone invasive nature o f oral SCC. W ith 
standard fractionation or hyperfractionation schemes, increased survival duration requires 
the use o f the endoscopic or percutaneously placed esophageal or gastrostomy feeding 
tube (PEG  tubes). These tubes allow  cats to be nutritionally managed with ease, allow ing 
for longer survivals in the situation o f poorly responsive oral m alignancy.
Salivary gland tumors are observed in cats, and most particularly in Siamese cats. 
Median age at onset is 12 years. Cats present with non-painful sw ellings in the region o f 
the salivary gland that are often invasive and fixed to underlying tissues. Cats may have 
metastasis and advanced disease at time o f diagnosis. Radiation therapy and 
chemotherapy with doxorubicin or carboplatin and gemcitabine may offer some benefit 
to patients with metastatic disease or as an adjunctive therapy to surgery and radiation. 
Median survival time has been reported to be 516 days for cats with salivary carcinoma.
Feline nasal tumors - C ats also  in cu r carcinom atous nasal tum ors, although not as 
com m only as dogs. R ad iatio n  therapy is  the treatm ent of choice, and the 
p ro b ab ility  of su rv iv a l is  excellent, esp ecially if  the tum or is  o f lym p h o reticular 
o rig in . N asal lym phom a is  m uch m ore com m on than in  nasal ep ith e lia l tum or in  
the cat. Local radio therap y to total fraction doses of greater than 32 gy have been 
associated w ith  com plete d u rab le lo cal control of nasal sin u s lym phom a in  cats. 
System ic chem otherapy m ay be needed fo r dissem inated disease, how ever.
Primary lung tumors are rare in dogs and cats and tend to occur in older anim als. 
Adenoarcinomas are the most prevalent lung tumor. The frequency o f carcinomas has 
been increasing; this may relate to an increasing life  span o f companion anim als or to an 
increased number o f necropsies being performed. Exposure to environmental 
carcinogens, including passive smoking, may influence the rate o f occurrence. These 
lesions may be found incidentally during the course o f thoracic radiography, but cats may 
be symptomatic with dyspnea, cough, lethargy, anorexia, weight loss, and fever. The
lung-digit syndrome is unusual to cats. In  this disease m anifestation, cats are lame and 
have sw elling , paronychia and apparent pododermatitis due to metastasis to nail beds. 
Prim ary lung tumors may be solitary, but these lesions are also prone to intrapulmonary 
metastasis. In  this scenario a larger mass is found in association with m ultiple sm aller 
masses distributed throughout the lung fields. IT  has been reported that more than 75%  
o f feline pulmonary carcinom as are metastatic at the time o f diagnosis. Lesions may be 
associated with pleural effusion due to breaking through the pleural surfaces. Tracheal 
bronchial or perihilar node involvem ent may be o f sm all size, and this dissem ination, 
along with very sm all intrapulm onary metastasis, may be bested detected by pulmonary 
C T scans. Fine needle aspiration cytology is not recommended for solitary lesions, as 
this may compromise complete surgical excision, but FN A is often used in  cases o f 
m ulticentric disease not amenable to surgical resection. Prim ary lung lesions are 
norm ally treated w ith surgical excision via complete or partial lobectomy. Carcinom as o f 
the thoracic cavity, including carcinoma metastatic to lung and pulm onary carcinomas 
that are non-resectable, can be treated with chemotherapy. A  variety o f agents may show 
lim ited efficacy, including: doxorubicin; cisplatin; carboplatin; or with agents such as 
gemcitabine and the taxanes. Dose escalation studies o f gem citibine single agent 
chemotherapy and carboplatin gem citibine com bination therapy are ongoing. A  new 
version o f vinca alkaloid called vinorelbine (N avelbine) has been used in the cat for the 
treatment o f a variety o f m alignancies. Vinorelbine is particularly interesting for 
treatment o f lung cancers as it has been reported to 14 times greater pulmonary 
concemtrations than other vinca alkaloids. Doses have ranged from 7.5 to 9.0 mg/m2 
administered as a rapid intravenous bolus, on a 5 weeks on, one week o ff schedule o f 
adm inistration. Piroxicam  or m eloxicam  N SA ID  therapy may have some anti-angiogenic 
and analgesic affect and thus are often used adjunctively to other therapies for pulmonary 
carcinoma.
Carcinomas of the gastrointestinal system - Most tumors o f the stomach, intestine and 
colon in cats are lymphomatous, but carcinomas can be seen. G astric carcinomas are 
vanishingly rare in cats, but intestinal carcinomas may be seen and have a breed 
predisposition for Siamese cats. Sm all intestinal adenomatous polyps have been 
identified in the cat. Lesions may arise at the ileocecocolic junction with some degree o f 
frequency, and metastasis to mesenteric nodes is common. Even w ith nodal involvem ent, 
intestinal carcinom a cases in cats should be managed by surgical resection and long 
survivals (5-15 months) have been reported from surgery alone. Intestinal carcinoma 
lesions are reported to be metastatic to nodes in 50% o f cats, to the mesenteric surfaces in 
30% (carcinom atosis) and to the lung in 20% o f cases. Chemotherapy may not be helpful 
for a ll cases, but survival benefit has been noted for some cats w ith metastatic 
carcinomas. D oxorubicin, carboplatin, gem citibine, and vinorelbine have been 
administered. Intracavitary carboplatin has been used to treat cases w ith abdominal 
carcinom atosis.
Although the incidence o f colorectal and perianal neoplasia in feline patients is 
relatively low , the location o f these neoplasms provides unique challenges with 
respect to therapy. In  general, the tumor types found in  colorectal cancers o f the 
dog and cat are the same histologically as those found in sm all intestinal
neoplasia in  these species, and include adenocarcinoma, leiomyoma and 
leiomyosarcoma, and lymphosarcoma. History and clin ical signs associated with 
colorectal neoplasia in the dog and cat include anorexia, weight loss, vom iting, 
diarrhea, hematochezia, tenesmus, and dyschezia. Tumors o f the perianal region 
o f dogs and cats can include any form o f cutaneous tumor, including melanomas, 
mast cell tumors, lymphomas, and squamous cell carcinomas. Several reports 
indicate that rectal or perirectal location in these neoplasms, particularly mast cell 
tumors and melanomas, can be associated with more aggressive biologic behavior 
o f the tumors. Perianal adenomas and adenocarcinomas are not commonly found 
in the cat, although rare cases have been reported.
Anal sac apocrine gland adenocarcinoma is rare in cats but has a highly malignant 
behavior, with an invasive and ulcerative local involvem ent that makes surgical 
resection particularly challenging in cats, and early metastasis to the sublumbar 
and ilia c  lymph nodes. Hypercalcem ia is rarely a feature o f this neoplasm in the 
cat, and arises due to production o f a parathyroid-related protein (PTH rp) that 
induces hypercalcem ia and hypophosphatemia. Although surgical excision o f the 
prim ary tumor is recommended, surgery is often d ifficult due to the size o f the 
tumor and its invasiveness. Com plications include fecal incontinence, wound 
infection, and sepsis. Local excision followed by adjuvant radiation therapy is 
recommended, with sublumbar lymph nodes included in the radiation field. 
Chemotherapeutic strategies to control distant metastases have included the use 
o f doxorubicin, actinom ycin D and carboplatin can also be employed as palliative 
therapy for relatively long-term control.
Bladder tumors comprise less than 2 % of a ll feline m alignancies. It is more 
common in the dog than the cat, and in the cat the tumor is seen in very geriatric 
individuals with a male predominance. C lin ical signs most often associated with 
bladder tumors include hematuria, pollakiuria, and stranguria. Other clin ical signs 
include polyuria, polydipsia, urinary incontinence, urinary obstruction, abdominal 
pain, tenesmus, ribbon-like stool, and lethargy. Bladder tumors may be 
sym ptom atically sim ilar to feline lower urinary tract disease, and thus cats with 
recurrent or non-rem itting signs should be evaluated w ith diagnostic imaging. 
Physical exam findings may reveal caudal abdominal mass, bladder distention or 
obstruction, abdominal pain, and weakness. Most often, routine blood work and 
physical exam ination are normal and the bladder mass cannot be detected by 
abdominal palpation. U rinalysis may often be consistent with a bacterial cystitis 
(bacteruria, pyuria, hematuria, and proteinuria). Neoplastic cells can be identified 
in the urine sediment. There can be over interpretation o f the criteria o f 
malignancy in  cells in  the urine sediment as inflamm ation by itse lf can cause 
changes that closely m im ic m alignancy. Secondary bacterial infection may 
confound the diagnosis, and there is often reported an in itia l response to antibiotic 
therapy follow ed by a return o f the clin ical signs when antibiotic therapy ceases. 
This is a particularly troublesome finding in  the cat as they are less prone than 
dogs to bacterial U T Is and any recurrent bladder infection bears investigation in 
this species. Radiography is a valuable tool in  the diagnosis o f bladder tumors.
Plain radiographs o f the abdomen usually do not provide the diagnosis, however, 
positive and negative contrast cystograms readily identify mucosal irregularities, 
fillin g  defects, and masses. Bladder tumor lesions in the cat tend not to be 
localized to the trigone, in contrast to the common canine presentation. 
Ultrasound can be used as a diagnostic tool to look for bladder masses as w ell as 
evaluate the kidneys for evidence o f hydroneprhosis, ureters, and sublumbar 
lymph nodes for metastatic disease. Further, masses w ithin the bladder can be 
easily measured at each ultrasound and used to evaluate response to treatment. 
Intraveneous urograms are often not necessary to diagnose bladder masses unless 
urethral obstruction prevents urinary catheter passage. Itis estimated that 20% o f 
dogs w ith TC C  have metastasis at the time o f diagnosis, although this metastasis 
may be confined to sublumbar lymph nodes, w hile metastasis is more rare in the 
cat. Thoracic radiographs to detect evidence o f lung metastasis should be 
performed at the time o f diagnosis. Most typical patterns o f pulm onary metastasis 
seen w ith TC C  are interstitial nodular and diffuse interstitial patterns. W hile 
much can be gained from perform ing the above diagnostic tests, the final 
diagnostic step should include biopsy. Biopsy can be obtained by cystoscopy, 
traumatic catheterization, or cystotomy via  laparotomy. Surgical resection, if  
possible, is the treatment o f choice and can be curative for sm all tumors located 
distant to the trigone. Feline tumors are more amenable to surgical resection than 
are canine tumors. Ifthe cancer is located in the apex o f the bladder, a very wide 
ful 1-thickness partial cystectomy may be attempted. More than 80% o f the 
bladder can be removed with eventual return to normal function and capacity. 
Even if  surgical resection is possible, most patients w ill have local recurrence or 
m etastsis w ithin one year. Piroxicam  or m eloxicam  are nonsteroidal anti­
inflam m atory agent that acts as a non-selective cyclooygenase inhibitors. Use o f 
these agents may provide some anti-tum or and anti-angiogenic effect and 
palliative analgesia. The mechanism o f anti-tum or activity is thought to be 
blockade o f PGE2-mediated im m unosuppression, but there is also some evidence 
to support cyclooxygenase-2 signaling as a direct growth stim ulant to urothelial 
cells. This effect has not been w ell studied in  the setting o f feline TCC. 
Doxorubicin, mitoxantrone, carboplatin and gem citibine have a ll been used to 
treat feline TC C  with lim ited success. There are few reports on the effectiveness 
o f radiation therapy use in the control o f bladder tumors in cats.
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Feline Cutaneous Neoplasms
Barbara E. Kitchell, DVM, Ph.D., DACVIM
C ats are vu ln erab le to the developm ent o f sk in  tum ors, as are other species. The 
sk in  is  at ris k  fo r carcinogenesis because o f its co n tin u ally  rep lica tin g  pattern of 
ce ll grow th, and because of its lo cation as a p rim ary b a rrie r against 
environm ental carcinogenesis. S kin  tum ors m ay arise from  any ce ll re sid in g  in  
the sk in  and subcutaneous tissues, and therefore m ay be e p ith e lia l, 
m esenchym al, m elanocytic, or ro un d  ce ll in  nature. M ast ce ll tum ors are 
d iscussed  elsew here. The frequency of fe lin e  cutaneous tum ors has been 
reported to be ranked as fo llo w s: Basal ce ll tum or (15-26% , of w h ich  1% are 
reported to be m alignant carcinom as); M ast ce ll tum or (13-21% ) Squam ous ce ll 
carcinom a (10-15% ); Fibrosarcom a (15-17% ); sebaceous adenom a (2-4% ); Fibrom a 
(3% ); A po crine adenocarcinom a (3-5% ) w ith  a ll other lesio ns being less 
prevalen t. The tendency fo r cats to develop cutaneous m alignancies m eans that 
any m ass le sio n  in  a cat sho uld  be investig ated vig o ro u sly.
C utaneous tum ors is  u su a lly  re a d ily  id e n tifie d  on p h ysical exam ination due to 
th e ir surface location. O w ners m ay id e n tify  m asses, non-healing w ounds, 
u lce ratio n  o r scabbing at the site o f a sk in  tum or in  cats. Body m aps are m ade to 
facilitate  trackin g  benign sk in  lesio n s o ver tim e. A ny m asses in  the sk in  sh o uld  
be m easured, aspirated, and recorded on a body m ap to serve as an objective 
record of the lesio ns. T h is w ay, ad d itio n al lesio n s or changes in  p re-existin g  
lesio n s can be noted on sequential ve terin ary v is its  o ver tim e. C ytology a n d /o r 
b io p sy are indicated fo r m asses that are g ro w ing , changing in  appearance or are 
n ew ly id en tified . B iopsy m ay be in cisio n a l o r excisio n al, depending on size and 
lo cation of the m ass. Fo r som e lesio n s, im m unohistochem ical stain in g  and m ore 
precise h isto lo g ic assessm ent of grow th rate (intratum oral necrosis, m itotic 
in d ex, p ro life ra tio n  m arkers) are req u ire d  to fu lly  characterize the sk in  tum or.
F o r m ost cutaneous lesio ns, su rg ica l excisio n  is  the appropriate therapy. Fo r 
m u lticen tric lesio ns, biopsy fo r d iag n o sis fo llo w ed  by topical o r system ic therapy 
m ay be m ore appropriate. T o p ical im m unostim ulatory therapy w ith  im iquim od 
m ay be u sefu l fo r treatm ent of su p e rfic ia l squam ous ce ll carcinom a, as m ay 
stro ntium  90 plesiotherapy o r cryotherapy. Basal ce ll tum ors are com m on but 
g e n erally not threatening and m ay be resected if  they are bothering the cat o r at 
the o w n er's d iscretio n. T h is h isto lo g ic designate m ay encom pass several types of 
e p ith e lia l tum ors, in clu d in g  c e ll of ep iderm al, fo llic u la r, and adnexal o rig in . 
Trichoblastom as are often classed as basal ce ll tum ors. Basal ce ll carcinom as are 
characterized by a p red isp o sitio n  to lym p h atic spread that occurs e a rly  in  the 
course o f the disease. W ide su rg ica l excisio n  o f lo cal tum or along w ith  d ra in in g  
lym p h atics and affected nodes can be cu ra tive  for these lesions. Sebaceous 
adneom as and adenocarcinom as are m uch m ore rare than are basal ce ll tum ors,
but are sim ila rly  m anaged w hen they are encountered. A p o crin e gland tum ors 
are found in  the anal sac of cats, and also  in  the foot pads. These tum ors are 
associated w ith  an in v a siv e  b io lo g y and ra p id  m etastasis as seen in  dogs.
Squam ous ce ll carcinom a is  a com m on sk in  m alignancy in  cats and can arise 
from  excess exposure to su n lig h t (actin ic S C C ), w h ich  is  seen in  cats that lack 
pigm ent on the eartip s, eyelid s, nasal planum , and p re -a u ricu la r regions of the 
face. These lesio ns ty p ica lly  o ccur in  outdoor cats in  h ig h ly  su n n y areas, such as 
the Southern US o r in  m ountain reg io ns. These lesio n s m ay be preceded by fla k y  
sk in  w ith  an inflam m atory appearance, and it is  not uncom m on fo r clien ts to 
o rig in a l attribute the lesio n s to no n-healing cat fig h t in ju rie s. These le sio n s can 
progress to becom e p ro life ra tive  m ass lesio n s o r ero sive, u lce rative  le sio n s that 
can destroy norm al tissue architecture. A ctin ic S C C  m ay be m etastatic to lym p h  
nodes w hen in  an advanced stage, but in  general the m ost sig n ifica n t problem s 
associated w ith  these le sio n s are lo cal disease progression. A n im als w ith  chro nic 
actin ic S C C  m ay have elevated serum  g lo b u lin  le vels, but the lab  w o rk is  
otherw ise unrem arkable. D iffe re n tia ls in clu d e  in fectio n w ith  fu n g al organism s, 
non-healing traum atic w ounds, and a ctin ic derm al hem angiosarcom a or 
hem angiom a that arises in  the sam e lo cation. . T herapy fo r actin ic S C C  is  
su rg ica l w hen po ssib le, and can in clu d e  pinnectom y either th e rap e u tically  or 
p ro p h y la ctica lly  in  the case of a ctin ic kerato sis, as w e ll as resection o f the nasal 
planum . Im iq u im o d  cream  m ay be h e lp fu l as a to p ical inm m unotherapeutic 
agent fo r su p e rfic ia l S C C  le sio n s, but th is agent can cause cru stin ess, sca b b in g , 
and discom fort in  the treated cats thro ugh the a b ility  o f the d ru g  to re cru it a 
m acrophagic inflam m atory response. C ox-2 in h ib itio n  w ith  agents such as 
p iro xicam  or m eloxicam  can be p a llia tiv e  fo r p ain , anti-inflam m ato ry, an ti- 
angiogenic, and in  ra re  cases m ay a ctu a lly  fa cilita te  rem issio n  o f the S C C  ce lls 
them selves. Laser ablatio n, and electro n or photon rad io th erap y can also  be 
used to con trol these lesio n s. S tron tium  90 p lesio therapy w ith  a lo ca l ra d ia tio n  
ap p licato r has been successful in  treatin g  cats w ith  SCC . In ve stig a tio n a lly , 
in trale sio n a l chem otherapy u sin g  a p u rifie d  bo vin e collagen-based rep o sito l 
d e liv e ry  system  fo r treatm ent w ith  5-FU  and cisp la tin  p ro ved  efficacio u s in  85% 
o f cats treated, but th is agent is  not com m ercially availab le. U sin g  free 5-FU  or 
c isp la tin  is  con traindicated in  cats due to p o ten tia lly  lethal n euro lo g ic and 
pulm o nary to xicities, resp ective ly. In je ctio n  of carb o p latin  o r bleom ycin d ire ctly  
in to  the lesio n s is  tolerable but efficacy is  not as successful as w ith  the tim e- 
release collagen d e liv e ry  ve h icle.
M u lticen tric squam ous ce ll carcinom a in  situ  (fe lin e B ow en's d isease) is  a form  of 
SC C  that arises in  h aire d  sk in  and is  associated w ith  p a p illo m a viru s in fectio n  in  
cats. These lesio n s are ty p ica lly  crusted  and ve ry  su p e rficia l. They can a rise  at 
any lo cation over the cat's body and are not associated w ith  su n lig h t exposure. 
The lesio n s are id e n tifie d  by the fact that they do not in vad e the ep iderm al
basem ent m em brane. P a p illo m a viru s D N A  has been id en tified  in  these lesions. 
Bow en's disease lesio n s are ty p ica lly  treated w ith  a course of im iquom od 
(A ld ara) therapy and w ill reso lve over several w eeks as the p a p illo m a viru s 
antigen is  recognized by im m une ce lls that hom e to the site of inflam m ation 
caused by the agent. P lesio therapy w ith  strontium  90, in trale sio n a l 
chem otherapy, and su rg ica l resection can also be h e lp fu l fo r these lesio ns. N a il 
bed (p aro n ych ial) tum ors in  cats are m ost lik e ly  SCC , although cats also suffer 
from  a d ig it-lu n g  syndrom e w h erein  the p rim ary pulm onary carcinom a 
colonized the p aro n ych ial va scu la r or lym phatic plexus to create m ulticen tric 
m ass lesions. P rim ary d ig ita l S C C  of cats w arrants a guarded pro g no sis, w ith  
m edian su rv iv a l tim e of approxim ately 3 m onths despite d ig ita l am putation. 
P rim ary n a il bed SC C  is  u su a lly  so lita ry  w h ile  lu n g -d ig it syndrom e affects 
m u ltip le  toes.
Melanoma -  M ost cats are not p a rticu la rly  subject to occurrence of derm al 
m elanom a, although u ve al m elanom a can be problem atic fo r som e anim als. 
B iologic behavio r of these lesio n s in  cats is  som ew hat unpredictable. These 
lesio ns can be m etastatic although som e benign lesions do arise. In  a stu d y of 45 
cats w ith  cutaneous m elanom a treated by surgery, m ost (2 2 /4 5) cats that died 
d u rin g  the stud y had lo cal recurrence, w h ile  16 cats have m etastasis.
C ats are ra re ly  affected by derm al plasm a ce ll tum ors or h istio cytic tum ors. 
C utaneous lym phosarcom a is  noted in  cats, and can respond favo rab ly to 
standard of care chem otherapy w ith  a CH O P-based protocol.
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Supportive Care for the Feline Patient w ith Cancer
Cheryl Balkman, DVM 
July 30, 2011
Common clinical signs associated with variety of cancers
•  Anorexia or decreased appetite
•  Vomiting
•  Diarrhea
•  Weight loss
Management of these clinical signs will best be accomplished by treating the underlying disease but in 
some cases prior to obtaining a definitive diagnosis or while initiating appropriate therapy supportive 
care is necessary to  allow the patient the best possible chance of recovery. These clinical signs can also 
be associated with cancer therapy. This brief overview will address some common issues associated the 
treating cats with cancer.
Appetite
Anorexia and hyporexia (reduction in appetite rather than total loss) can be due to many causes such as:
•  Pain associated with eating or chronic pain associated with tumors elsewhere in the 
body
•  Anosmia associated with nasal tumors
•  Concurrent respiratory disease/dyspnea
•  Nausea -  primary disease associated or treatm ent associated (chemotherapy/radiation)
•  Decreased appetite associated with inflammatory cytokines secondary to a neoplastic 
condition (IL-1, IL-6, TNF-alpha and others)
Appetite and satiety are controlled by complex interactions between the central nervous system, the 
gastrointestinal tract, and environmental factors.
Neurotransmitters controlling appetite
•  Stimulatory
o Norepinephrine through alpha2- adrenergic receptors 
o Dopamine through D1 receptors
• Inhibitory
o Serotonin (5-HT) 
o Dopamine
o Catecholemines through beta-adrenergic receptors
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Appetite stimulants
Appetite stimulants can be tried in clinically stable patients that have a decreased appetite but are still 
eating. W e often use them  in patients that have a decreased appetite associated w ith chemotherapy 
administration.
Cyproheptadine
•  Antihistamine w ith antiserotonin properties
•  Inhibits serotoninergic receptors that control appetite
•  Oral bioavailability -1 0 0 % , elimination half-life 13 hours
•  Dosage: % to  Vi o f 4mg tablet per cat SID-BID PO
Mirtazapine
•  Significant anti-nausea, anti-em etic, and appetite stimulating properties
•  Presynaptic alpha2-adrenergic receptor antagonist
•  Increases noradrenergic and serotonergic neurotransmission by blocking presynaptic 
inhibitory receptors, resulting in increased norepinephrine release into the synaptic cleft 
and increasing postsynaptic availability
•  Serotonergic effects occur through 5-HT1 receptor-like activity as well as enhancement 
of serotonergic transmission by norepinephrine
•  Potent postsynaptic 5-HT3 and 5-HT2 antagonist
•  Dosage: 1 /8  - 1 / 4  o f 15mg tablet (1.88mg -  3.75mg) PO every 3 days
•  Drug half-life o f 1.88mg dose -  approximately 9 hours
•  Drug could theoretically be given daily to healthy young cats based on the short half life
and the limited pharmacokinetic/pharmacodynamic studies available. Studies on
geriatric or clinically ill cats have not been published to date.
Feeding tubes
Feeding tubes are recommended for patients that have complete anorexia or a chronic history of 
hyporexia and a treatable form o f cancer. It is especially im portant for patients that will be receiving 
therapy that may cause or exacerbate a poor appetite (chemotherapy, radiation therapy).
Types of feeding tubes:
•  Nasoesophageal(NE)tubes
•  Esophagostomy (E) tubes
•  Gastrostomy (G) tubes
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Nasoesophageal (NE) Tubes:
•  Short term  nutritional support (<14 days) or for patients that are not candidates for 
general anesthesia
•  Easy to place, inexpensive
•  Should not be placed in patients that are vomiting or have a decreased gag reflex
•  Small diam eter limits diet selection to liquid enteral formulas
•  Radiographic confirmation of proper placement essential
•  Complications
o Epistaxis 
o Rhinitis
o Tracheal intubation (secondary aspiration pneumonia)
o Tube can be dislodged by coughing, sneezing, vomiting, scratching or pawing (e- 
collar necessary)
Esophagostomy (E) Tubes:
•  Requires general anesthesia
•  Relatively quick procedure
•  Specialized equipment not required
•  Confirmation of correct placement with radiographs essential
•  Can be used for extended period o f tim e (weeks to months or longer in select cases)
•  Tube diam eter allows for wider selection of diets
•  Complications
o Infection at ostomy site 
o Kinking or obstruction of tube 
o Tracheal intubation 
o Vomiting
o Displacement of the tube (especially if patient vomits) 
o Swelling of the head (rare)
Gastrostomy (G) tubes:
•  Requires general anesthesia
•  Can be placed surgically or via endoscope (percutaneous endoscopic gastrostomy) PEG
•  Bypass esophagus
•  Allows for prolonged feeding (although e-tubes have been used for > lyear in some 
patients)
•  Larger bore tube -  increased selection o f foods
•  Complications
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o Cellulitis around ostomy site 
o Gastric pressure necrosis 
o Tube migration 
o Pyloric outflow obstruction 
o Inadvertent tube removal 
o Leaking food around ostomy site 
o Vomiting/secondary aspiration pneumonia
Vom iting
Vomiting can be associated w ith the primary disease process or treatm ent associated. The potential for 
chemotherapy induced vomiting is determ ined by the particular drug, dose and individual sensitivity. 
Typically gastrointestinal side effects of chemotherapy are mild and self limiting and occur 3-5 days after 
administration. Some drugs can cause im m ediate emesis during administration or shortly thereafter.
Pathophysiology o f vomiting:
Vomiting is a reflex initiated by stimulation o f the vomiting (or emetic) center in the medulla oblongata 
of the brain. The vomiting center receives afferent input from  peripheral receptors in viscera, the  
chemoreceptor trigger zone in the floor o f the 4 th ventricle, the vestibular apparatus, and from higher 
centers o f the cerebral cortex.
Complex pathways can trigger vomiting:
Humoral pathway -  initiated by blood borne substances, plays an im portant role in chemotherapy 
induced nausea and vomiting
•  Activation of the chemoreceptor trigger zone (CRTZ) in the area postrema
o Blood brain barrier -  less effective in this area 
o Allows the CRTZ to  be exposed to chemical stimuli found in circulation 
o Chemotherapy, chemotherapy metabolites, other drugs, uremic toxins,
electrolyte, osmolar, and acid-base disorders, other metabolic derangements 
o Feline CRTZ dopaminergic receptors are poorly developed however stimulation 
of alpha2-adrenergic receptors stimulates CRTZ
Neural pathways
•  Afferent vagal
•  Sympathetic
•  Vestibular
•  Glossopharyngeal
•  Cerebrocortical
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Peripheral receptors found throughout the body - can be triggered by directly by chemotherapy drugs or 
indirectly when chemotherapy is causes substances released by peripheral tissues
•  Duodenum contains highest concentrations of these receptors
•  Disease/irritation o f the Gl tract, other abdominal organs, or peritoneum can directly 
stimulate vomiting through vagal afferent pathways
•  Receptors found in kidneys, uterus, urinary bladder send afferent impulses via 
sympathetic nerves
•  Receptors located in the pharynx and tonsillar fossae transmit impulses through afferent 
fibers of the glossopharyngeal nerve
•  CNS disease may directly stimulate the vomiting center through extension of 
inflammatory stimuli, hydrocephalus, or space-occupying lesions
•  Supramedullary receptors may also influence the reactivity of the vomiting center
•  Psychogenic vomiting -  arise from  cerebral cortex and may occur as a result of fear, 
stress, or pain
•  Some chemotherapy drugs may cause a direct release of serotonin from the small 
intestine causing emesis mediated through vagal nerves or direct stimulation of 
centrally located 5-HT3 receptors
•  NK-1 receptors located in the emetic center, chemoreceptor trigger zone, and enteric 
plexus is stimulated by the neurokinin known as substance P resulting in emesis
Mild self limiting nausea/vomiting can be treated conservatively at home by withholding food and water 
for 8 -1 2  hours with or without the administration of anti-emetic drugs, and then slowly introducing 
water and bland, low-fat diet. Subcutaneous fluids can be given to patients that are mildly dehydrated 
or have other underlying metabolic conditions such as renal insufficiency. Anti-emetics can be given 
prophylactically to patients with a known sensitivity to certain chemotherapy agents.
Anti-emetics
Metoclopramide
• Prokinetic -  release of acetycholine in gastric and small intestinal smooth muscle
o Increased gastric emptying 
o Increased intestinal motility
• Central acting antiemetic
o Antagonist at dopamine receptors of the chemoreceptor trigger zone 
o Also inhibits 5-HT3 receptors
o May not play a role in feline vomiting through these receptors
• Other central antiemetics may be more effective for uremia, pancreatitis and 
chemotherapy induced vomiting
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•  Dosage:
o 0.2 -  0.4 mg/kg SC or PO every 6-8 hours
•  M ay be more effective as a constant rate infusion 1-2 m g/kg/day
•  Reduce dose in cats w ith renal failure by 50% or more
•  High plasma concentrations
o Frenzied behavior or tremors 
o Discontinue drug until signs resolve 
o Consider reinstituting at half previous dosage
Ondansetron and dolasetron
•  5-HT3 receptor antangonist - central nervous system and gastrointestinal tract
•  Effective as a prophylactic for chemotherapy induced vomiting, refractory vomiting in 
pancreatitis, hepatic lipidosis, severe inflam matory bowel disease, gastrointestinal 
neoplasia, cholangitis
•  Dosage:
o Ondansetron - 0.5m g/kg every 12 hours 
o Dolasetron -  0 .6 mg/kg - 1 . 0  mg/kg IV or PO SID
Prochlorperazine and chlorpromazine
•  Phenothiazine central antiemetics
•  Antagonism o f dopamine, histamine type 1, alpha2-adrenergic and muscarinic receptors
•  Inhibit vomiting at the chemoreceptor trigger zone and directly at the emetic center
•  Used for refractory vomiting in patients w ith pancreatitis, Gl neoplasia, chemotherapy in 
conjunction with intravenous fluid support
•  Dosage:
o 0.1-0.5  mg/kg SC every 8 hours
•  Can cause sedation, hypotension (due to alpha adrenergic blockade)
•  Not recommended fo r empirical outpatient use or in dehydrated patients
•  Risk o f tremors due to dopamine antagonism -  especially when combined with  
Metoclopram ide
M aropitant (Cerenia)
•  Neurokinin-1 (NK-1) receptor antagonist
•  Inhibits substance P binding to NK-1 receptors located in the em etic center, 
chemoreceptor trigger zone, and enteric plexus
•  Dosage:
o 1 mg/kg SC or PO every 24 hours for 5 days followed by 2 days of rest
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o Can cause pain at injection site (may be less painful when refrigerated)
•  Should not cause cumulative side effects in combination with Metoclopramide or 5-HT3 
antagonists
•  Approved for dogs only however studies have shown efficacy in cats as well
Diarrhea
Diarrhea can be associated w ith primary cancers of the gastrointestinal tract or a side-effect of 
chemotherapy. As with vomiting, chemotherapy induced diarrhea is usually mild and self-limiting and 
occurs 3-5 days after the administration of certain chemotherapy drugs.
For mild cases empirical treatm ent usually involves increasing fiber in the diet, metronidazole, and 
occasionally probiotics. Rarely patients will need to be hospitalized for fluid therapy to combat 
dehydration and electrolyte imbalances.
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F e lin e  Ju ve n ile  G ingivo sto m atits: 
A n  O verlooked D isease
i f  '
Jennifer Rawlinson, DVM
Diplomate, American Veterinary Dental College 
Lecturer, Cornell University College o f Veterinary Medicine 
Section Chief, Dentistry and Oral Surgery
M ost Com m on O ral Pathology
• Gingivostomatitis
-Juvenile  Gingivostomatitis (JGS)
-  Chronic Gingivostomatitis (CGS)
• Periodontal Disease
• Tooth Resorption
• Neoplasia
-  Squamous cell carcinoma
H isto ry
• History
— Change in food preference
— Appetite but loses interest
— Frustration during eating
— Decreased grooming
— Reclusive behavior
— Ptyalism +/- blood
O ral Exam
Go slow and look before tissue manipulation 
Slight opening of mouth for mandibular Ml 
Opening mouth
-  Examine mucocutaneous junction first
-  Respect the stop
-  Glossopalantine arch
-  It may not be worth it!
In trao ra l R adiographs -  A  N ecessity
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A nesthetized O ral Exam
G in g iv o s t o m a t it is
/  / '/  /  
f /
i: J :\
m  pi*
G in g ivo sto m atitis (G S ) Ju ve n ile  G S
• No research studies ' * '***
describing pathology
• Two sentence mention
in Wiggs and Loprise’s ' t
Veterinary Dentistry
-  Severe inflammation of
the gingiva
-  Resolves at around 3
years o f age.
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Juvenile G S
• Unexplained etiology
-  Exfoliation of deciduous 
teeth
• P seudopocke t fo rm ation
• Inc rease  detrim en ta l bacterial 
popu lation  (g ram  nega tive 
b ac teria)
-  Associated with calicivirus 
infection
-  Genetically “sensitive” 
inflammatory response
• Halitosis!!!
• Bloodwork normal
Pathogenic Gram -Negative Organisms
• Direct tissue injury
-  enzymes: hyaluronidase, chondroitin sulfatase, 
proteolytic enzymes
-  cytotoxins: organic acids, ammonia, hydrogen sulfide, 
lipopolysaccharides (LPS)
• Inflammation-inducing bacterial by-products
-  LPS most important
• stimulates macrophages, endothelial cells and fibroblasts to 
produce cytokines
• helps to activate complement pathway 
■ antigenically stimulating
>
Destruction o f Connective Tissue and 
Bone Resorption by Inflam m ation
Prom inent H ost Factors
• Host factors
-  Biofilm -  can only be removed physically
-  Inflammatory and immune response - connective tissue 
destruction and loss alveolar bone
-  Host sensitivity -  individual’s pro-inflammatory (T N F a , 
IL -1 , IL-6, P G E 2 , M M P ) to inflammation-reducing (IL -10 , 
T G F p , MMP-inhibitor) cytokine ratio
-  Genetics -  animals bom with their predisposition to 
periodontitis
-  Environmental -  stress, systemic health, housing (second­
hand smoke)
• Significantly influence susceptibility, expression 
(type and severity) & progression of gingival 
inflammation
Ju ve n ile  G S - Treatm ent
Control inflammation and change bacteria
-  Anesthetized oral exam and radiographs
— Dental cleaning +/- periodontal therapy
C o m p licatio ns from  D ental 
P ro p h ylaxis
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Ju ve n ile  G S - Treatm ent
Control inflammation and change 
bacteria
-  Gingivectomy
• Reduces pseudopockets associated with 
gingival overgrowth
• Promotes healing
• Incorporates scar tissue into gingiva
-  Procedure
• Dental bur and a careful hand
• C02 laser but beware of thermal damage to 
tooth!
C o n tro l In fe ctio n  and Prom ote 
C hange in  B a cte ria l P o pulation
• Three week course of an 
antibiotic
-  Clavamox:
• 13.75 mg/kg po bid
-  Clindamycin
• 5-10 mg/kg po bid
-  Metronidazole
• 10-30 mg/kg po bid
-  Doxycycline
• 5 mg/kg po bid
Ju ve n ile  G S - Treatm ent
• Maintain oral health at home
• Retreat as needed (3-9 
months)
-  Most need just 1 to 2 
treatments
• Spontaneous remission 2-3 
years
— Without inflammation control 
severe periodontal disease will 
result
O ral H ygiene T herapy
T/D diet or comparable 
Biotene gel
CHX gel or rinse \ /  »h»hmh«h 
Biotene drinking water 
additive 
CET chews
f,
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C h ro n ic G S
Exaggerated inflammatory reaction to 
bacteria associated with dental structures 
Multifactorial disease:
-  Bacteria (Bartonella henselae)
-  V iral (ca lic iv irus, herpes, FIP, FeLV, F IV )
-  G enetic  (b reed  pred isposition  and  fam ilial)
-  N u trition
-  E nv ironm en t (secondary  sm oke)
-  Domestication
Bx: Lymphocytic-plasmacytic stomatitis 
Bilateral, near symmetric oral distribution! 
Rule out systemic disease 
High TP and globulin
-  U sually  polyclonal (m onoclonal sp ike)
Chronic G S  - Treatment
• Prognostic indicators
• Medical
-  O ra l Hygeine
-  Antibiotic Therapy
-  Immunosuppression
• Prednisolone 0.5-2 mg/kg sid with taper to lowest 
effective dose
• Methylprednisolone 20 mg q 3weeks for 3 months
• Cyclosporin (dosage depends on supplier)
-  Neoral (Novartis) 2 mg/kg po bid
— Take blood levels q 4-6 weeks!!!
Chronic G S  - Treatment
• Surgical extraction
-  ALL DENTAL STRUCTURES MUST GO!
-  Full or caudal mouth extractions
• 60% clinical remission
• 20% significant improvement with no medication
• 13%  medication still necessary
• 7% no improvement
• Proliferative tissue debridement: C02 laser
• Interferon omega therapy
C 0 2  L ase r Therm oablation
• Uses
i
-  Gingivectomy
-  Mucosal debridement
• Advantages
m l / *-  Bactericidal f ®  m
-  Removal proliferative tissue
-  Fibrosis a  ip  " , , 1
-  Decreased pain sensation
S l e s f i i l W S B s
C 0 2  L ase r Therm oablation
Settings
-  Gingivectomy
• 3-8 W continuous with 
0.8-1.4 ablating
-  Mucosal debridement
• 2-6 W continuous with 
0.8-1.4 ablating
I
Luxnre nsn
LA S E R  TIP S P U Z E  I  V T
P U N TA S EM BO UT L J M -
005LS
lilLJiSXR LOT 312000
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In terfero n  Om ega
• Effectiveness anecdotal
• Import
• Expensive ($ 120/vial)
• Needs refrigeration
• Treatment regimen
-  Intralesional injection 5 M U
-  Remaining 5 M U  diluted with 100 cc 
sterile saline
• Divide: 10 ml per 10 sterile vials
• 1 vial refrigerator; freeze rest till needed
• Give 1 ml po sid alternating sides of mouth 
for 3+ months
* Virbagen' Omega
.lO tJ
c
T y p ica l C ase Presentation Q
Chronic GS with Diabetes Mellitus (DM)
• H istory
-  Management o f CGS 6 yr
• Medical -  Depomedrol 20 mg SQ 
every 4 weeks
• Surgical -  caudal mouth extraction 
followed by maxillary canine 
extraction
-  Develops DM
• unable to control D M  - ever 
increasing dose insulin
7/15/2011
S u rg ica l E xtractio n  
13 R etained Roots
S u rg ical D ebridem ent
P ost-operative
• P ost-op
-  IV fluids and Unasyn
-  Buprenorphine x 2
• 0.01 m g/kg IV  q 6  hr
-  Fentanyl patch
• 12.5 mcg/hr
-  Insulin with glucose monitoring
-  A/D slurry
• To go  hom e
-  Convenia 8 mg/kg q 7 days ( 1 -3  weeks)
-  5 additional days Buprenorphine post-patch
-  Insulin and glucose monitoring with rDVM
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P arasites o f  the Feline Lung
Dwight D. Bowman, MS, PhD 
Department o f M icrobiology and Immunology 
College o f Veterinary M edicine 
Cornell U niversity, Ithaca, N Y
Histosection o f lung o f cat showing m edia l hypertrop hy  
of th e  pu lm onary  arte ry  due to  na tura l T. c a n is  in fection
Histosection o f lung o f cat na tura lly  in fected w ith  T. c a n is  
w ith  sections o f larva
There are three parasites o f cats that are routinely relatively overlooked relative to their 
effects on the feline lung. These parasites are the canine heartworm Dirofilaria immitis, the 
feline lungworm Aelurostrongylus abstrusus, and infections o f cats with roundworms o f the 
genus Toxocara, both T. cati o f the cat and T. canis o f the dog. Cats tend to respond in the lungs 
to helminth infections, even if  the infections do not mature, with a significant reaction that 
includes cellular infiltrate and the development o f significant hypertrophy o f the vessels in the 
lung. Such manifestations are common with all three o f these infections which are much more 
common than typically considered.
Recent data (Table) that has been collected from the laboratories o f ID E X X , Antech, and 
Banfield Pet Hospitals (appearing on the interactive maps on www.capcvet.org') reveals that 
feline heartworm is much more common in cats around the nation than previously recognized. 
Actually, when the data on some 250,000 cats is compared to data collected on some 5 m illion 
canine samples from around the country, there are only 5 states, Arkansas, Louisiana, 
M ississippi, Oklahoma, and Texas, where dogs have a higher percentage o f animals testing 
positive for heartworms. This might be due to the prevalence o f cats being inflated by the "good 
clinician" syndrome, i.e., where veterinarians make a diagnosis based on clin ical signs and then 
order the test in cats to verify their clin ical suspicion, but the numbers are still quite staggering in 
their content. The fact that 2.7%  o f the cats tested around the nation are antigen positive for 
heartworm is an indication that a fairly large percentage o f cats entering veterinary clin ics around 
the United States have livin g heartworms in their pulmonary arteries. The antigen testing 
representing the true status o f heartworm infection in cats is, however, supported by surveys 
examining shelter cats at necropsy for the presence o f heartworms (Ryan and Newcomb, 1995).
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Results of Antigen Tests on 249,597 Cats around the United States
STATE
Number
samples
Number.
positive
Percent
Positive STATE
Number
Samples
Number
Positive
Percent
Positive
AK 108 3 2.8% MT 0 0 0.0%
AL 3,638 178 4.9% NC 13,279 364 2.7%
AR 58 1 1.7% ND 0 0 0.0%
AZ 4540 84 1.9% NE 713 8 1.1%
CA 27,943 823 2.9% NH 574 9 1.6%
CO 6,657 170 2.6% NJ 8,299 221 2.7%
CT 4,519 102 2.3% NM 1,445 50 3.5%
DC 757 15 2.0% NV 1,916 53 2.8%
DE 1,678 44 2.6% NY 11,398 299 2.6%
FL 43,147 1,390 3.2% OH 4,514 59 1.3%
GA 11,639 407 3.5% OK 2,311 59 2.6%
HI 634 33 5.2% OR 3,389 47 1.4%
IA 251 5 2.0% PA 10,214 180 1.8%
ID 0 0 0.0% Rl 747 19 2.5%
IL 6,515 116 1.8% SC 5,304 161 3.0%
IN 3,129 56 1.8% SD 0 0 0.0%
KS 679 10 1.5% TN 4,745 221 4.7%
KY 1,263 24 1.9% TX 17,567 535 3.0%
LA 1,761 78 4.4% UT 793 11 1.4%
MA 8,856 202 2.3% VA 9,729 210 2.2%
MD 7,114 128 1.8% VT 373 21 5.6%
ME 0 0 0.0% WA 3,628 45 1.2%
Ml 5,605 113 2.0% Wl 510 6 1.2%
MN 4,647 54 1.2% WV 0 0 0.0%
MO 2,662 74 2.8% WY 0 0 0.0%
MS 349 9 2.6% Total 249,597 6,697 2.7%
We now also are aware that cats suffer from disease due to the presence o f young adult 
heartworms in the heart even if  they do not mature; the disease has come to be called H ARD  for 
Heartworm Associated Respiratory Disease (Blagbum , 2009). Results indicate that lesions and 
signs o f are associated with death o f pulmonary stages o f D. immitis resemble those o f other 
diseases such as feline asthma or other cause o f tracheitis/bronchitis and interstitial lung disease. 
Thus, we now know that heartworm infections in cats even if  the worms are not their long 
enough to stimulate an antigenemia in infected cats are still likely to induce disease in these cats. 
It should not be forgotten when considering feline heartworm disease that the worms that enter 
the heart o f the cat after 70 to 100 days o f development are 2 to 3 cm long when they arrive at 
the pulmonary arteries. Again, cats tend to over react to the presence o f nematodes in their lungs 
with the indication o f sever lung changes which in HARD are also associated with medial 
hypertrophy o f the pulmonary vessels.
Both these findings, the high number o f infected cats and the present o f H ARD  in cats, 
are further verification o f the need to provide cats with heartworm prevention. This lung disease 
is preventable if  the cats are on heartworm preventives. These preventives are also likely to 
protect cats from infections from pulmonary disease due to lungworms and roundworms.
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The feline lungworm o f cats,
Aelurostrongylus abstrusus, is a parasite that 
is often considered rather rare and unusual.
It would appear that this may not actually be 
the case. In  a survey o f two shelters from 
Cortland and Tompkins County New York, 
o f the 1,322 samples that were examined 
from individual cats, 6.2% were found to 
contain larvae o f A. abstrusus (Lucio-Forster 
and Bowman, 2011). In  this work, it is 
expected that since the manner o f diagnosis 
was centrifugal flotation with zinc sulfate 
flotation that the number o f cases detected 
was actually lower than the true prevalence.
The biology and disease caused by A. abstrusus has been fairly w ell described. Cats get 
infected with this lungworm by eating m olluscan intermediate hosts common in most gardens 
(slugs or land-snail, e.g., Deroceras, Arion, Helicella) or various paratenic vertebrate hosts, such 
as amphibians, reptiles, birds, and sm all mammals. Larvae are shed in the feces o f infected cats 
in slightly more than a month after the infection is initiated. The larvae are only infective to 
another host if  they pass through a snail. The adult worms live in the terminal respiratory 
bronchioles and alveolar ducts. The disease is due to the presence o f the worms and, probably 
even more so, to the eggs that are laid in the surrounding tissue in which the larvae develop and 
hatch. Cats with m ild infections often have only m inimal clin ical signs, but heavily infected cats 
can present with severe bronchopneumonia and open-mouthed abdominal breathing. This worm 
seems restricted to felids, and does not pose any known risk to people.
We know that we can use certain products off-label to treat cats infected with A. 
abstrusus. Cats can be successfully treated with either a single treatment with m oxidectin at the 
routine dose as in the monthly preventive for cats and by a three-day course o f fenbendazole 
(Traversa et al., 2009). Thus, it would appear that Advantage M ulti for cats may act as a 
preventive for this infection. We do not know if  the dose in the heartworm products containing 
iverm ectin, selamectin, or m ilbem ycin oxime would be effective in treating and preventing feline 
infections with this lungworm.
Diagnosis o f lungworm infection in cats is not always easy. It is by finding the larvae in 
the feces. Methods used include direct smears, zinc-sulfate or sugar flotation, and the use o f a 
Baermann funnel method used to harvest the motile larvae from larger volumes o f fresh feces. 
The direct smear and funnel method have the advantage that they provide the observer with 
actively motile larvae that aid in identification. The larvae obtained in zinc-sulfate flotations are 
characterized by the dorsal spine on the tail. In sugar, the larvae may be hard to visualize, 
because they are crenated by the osmotic pressure of the sugar solution, but they can often still 
be recognized if  the tail can be found.
A. abstrusus is only one example o f a good reason why it is necessary for pets that are on 
good all-year-round health parasite prevention to have regular fecal exams. An indoor cat may 
be more likely to eat an infected mouse in the winter than the summer, so seasonality may not 
play a major role in when infections with this parasite appear. A cat that gets to go outdoors is 
always at risk o f getting infection if  it hunts.
Fecal results o f 1322 cats from  tw o  shelters in upsta te  NY
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The survey by Lucio-Forster and Bowman (2011) cited above on cats in N Y  revealed that 
the prevalence was very high; basically 1 in every 5 cats in the shelters were found to be have 
Toxocara cati eggs in their feces. This seems to match almost exactly a national survey o f 
shelter cats based on some 4,000 fecal samples (D r. B. Blagbum, Auburn U niversity, personal 
communication). The sampling in  N Y  may be skewed by the fact that we did not know the ages 
o f the cats examined in sufficient detail to tease apart what percentage o f the cats were kittens, 
but the number is rem arkably high
Data from the same maps on the www.capcvet.org website that was cited above relative 
to heartworms also has data on roundworms. N ationally, the prevalence o f T. cati eggs in the 
feces o f cared-for cats was 6.1%  based on 780,000 samples. For the 4 m illion dog samples, there 
were 2.9% containing the eggs o f T. canis. N ationally, there were only 4 states, Alaska, Arizona, 
Nevada, and C alifornia where there was a lower percentage of cats infected than dogs. In  New 
York and Pennsylvania (some 144,000 samples), nearly 10% o f the fecal samples were positive 
for T. cati.
What is often not realized is the effect that Toxocara cati has on the lungs o f the infected 
cat. The m ajority o f work done in this regard was published only in  the form o f a thesis 
submitted in 1969 (Swerczek, 1969). In  this work, it was presented in great detail that the 
experimental infection o f cats with T. cati induced severe lesions, medial hypertrophy o f the 
pulmonary vessels, in  the lungs. It was concluded that these studies showed "that the lesion is 
produced earlier and is much more extensive than in A. abstrusus infection. The earliest change 
noted in the arteries was m ild intim al proliferation 2 weeks post infection, and medial 
hyperplasia was observed as early as 3 weeks and was severe by 6 weeks postinfection." It was 
felt that the observed lesions seen in random-sourced cats was probably most commonly caused 
by T. cati. A lso, the lesions did not clear in cats that had been infected, and it was considered 
that the induced lesions were irreversible. A lso noted in these cats, like with A. abstrusus 
infections, was the occurrence o f peribronchial mucus gland hyperplasia. A  single egg inoculum  
caused the lesion, and repeated reinfection sim ply caused them to worsen and to persist for 
longer periods.
Swerczek also reported on the disease induced in cats after their experimental infection 
with the eggs o f the canine roundworm, Toxocara canis. About this infection, he stated that "the 
focal pneumonia associated with the m igration o f T. canis larvae was much more severe than that 
seen in T. cati infection." and "M uscular hyperplasia o f the bronchioles and term inal alveolar 
ducts was also seen and was more severe in cats with evidence o f sever ascarid infection." A  cat 
was found naturally infected with larvae identified as those o f T. canis with very large 
granulomas in the kidneys that also had significant lesions is the lungs (Figures on page 1) 
sim ilar to those described by Swerczek in his thesis (Parsons et al., 1988). The lesions in the cat 
were sim ilarly reproduced in cats that were experim entally infected with Toxocara canis, and 
these lesions also included severe lung disease with medial hypertrophy o f the pulmonary vessels 
(Parsons et al., 1989).
O verall, based on the high prevalence o f T. cati seen in cats, the knowledge that this 
parasite causes lung lesions, and the fact that infections with T. cati and T. canis can occur all 
season long, is an argument for keeping cats on preventive therapy. When coupled with the 
amount o f lung disease associated with heartworms and lungworm, the three together argue very 
strongly for year-round heartworm and broad spectrum parasite control in cats.
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T h e  In te s tin a l C o n u n d ru m  P ro to z o a l P a ck a g e
Dwight D. Bowman, MS, PhD 
Department o f M icrobiology and Immunology 
College of Veterinary M edicine 
Cornell University, Ithaca, N Y
There are four protozoa parasites o f cats that gamer a good deal o f attention for different 
reasons. The different species o f Cystoisospora, C. fe lis  and C. rivolta, are o f interest because 
they are so very common. Giardia  organisms are 
commonly found in  cats, and infections 
sometimes causes diarrhea, but this genus of 
parasites gets most attention due to the concern 
that it might be a zoonotic agent. The 
Cryptosporidium  species in the cat,
Cryptosporidium  felis, likew ise gamers attention 
because it is a potential zoonotic agent. Finally the 
fourth species, Tritrichom onas foetus is now
known as a pathogen that may cause large bowel 
diarrhea in cats. % Positive Samples
Cystoisospora species
The feline coccidia, Cystoisospora felis  and Cystoisospora rivolta, undergo enteric 
development only in the intestinal mucosa o f the domestic cat and perhaps other felids. There 
has been very little work in  recent years on the potential o f different species occurring in w ild 
felids to be shared with the domestic cat. Also, it is not uncommon for no attempt to be made in 
the fecal examination o f cats to distinguish between C. fe lis  and C. rivolta. A  survey in Germany 
reveals that 5.4% o f 3,167 cats were shedding oocysts (8.2%  o f cats less than 1 year o f age) 
(Barutski and Schaper, 2003) and a study in shelter cats in upstate New York revealed that 21% 
o f the shelter cats were shedding oocysts (Lucio-Forster and Bowman, 2011). Cats can be 
infected directly by the ingestion o f the oocysts that have sporulated in the environment after 
passage in the feces o f a cat or indirectly by the ingestion o f paratenic hosts, typically rodents or 
birds that have cystozoites in their tissues. After infection, oocysts are shed by the infected cat 
about a week later. In  most cats the period o f oocyst shedding w ill last about a month at the 
most.
Cystoisosporosis is a disease caused by the destruction o f the epithelium and perhaps 
some lamina propria cells in  the mucosa o f the sm all and large intestines. In  cats, clin ical signs 
include soft, mucoid feces, and infections in young kittens can induce enteritis, emaciation, 
blood-tinged feces, and death. Disease can be severe and deadly in kittens that are not yet 
weaned. The diagnosis o f the infection is by the finding the oocysts on fecal flotations.
Treatment has been examined most carefully in  dogs where sulfadimethoxine is approved 
as a treatment for "bacterial enteritis associated with coccidiosis in  dogs." Toltrazuril (10, 20 or 
30 mg/kg o f a 5% suspension for three days) and ponazuril (20 mg/kg daily for one to three 
days) have also been shown to clear abrogate oocyst shedding and to improve clin ical signs. It 
must be remembered that oocysts which have already formed w ithin the intestinal mucosa w ill 
not be affected, because the anticoccidials are not capable o f penetrating the oocyst w alls.
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Fecal flotation results on 1322 shelter cats in upstate NY
Giardiasis
Cats (and dogs) have been put forth by many as regular sources o f human infection with 
Giardia duodenalis and as carriers o f this "zoonotic" agent (reviewed by Bowman and Lucio- 
Forster, 2010). Such an assessment can have major effects on the acceptance o f pets w ithin a 
household and significant effects on hospital and elderly/shut-in visitation programs by pets, 
possibly increasing program costs or causing their cancellation. Some occupational health and 
safety officers want to or already have instituted regular fecal screening for Giardia  cysts o f a ll 
personnel who work with dogs and cats w ithin a facility. T ypically, cats are infected with a form 
of Giardia  that is called Assemblage F. There are two additional Assemblages, A  and B, that 
have been reported from both people and cats.
Assemblage B is common in people, and has only rarely been reported from dogs and 
cats. We have on rare occasion found Assemblage B in fecal samples from shelter cats 
(Bowman, personal communication). Infections with Assemblage A  have been reported on a 
number o f occasions from cats. Assemblage A  is divided into sub-Assemblages based on 
various patterns w ithin the phylogenetic analyses using different allozym es or genes. Sub- 
Assemblage A l is considered potentially zoonotic and sub-Assemblage A ll is considered 
anthroponotic. A  recent m ultilocus genotyping study using the sequence analysis o f four genes 
(ssrRN A, P-giardin, glutamate dehydrogenase, and triose phosphate isomerase) o f Giardia 
duodenalis recognized a third group, sub-Assemblage A III, that is restricted to w ild hoofed 
stock. There has been only a single report o f A ll from a cat. Part o f the problem with defining 
host associations to the different sub-Assemblages is that they remain somewhat still in a state o f 
flux as to their definition. O verall, however, cats are infected with Assemblage and F and on 
occasions, A I. The finding o f B in  some shelter cats is a bit worrisom e, but this may require that 
we work to identify the sub-Assemblage and then determine if  it is cat adapted or an actual 
zoonotic agent.
Giardia duodenalis is one o f the most common parasites o f cats around the world. A  
recent survey in A ustralia found Giardia  cysts in 2.0%  o f 1,063 feline samples (Palm er et al., 
2008). A  survey o f cats in  the United States using a com m ercial ELISA-based test revealed a 
positive antigen result in  the feces o f 10.8% o f 4,978 cats that were considered symptomatic by 
the testing clin ic (C arlin  et al., 2006). Cats in m etropolitan R io de Janeiro have been reported to 
be infected at a rate o f 6.1%  (Serra et al., 2003). In  Tehran, Iran, 11.6%  o f cats were found to be 
infected (Zarebavani et al., 2006).
Giardia  infections in cats are common in apparently normal anim als, and thus, w ith the 
development o f the new patient-side E L IS A  test from ID E X X  Laboratories, veterinarians 
realized what veterinary parasitologists had known and told them for a long time: the prevalence 
o f Giardia  infections in  these hosts is high, typically, anywhere from 10% to 40%, or higher. 
G iardiasis can sometimes make dogs and cats sick, but anim als with signs are atypical. The 
stools o f dogs and cats with apparent signs o f giardiasis do not have the same frothy and foul­
sm elling features associated with the stools o f symptomatic people. Practitioners do see cases 
that require treatment and which respond to treatment. Unfortunately, there are no approved 
drugs for cats: giardiasis is often treated with form ulations o f nitroim idazoles (m etronidazole) 
and/or benzim idazoles (fenbendazole or the pro-benzim idazole febantel).
Cryptosporidium felis
The species o f Cryptosporidium  occurring in the cat is C. felis. It is hard to im possible to 
infect cats with Cryptosporidium parvum. On rare occasions, the murine gastric species o f 
Cryptosporidium, C. muris, may be found in cats, but it may be due sim ply to prey ingestion.
Cats do not shed for long periods, so surveys give m ainly an indication o f what cats are 
shedding at any given time, not an indication as to what percentage o f cats may have been 
infected with this parasite. B asically, studies from around the world have indicated that 
somewhere between 0 to almost 30% o f cats can be shedding oocysts at any given time (Table)
Recent Reports of Feline Sampling for the Prevalence of 
C r y p t o s p o r id iu m  oocysts (2005-2009)
For earlier data see Santin and Trout 2008
Country
% Positive 
Samples
M ethod/notes Species Detected REF
North America
Canada 7.3% (3/41) BFM2 and FecAg Detection3 ND Shukla 2006
USA 12.0% (30/250) IFA4 and PCR C. felis Ballweber 2009
USA 4.7% (16/344) IFA and FecAg Detection ND Mekaru 2007
South America
Brazil 3.9% (2/51) BFM ND Coelho 2009
Brazil 11.3 % (37/327) BFM ND Funada 2007
Colombia 13.0% (6/46) PCR C. felis & C. muris Santin 2006
Europe
Italy 24.5% (49/200) BFM ND Rambozzi 2007
Netherlands 4.6% (1/22) BFM ND Overgaauw 2009
Romania 29.4% (53/180) BFM and FecAg Detection ND Mircean 2007
Spain 4.0% (2/50) BFM ND Gracenea 2009
UK 0% (0/57) BFM ND Gow 2009
UK 1.0% (13/1355) BFM ND Tzannes 2008
Australia
Australia 2.4% (26/1063) BFM and PCR C. felis Palmer 2008
Australia 7.0% (3/46) BFM ND O'Calaghan 2005
1. Positive Samples % (Positive Samples/Total Samples Examined)
2. BFM: Bright-Field Microscopy, including D1C and/or phase microscopy, stationary and/or centrifugal fecal flotation methods, centrifugal
sedimentation methods, and/or acid-fast, malachite green, or methylene blue gram safranin staining.
3 . FecAg Detection: Includes various enzyme immunoassays (EIA), and 2 were nonenzymatic immunoassays
4 . I FA indirect fluorescent antibody assay (may include direct fluorescent assays)
Most cats do not develop disease from an infection with C. felis. O ccasionally, a cat, 
especially in  a closed colony, may develop diarrhea due to its infection. There is no treatment 
currently registered in  the USA for Cryptosporidium  infection in cats. Tylosin has been used 
successfully in cats, but requires a long course o f treatment; nitazoxanide is registered for the
treatment o f cryptosporidiosis in children and also reduces oocyst shedding in  cats (Lucio- 
Forster et al., 2010).
A  recent review  o f Cryptosporidium  in humans and companion anim als (Lucio-Forster et 
al., 2010) has reported on studies concerning the distribution o f Cryptosporidium  spp. in  humans. 
In  the USA, o f 228 cases o f cryptosporidiosis where genotyping was done, 143 cases (63% ) were 
linked to C. hominis, 78 to C. parvum  (34% ), six  to C. fe lis  (2.6% ) and a single case to C. canis 
(0.4% ); which was sim ilar to that reported from the U K. C. fe lis  was isolated only from H IV - 
positive adults in  the USA, but it has been seen in immunocompetent humans in other countries, 
especially in children in developing countries where 3.3%  o f cases were due to C. felis. In  total, 
there have only been 97 C. fe lis  cases reported in  people (6 in the U SA ). Thus, m olecular 
epidem iologic data to date support the belief that the risk o f zoonotic transm ission o f 
Cryptosporidium  spp. from cats to people. Veterinarians and physicians can inform  their clients 
o f this m inim al risk, but nevertheless advise them to m inim ize contact w ith pet feces, especially 
if  their clients or other members o f the household are immunosuppressed.
Tritrichomonas foetu s
For a long time, it was considered that Tritrichomonas foetus  was a parasite o f the genital 
tract o f cattle. However, it has recently been shown using m olecular and other methods that the 
form present in the feces o f cats with diarrhea is the same as the species in  cattle. Amongst cats, 
there is no known breed or sex predilection; although diarrhea is more commonly seen in 
younger anim als. T. foetus  was diagnosed in  the stools o f 31%  o f 117 purebred cats from 89 
catteries attending a show. In  a study o f catteries in w hich infection was found, more cats had 
diarrhea when there were more cats per square foot o f floor space (G ookin et al, 2004). An 
examination o f the feces from 100 feral cats and 20 healthy indoor cats using m icroscopy and 
protozoal culture o f feces failed to reveal any cats infected with this parasite suggesting that it is 
not commonly found in cats outside o f the cattery-type housing environment.
The life  cycle is direct. Transm ission is fecal-oral, with trophozoites passing between 
hosts. Trophozoites survive for short periods in fresh feces. Follow ing experim ental infection, 
some cats began to shed trophozoites in  their feces as early as 2 days after oral inoculation with 
the organisms (Gookin et al., 2001). Infections without clin ical signs can be prolonged, years, 
without the animals having clin ica l signs o f infection (Foster et al., 2004)
Infections with this pathogen cause chronic large bowel diarrhea. The diarrhea tends to 
occur sporadically and may on occasion contain fresh blood or mucus. T ypically, however, in 
spite o f transient diarrhea, the cats rem ain in  good health with good body condition. The feces 
tend to be semi-formed and considered malodorous. It has been noted that in very young cats 
held in poor housing conditions that the anus may appear edematous, erythematous, and painful; 
this may be associated with involuntary dribbling o f feces. On rare occasions rectal prolapse can 
occur. Diarrhea tends to be associates m ainly with cats that are one year o f age or younger.
Trophozoites should be looked for in  fecal smears prepared with saline rather than water 
to prevent the lysis o f the parasite. The directional swimming motion o f the trophozoites can be 
used to distinguish them from the trophozoites o f Giardia fe lis  that move but tend to be unable to 
orient under most conditions. A  very useful method for obtaining cultures o f trophozoites is the 
In-Pouch TF kit (BioM ed Diagnostics In c.), typically used for diagnosing trichom oniasis in
cattle. There are also m olecular methods used in several laboratories for the diagnosis o f 
Tritrichomonas foetus  infections.
There has not been a satisfactory m odality o f treatment that has been identified. Many 
antim icrobial drugs (metronidazole, fenbendazole, albendazole, sulfadim ethoxine, trim ethoprim - 
sulfadiazine, furazolidone, tylosin, enrofloxacin, am oxicillin, clindam ycin, paromomycin, and 
erythromycin) have been utilized in therapy, often without success (G ookin 2004). In  some 
cases cats w ill not be cleared o f their infection by treatment, but the signs may imporve w hile on 
therapy.
In  a long-term study o f 26 cats that had diarrhea and were infected with Tritrichomonas 
foetus, 23 o f the cats had a resolution o f their clin ical signs w ithin 2 years o f the onset o f the 
diarrhea (median time to resolution 9 months) (Foster et al., 2004). More than have o f the cats 
with clin ical signs still had infection detected by PCR a median o f 39 months after it had been 
reported that their Trichomonas foetus associated signs o f diarrhea had cleared.
The trophozoites are highly labile and probably die under most circumstances w ithin 
hours after being passed in the stool. The trophozoites w ill lyse in clean water and are likely  to 
be killed by the application o f heat, either dry, out o f heated high pressure washers, or from 
steam cleaning. Most disinfectants, soap, bleach, ammonia, etc., are going to rapidly k ill the 
trophozoites o f this parasite.
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This parasite first appeared in domestic cats in M issouri in 1973, and the concern at that 
time was that it was an introduced species o f importance to agriculture, perhaps related to 
Theileriaparva  (W agner, 1976). It was also at this time described as a new species: Cytauxzoon 
fe lis  K ier, 1979. Cytauxzoon fe lis  used to be thought to be transmitted to cats from bobcats, Lynx 
rufus, by the bite o f the Am erican Dog Tick,
Dermacentor variabilis (B louin et al., 1984). We 
have more recently learned that the vector is the 
lone star tick, Amblyomma americanum  (Reichard 
et al., 2009). This matches what is known about 
where the disease is located, it occurs in  the 
overlapping ranges o f the bobcat and the lone star 
tick, not in  the overlapping areas o f the 
Dermacentor and the bobcat ((Birkenheuer et al.,
2008). The sexual stages occur in the tick which 
inoculates sporozoites into the host when it bites.
So now, the reservoir host is  the bobcat, and the 
vector is the lone star tick.
In the cat, there are two important life  cycle stages, schizonts and merozoites (M eier and 
Moore, 2000). Schizonts are found in histiocytes and macrophages o f the bone marrow, veins, 
and venules o f various organs, including the lungs, liver, spleen, lym ph nodes, brain, and 
kidneys. M erozoites occur in  circulating red blood cells later in the infection, and therefore, 
often w ill not be found in cats dying o f acute disease.
Disease occurs in  cats that are bitten by the vector. In  the cat, schizonts develop w ithin 
monocytes, which become m arkedly enlarged. Cats with acute disease typically develop anemia, 
depression, fever, dehydration, and icterus. The m ajority o f cats die w ithin nine to 15 days o f 
infection. The cause o f death is occlusion o f veins and venules with schizont-laden 
macrophages. Hem atologic changes may be severe, and result from displacement o f 
hematopoietic tissue w ithin the bone marrow. If  the cat survives for more than six days, 
erythrocytes become infected and the merozoite stage develops, typically with no more than 1 % 
to 4% o f red blood cells infected. In  the case o f the bobcat, the schizogonous stage is shortened, 
and they become prolonged carriers o f the erythrocytic stage (B louin et al., 1987).
One o f the main sites o f disease in the cat is the lung. An exam ination o f lungs from 148 
cats that had died o f cytauxzoonosis were examined in Oklahoma from retrospective samples 
collected between January 1995 and June 2005 (Snider, 2010) Evaluated parameters included 
the presence o f interstitial pneumonia, increases in the number o f alveolar macrophages, degree 
o f intra-alveolar hemorrhage, neutrophils infiltrating peribronchial and septal interstitium , and 
degree o f vascular occlusion. O verall, interstitial pneumonia was moderate; alveolar 
macrophage numbers were m ild, and vascular occlusion was moderate to severe w ith prominent
pulmonary edema. The findings shed light on the fact that the pathogenesis o f cytauxzoonosis is 
due to vascular occlusion by macrophages that are enlarged by the schizont stages o f the parasite.
In  a survey o f cases from the m id-Atlantic states o f the US, o f 34 cats infected with C. 
felis, 32 succumbed to the infection (Birkenheuer et al., 2006). The most common signs are 
pancytopenia and icterus. During the acute disease, organisms can be identified in smears o f 
bone marrow or in biopsy specimens. Chronic disease is diagnosed by finding the merozoites in 
red blood cells. No treatments are consistently efficacious during the acute stage o f the disease. 
Antiprotozoals with supportive care and antibiotics are often adm inistered, but the prognosis 
remains poor. This is  a disease that is currently best prevented by keeping cats indoors in  areas 
where the ticks are active or using products that w ill k ill or repel ticks.
Natural cases o f cytauxzoonosis in cats have typically been described from the 
southeastern and south central United States, cases being reported from  Kansas, Oklahoma, 
M issouri, Arkansas, Texas, Louisiana, M ississippi, Georgia, and Florida (Jackson and Fisher,
2006). More recently, C. fe lis  has been diagnosed in Kentucky, Indiana, Tennessee (70 cases), 
coastal North Carolina and South Carolina (Jackson and Fisher, 2006). Thus, it is becoming 
obvious that cytauxzoonosis is spreading beyond its typical confined range in the south-central 
United Stated up into the lower M idwest.
In  the series o f 80 cases described by Cohn et al. (2011) the most common historical 
complaints were lethargy (n =  78), and anorexia (n = 60). Vom iting (usually once or tw ice) was 
reported in 6 cats. Other com plaints that were reported were unsteady gait (3), abnormal 
behavior (1), abortion (1 ), and hematuria (1). The most common abnorm alities on physical 
examination were hyperthermia (temperature >39.2 C ; n = 72), icterus (31), elevated nictitans 
(31), dehydration (22), the presence o f ticks (22), tachypnea (respiratory rate >40 breaths per 
minute; 20), tachycardia (heart rate >200 beats per minute; 13), pallor (9), murmur (8), 
vocalization (5), discom fort on abdominal palpation (5), lymphadenomegaly (5), and 
splenomegaly (5). Abortion, stupor, gallop rhythm, muscle wasting, ear mites, abscess, and 
disorientation were each found in  a single cat. Temperature range in the 78 cats with legible 
recorded temperature was 38.3—41.7 C  (101.0-107.01F).
Diagnosis has been im proved through the development o f PC R  assays (Brow n et al, 
2010), and this has led to the ability to detect infections in asymptomatic cats. It may be that 
there are different strains o f C. fe lis  circulating in  the w ild and domestic populations with some 
being deadly and some being relatively benign. However, the risk rem ains. This is actually a 
very good argument for cats being kept indoors in areas where the disease is  known to occur.
Treatment now appears to be best through the use o f atovaquone (15 mg/kg PO q8h) and 
azithrom ycin (10 mg/kg PO q24h, with heparin, fluids, and supportive care (Cohn et al., 2011). 
Previously treatment had been w ith im idocarb (3.5 mg/kg IM ). In  an open-label, randomized 
prospective study, o f 53 cats treated with the atovaquone and azithrom ycin, 60% survived to 
discharge. Unfortunately for the 27 cats treated with im idocarb, only 26% o f the cats survived to 
discharge. The mean temperature o f cats randomized to receive atovaquone and azithrom ycin 
(104.5 + 1.1 F; 40.3 C ) was identical to that o f cats randomized to receive im idocarb (104.5 + 1.1 
F; 40.3 C ). O f 80 cats included in  data analysis, 39 survived and 41 died. O f the 41 that died, 5 
were euthanized because o f severe clin ica l deterioration and moribund condition. Twenty-four o f 
41 cats that died did so the day o f or the day after presentation for care; only 3 cats died or were 
euthanized more than 3 days after presentation. O verall, survival was greater in cats treated with
atovaquone and azithrom ycin than in  cats treated with im idocarb (P = 0.0036; odds ratio 7.2; 
95% C l 2.2, 24.0).
A s more and more people move into housing developments on the fringes o f tick areas, it 
can be expected that more and more cases o f this and other tick-transm itted diseases w ill be seen. 
This is due in part to the continued expanding range o f the Am erican bobcat, particularly in the 
Midwestern and several m id-Atlantic States U .S. Fish and W ildlife Service website). The range 
is increasing and the numbers are increasing. It is estimated that there are now at least some 1.5 
m illion bobcats in the United States, but this may be an underestimate due to poor animal 
sighting abilities by census takers (H arrison, 2006). The annual harvest for fur was about 35,000 
per year in the mid 1990s (US Fish  and W ildlife Service website). In  recent years, there has 
been an increase in the harvest due to the demand o f the fashion industry, but this does not seem 
to be decreasing populations in any areas (H arrison, 2006). The expanding range o f the host o f 
the parasite and the vector would be expected to expand the range o f both agents. Thus, it should 
be expected that cats w ill be under greater and greater risk o f disease due to this pathogen 
throughout the United States.
It would seem that in areas where this disease is present that the best prevention for cats
is an indoor existence. The disease often has a highly fatal outcome, and we as o f yet do not
have a perfect tick preventive for cats. If  cats do go outside in  these areas, they should have 
some form o f tick prevention applied, but the lone star tick 
attacking and biting a host if  it so chooses.
C uterebriasis
Cuterebra, a genus o f dipteran obligate parasites o f 
rodents and lagomorphs in North Am erica, undergoes an 
obligatory deep m igration through the tissues o f its host 
before the third-instar larva appears in  a subcutaneous boil 
where it undergoes rapid growth before dropping to the soil 
to pupate (Sabrosky, 1986). Surprisingly in the rodent and 
lagomorph hosts, there is  actually very little loss o f fitness 
o f the host from infections with these parasites that can 
appear strikingly large in  com parison to the host (Slanksy,
2007). There are 34 species o f Cuterebra  throughout North 
Am erica (Sabrosky, 1986), and dogs and cats are known to 
sometimes have the larvae develop into mature larvae 
w ithin the lesions in their skin, nasal cavity, or eyelid (Scott 
et al., 2001).
In  the northeastern United States there is the seasonal 
cats that has been associated w ith the m igration o f Cuterebra larvae through the spinal cord or 
brain (G lass et al., 1998). The larvae cannot be identified to species, and w hile third-stage larvae 
can be identified to subgenus, first and second instars cannot be identified m orphologically 
beyond the generic level (Sabrosky, 1986). Thus, it is unknown if  the disease in cats seen in the 
northeastern USA is due to one or more than one o f the six species o f Cuterebra  that occur in 
this area: three species in  the subgenus Trypoderma that use lagomorphs as their typical hosts,
is one that is hard to dissuade from
Cuterebra larva removed from the retro- 
orbital region of a cat in upstate New York
appearance o f neurologic disease in
C. T. abdominalis, C. T. buccatta, and C. T. cuniculi, and three in  the subgenus Cuterebra  that 
used rodents as the typical hosts, C. C. emasculator, C. C. fontinella, and C. C. americana. The 
flies all have univoltine life  cycles w ith the females laying eggs on blades o f grass in  spring or 
early summer near the entrance to the host's burrow, and the larva then leaves the egg to get onto 
the host when it is passing by and enters the host through one o f the body's orifices. The 
migratory patten in mice experim entally infected with C. C. fontinella  revealed that whether the 
larvae first entered the host via the nares or anus, they migrated first to the trachea and thoracic 
region before m igrating through the abdomen to the site o f development in  the subcutaneous 
tissues o f the postero-ventral abdominal region (G ingrich, 1981). A  mature larva in  a rodent or 
rabbit requires some 3 to 8 weeks including the m igratory phase o f the life  cycle (Bowman et al., 
2002).
In  cats, the disease usually presents between late June and the first k illin g  frost in 
October. In  most cats, and dogs, it seems that the larvae ultim ately reach the subcutaneous 
tissues and mature (although they seem incapable o f producing viable adults after pupation), and 
in  these cases the diagnosis o f infection is sim ply the finding o f the larva in  the subcutaneous 
boil. Unfortunately, in some cats, the infection produces respiratory signs follow ed by 
neurologic disease that is often fatal. In  late summer to early fa ll, cats can develop an acute 
onset o f neurologic disease that may be preceded by upper respiratory signs one to two weeks 
previously. These cats can present w ith depression, blindness, and behavioral changes. Lesions 
may be in  the cerebrum or cerebellum  in association with feline ischem ic encephalopathy, but in 
some cases the larvae are found w ithin the spinal canal.
Diagnosis is typically based on signs, response to treatment w ith high doses o f iverm ectin 
and corticosteroids, imaging with computerized axial tomography or magnetic resonance, or by 
necropsy. Treatment remains high-dose iverm ectin, often w ith corticosteroids, or surgical 
removal o f the offending bot. W ork is  underway to develop a means o f assisting the diagnosis 
with the utilization o f an E L IS A  for Cuterebra-specific IgG  and IgM  in  cats w ith known and 
suspected disease. It is hoped that this w ill ultim ately prove useful in ruling out the infection in 
cases where cats present with signs other than a bot w ithin a subcutaneous lesion.
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W hat’s new in pain control 
and anesthesia for cats
Andrea Looney, DVM, DACVA, 
CCRP  
Pain management and 
rehabilitation service, CUH A
How is pain defined?
• An unpleasant sensory or emotional experience
• Associated with actual, perceived, or potential 
tissue damage
• A physiologic and psychological experience
• A very subjective experience
Formed by a neural matrix 
Evolving=Subject to chang 
immediate 
long term
“New age” definitions
Acute pain
- Known causative factor
- Treatment usually 
satisfactory
- Examples:
• Myocardial pain
• Traumatic MS pain
• Headache
Chronic pain
- Causative factors?
• Known
• Unknown
- Ongoing duration
- Difficult to treat
- Examples:
• Oncologic pain
• Osteoarthritis
• Diabetic pain
• Nerve injury pain
W hat do these new definitions 
mean to us c lin ica lly?
• There’s no straight line from tissue alteration to 
pain response
• A tiny insult can result in exponential damage
- Autonomic changes
- Supportive and neural Tissue changes
• Structural
• functional
• What decreases these problems?
- Early aggressive treatment of pain
- Preventative treatment of pain=preempti
- Multimodal treatment of pain
W hy bother treating pain?
Immediate effects
- Increased sympathetic tone
- Hypercoagulability
- Increased myocardial work
- Diminished pulmonary function- Translocation and altered Gl blood flow
Long term effects
- Thromboembolic disease
- Chronic pain
- Myocardial disease
- Immune supression
- Poor wound healing
Lascelles B, 1999. A survey of current british veterinary 
attitudes to perioperative analgesia for cats and small 
mammals
• Veterinarians asked their opinion on an 
exploratory laparotomy in dogs and cats
-  Most considered this procedure painful in both 
species
-  Only 56% cats received analgesics
• Compared to 71% of dogs
•www.royalcanin.co.uk
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W hy are cats undertreated?
• Difficulty in recognizing signs of pain in 
this species
• Limited number of analgesics with label 
indications for cats
• Perceived fraility of the species
• Fear of adverse side effects
• Lack of published information
Assessm en t of pain is important
Normal cat spontaneous behaviors
• Stretching
• Back arching
• Climbing
• Grooming
• Laying lateral or curled up www.animalfriendsrescue.org
• Yawning
• Wide eyed and slow blinking
• Tail movements
• Play or trouble making!
Pain  assessm ent
Acute vs. chronic 
Physiologic and behavioral signs 
Knowing the norm for the animal 
Experience the animal outside the acute 
environment (in the case of chronic pain
Common clues to the presence of 
pain in cats
• Decreased movement
• Scratching or overgrooming affected areas
• Poor coat quality
• Lack of grooming and hair matting
• Decreased appetite and water 
consumption
• Hiding and isolation
• Escape attempts
• Slow cautious movement
Common clues to the presence of 
pain in cats
• Facial expression
-  Half mast pinna position
-  Squinting eyes
• Failure to urinate and defecate
• Toaster position
• Oversleeping
• Quietness or voice changes
• Drooling or difficulty prehending or chewing
2
Systematic approach to 
determining pain in cats
• Detailed history
-  Typical day, current medications, recent life changes, 
vaccinal history
• Observation from a distance
-  Cat on the ground, dim lights
• Assess response to owner’s approach
• Stranger interaction
-  Your Non invasive interaction
• Physical exam
-  Area of interest last
F is h e r
The bottom line in feline pain 
determination
Acute pain
- Respiratory rate
- Respiratory character
- Heart rate
- Interactive behavior score 
near and far from area of 
interest
- Adminster an analgesic _ Administer an analgesic
and watch response and watch response
Chronic pain
- Appetite?
- Movements?
- Interaction with owners 
normal?
- Urinary and bowel habits?
A great way to determine the 
presence or absence of pain
. Docum ent pre-existing state
• Adm inister an analgesic
• Note and document response
-  Spontaneous behaviors
- Induced or reactive (interactive) behaviors
- Physiologic parameters
• Heart rate and rhythm
• Respiratory rate and character
W hat to administer?
• Hydro or Oxymorphone 0.05-0.1 mg/kg SQ
• Buprenorphine 0.01-0.02mg/kg SQ or 
lingual
• Morphine 0.1-0.2mg/kg IM
• Meloxicam 0.1-0.2mg/kg
• Dexmedetomidine 5-10mcg/kg lingual,
SQ, or IM
Other more objective means of 
identifying pain
•zn m zun
Other factors which have great 
impact on pain control for cats
• Hydration and volume 
status
• Blood presure control
• Stress reduction
• Nutrition
• Electrolytes
• Glucose
• Movement
• Urinary and bowel habits
• Sleep
Drugs and therapies used to treat 
feline pain
Slow Acting Disease Modifying 
Agents
Fe line physiotherapy
Feline physiotherapy
•4
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Opioid usage
F o r  typical acute 
analgesia
• Buprenorphine 0.02mg/kg 
lingual, SQ, IM, IV q. 12 
hr
- Alternate with nsaid and/or 
dexmedetomidine
• Morphine 0.1-0.2mg/kg 
IM o rS Q q . 12 hr
- Alternate with nsaid and/or 
dexmedetomidine
For typical premed, pre 
anesth
• Buprenorphine 0.02mg/kg 
IM or IV
• Hydromorphone 
0.05mg/kg IM, IV, SQ
• Morphine 0.1 -0.3mg/kg 
IM
- All with dexmedetomidine 
and/or nsaid
Opioid usage
• For typical chronic analgesia:
-  Buprenorphine 0.01-0.02mg/kg buccal 
mucosa sid to bid
-Oxycodone 5mg/5ml syrup: 0.05-0.1 mg/kg 
orally sid to bid
-  Methadone 0.05-0.1 mg/kg sq sid to bid 
-Oxymorphone 0.05-0.1 mg/kg sq sid
-  Fentanyl patch 12.5 and 25mcg/hr q. week
Alpha two agonist usage
For typical acute 
analgesia
• Dexmedetomidine 3- 
10mcg/kg q. 12 hr 
buccally, SQ
* Medetomidine 7- 
15mcg/kg q. 12 hr 
buccally, SQ
■ either alternate with opioid 
of choice +/-nsaid sid
For typical premed, 
preanesthesia
• Dexmedetomidine 10- 
20mcg/kg
• Medetomidine 20- 
30mcg/kg
- Either with opioid of choice 
+/- nsaid
Alpha agonist usage
• For typical chronic analgesia
-Dexmedetomidine 3-10mcg/kg buccally sid to 
bid
-  Given alternating with
• opioid
• nonsteroidal of choice
N S A I D S
NSAID injectable*
KMoprotan. Cvproton, and MMoncem
■zm /zun
M y  favorite acute 
N S A I D  options
• Meloxicam 0.1 mg/kg SQ, IV, PO 
q. 2 days for 2-3 doses
• Carprofen 1 mg/kg SQ, PO n s a i d
Ketoprofen Carprofen, and Maioncam
q. 2 days for 2-3 doses
• Flunixin 0.25mg/kg SQ 
q. 2 days for 2-3 doses
• Ketoprofen 1 mg/kg SQ 
q. 2 days for 2-3 doses
M y  favorite chronic 
N S A I D  options
• Meloxicam 0.05-0,1 mg/kg PO q, 2-4 days
• Aspirin 5-10mg/kg PO q. 2-4 days
• Ketoprofen 0.2-1 m/kg PO  q. 3-5 days
• Carprofen 1 mg/kg PO q. 2-4 days
A d e q u a n  for cats
Indications
-  Osteoarthritis 
-Tendonitis
-  Polymyositis/myopathy
-  Chronic toxoplasmosis
-  Chronic cystitis 
Doses
-  4mg/kg lean bw sq every 4-7 days for one 
month
LO CO REG IO N AL BLO CKS
Locoregional blockade can be 
performed blindly or guided
• Ultrasound guided
Blind blockade
-  Pick nerve or plexus
-  Dilute local 
anesthetics
-  Deliver
• with eyes open
Electrostimulation
guided
C o m m o n  blocks, 
c o m m o n  doses
• Bupivicaine
0.2mg/kg with 
Lidocaine 1 mg/kg 
and saline to dilute 
if needed
• Saline:
-  Reduces toxicity 
potential
-  Reduces sting
-  Spreads the love
•zn4/zuv\
Catheters extend life of 
local blockades for acute pain
•uaaam m ilaint m m
Different additives extend the life 
of local blockades for chronic 
pain=neurolytic blocks
• Sarapin
• Alcohol
• Ammonium chloride
• Triamcinalone
• Methylprednisone
Continuous rate infusions M y  favorite intraop 
infusion rates
• Fentanyl-expect MAC reduction
-  0.3-0.5mcg/kg/min
• Remifentanil-expect MAC reduction
-  0.3-0.7mcg/kg/min
• Ketamine
-  3 mcg/kg/min
• Dexmedetomidine-expect MAC reduction
-  0.5 mcg/kg/HOUR
M y  favorite post op 
infusion rates
Fentanyl
-0 .1  mcg/kg/min 
Lidocaine
-  5mcg/kg/min 
Ketamine
-  1-3mcg/kg/min 
Dexmedetomidine
-  0.5-2mcg/kg/HOUR
Novel agents
tr
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Transdermal gels Going into feline practice? Have these by your side
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V ete r i n a r y  O n c o l o g y  P a i n  
A s s e s s m e n t  a n d  
T r e a t m e n t
Andrea Looney
Where does oncologic pain 
originate?
■ Etiologies:
That produced directly by the tumor (70° o)
■ What you will learn about in next couple o’ slides 
a That due to  various modalities o f  therapy (20° o)
■ That related to chronic debility (10%)
■ That related to non malignant concurrent disease 
(1 0%)
H ow  m u c h  pain  do 
various tu m o rs  cause?
l ) c  L o r im ie r  LI*, F a n  I M . 
U n d e rs tand in g  and  
r e co g n iz in g  can ce r p a in  in  
dogs and  ca ts, 2005
Chronic cancer pain is more 
difficult to evaluate (vs. acute pain)
■ Quality of life scores, 
scales and questionnaires
■ Behav ior characteristics 
assessment
■ ()\vner input essential
■ Abnormal gait or posture
■ Sleep or insomnia
■ Altered appetite
■ (I encral attitude
■ Care for daily activities
■ Tail and ear carriage
■ b'amilv interaction
■ Agitation potential
■ Urinary and bowel habits
Edmonton Staging System for 
Cancer Pain
■ Mechanism of Pain
■ Nociceptiv e, neuropathic, mixed and unknown
■ Pain characteristics
■ Nonincidental o r incidental
■ Breakthrough
■ A nxiety
■ Little o r major
■ Tolerance
■ ()v erall health
/Stage 1: good prognosis. 
Achieves a lo t o f  re lie f wire 
Simple analgesics 
O R
Stage 2: po o r prognosis , 
(.Achieve some re lie f w ith j  
\  analgesics /
1
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The physical exam of a chronically painful 
veterinary patient: extras related to cancer 
diagnosis and treatment
■ Where are we in the animal’s cancer treatment 
protocol?
■ What are the implications of the protocol on the 
animal, its pain, its treatment options?
■ Whar clinical conditions can I expect with rite 
cancer and with the protocol?
■ Any new pain in a patient with a history of cancer is a 
recurrence of the cancer until proven otherwise
Acute and chronic pain syndromes 
with cancer
Acute pain syndromes
■ Commonly due to 
diagnostic and therapeutic 
interventions
■ Casier to diagnose
I '.pidural puncture soreness 
Prostatic biopsy pain 
Postoperative pain 
Cytotoxic infusion pain 
Mucositis 
Radiation burn 
Joint and neuropathy pain 
Infection pain 
Thrombosis pain
Acute and chronic pain syndromes with 
cancer
■ A cute pa in  sy n d ro m es
■ B reak th ro u g h  pain
■ '/a to  2 /3  o f  cancer pain 
patients experience
■ I pisodes are usually sh< >rt 
in duration but become 
m ore frequent as disease 
progresses
■ 'lypcs
■ Incident
■ Spontaneous
■ I aid of dose failure
M ig u e l R V  In it ia l a p p ro a ch  to  the  p a t ie n t w ith  ca n ce r  pa in  
in  D e  L e o n -C a s sa so la  O A  ed. C a n ce r  P a in , S aunders  P h ila d e lp h ia  2006.
Acute and chronic pain syndromes 
with cancer
Chronic pain 
synd romcs
■ Caused by direct tumor 
infiltration
a May be caused by surgery, 
chemorx, radiation therapy
■ May be caused by pathology 
unrelated to cancer 
(debilitating disease)
■ Difficult to diagnose
Bone pain
■ Mctastases
■ Spinal <>r epidural compression 
Arthritidcs
Muscle or trigger point pain
1 leadache
Neuropathy
Post surgical pain
Post radiation pain
Poor prognostic factors for cancer 
pain management
Mneumonic: RAPID-N (Rapid Acceleration of 
Pain Indicates Damaged InrerNeurons)
Rapid accelerating pain 
Alcoholism 
Psychological issues 
Incidental or breakthrough Pain 
Delirium or mental obtundation 
Neuropathic Pain
2
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C om m on d iag n o stics  u tilized
Woodwork
■ CBC, Chemistry, I  \, urine C&S 
Sampling
■ Cenrcsis, !;N A, Biopsy, GSI-analysis 
Imaging
■ Radiolog)', Ultrasound, I'lunroscopy, MRI, GT 
Special diagnostics
« i :m g , v ;\
■ Scintigraphy - Mgomctry
■ Thermography -Gonionufry
■ lorcc platform and gait analysis Diagnostic nerve blocks
■ Muscle girth measurement -Video analysis
■ Behavioral assessment
! & 1
m Basics o f  multimodal therapy
■
■ Techniques
■ Body offers different targets
■ W e choose the arrows
■ W e choose which target(s) to 
aim at
■ Constant reassessment 
necessary
■ R< itatic hi i >f dmgs and 
techniques
■ Be open minded
■ Owners are resourceful and 
knowledgeable
Generalities regarding cancer pain 
treatment
A cute care m an ag em en t
■ The more acute or sev ere the 
pain, adherence to rules o f  
critical care in initial 
ev aluation and treatm ent is 
required
Cilo<-oM
I'.ltvlttilyli i* (i ilrniiit, whIiiiiii, dilnriilf, 
|K.I..»|IIIH, l|Utf II Mllllt)
Blood prom..
Mi art i.Hi', itiyllun anil i-oiiluiMiliiy 
Albumin
Oi,Wll„t«H,
Rtd blood i'. II Imnoglobiii roiinnlimiiin 
Kiii.il tiniriinii
Illinium kt.llllk, .1 ililHiiltt i|ingi Jin! si li i hull,  .
(il inutility .uni mm m il mligiily 
l>mg it I'xigi uni mi l.ibi 'li 'in 
S'ui/ilion 
Pain ronlrol
NurHiig full anil |>iii|i nl inobiliniilion 
W mu ill b.iiul.igi ran
Generalities regarding cancer pain 
therapy
■ (ioal is to stay one step ahead o f  pain
■ The more unlikely s< living the pain (terminal cancer pain!)
■ The more reasonable to remain on constant regular medication
■ lo w es t dose and frequency possib le to contro l the pain
■ I xpcet to  increase both over time
■ I xpect breakthrough pain
■ Pain is what the ow ner says it is
■ I lave them keep a diary
■ lo ca tion , actions o f  pet, when pain occurs, what makes it worse, what eases 
the pain,
■ Regularly scheduled recheck visits yy
■ ( Vitality o f  life assessments important! ,  1
H
Generalities o f QOL care
■ 1 lifetime nutritional management
■ Supplements/nutraceuticals can really assist
■ I Eliminate environmental carcinogens
■ Talk to the family, change the environment
■ Prevent nausea, vomiting, diarrhea, constipation
■ I low is the bladder working?
■ What is the animal’s sleep and awake cy cle?
■ Prev ent anorexia and cachexia; engage the nutritionist
■ Assure mental stability; treat stress
3
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Generalities of QOL care
■ Complementary treatments imply just that
■ Complementary treatments are useful
■ I ransdermal medications may work
■ I tome parenteral care may be needed
■ Mucositis needs to be treated aggressively
■ Dermatologic disease needs lo be treated aggressively
■ Watch your white blood cell counts
■ Leant to embrace imaging modalities
■ Prepare the owner for realistic outcomes
H o w  to treat can cer pain
Severity based treatment 
« W! 1() ladder treatm ent philosophy
* ( T o l .  arc l i t r T )
Mechanism based treatment 
■ 1.x. Rapid D N  A typing tha t guides antibiotic therapy
Problems with the W HO ladder and 
veterinary oncology pain therapy
■ Why the W 11(.) ladder no longer works
■ Multidimensional aspects of modern 
cancer and pain treatment >> a 
more complex ladder
■ Imaging modalities have taught us 
much
■ Replace it with escalator based on
■ ind iv idua l needs
■ .Multimodal therapies
■ Preferences
■ likely responses based 011 what wc 
know
The veterinary pain ladder has 
unsteady bottom steps!
/^Realistic expectations^ 
from o w n e r? ^ ^ ^ !
^Concurrent p rob lem sT T  \
Jnp a tien t or outpatient Rx? X a \
Role in family and
N... Financial assessment? ^owner commitment?
Appropriate diagnosis. J) ( Appropriate initial interventions?^
H o w  to treat can cer pain
■ Sequence of analgesic therapy should he based 
on taxonomy of INDIN71 DUAL cancer pain
■ Rather than an epidemiologic based approach based 
on intensity of pain (VVI 1C) ladder)
■ Iherapy should be guided by classification systems
■ I ASP
■ Kdmonton
■ ( )vcrall health/lifestyle o f  patient
■ Cancer therapies outside o f  pain m anagement
4
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T y p i c a l  c a n c e r  p a i n  
relief a g e n t s
O p io id s  in  vet oncology pain therapy
Best pain relievers for acute 
and severe pain 
-  PURL Ml'AGONISTS 
Side effects
■ (il
■ GU
■ Resp depression'
Can be used parenterally, 
orally, neuraxial, locally 
Reversible if needed 
(Controlled!
Oral forms limited 
l ew if  any contraindications 
I IRSTI.INI WAI.OI .SICS tor 
7  SI A I KI. I* \ l \  RUG \RDI.I SS 
, ( )f animal’s health status
N eu rax ia l o p io id s
S p ina l o r  ep id u ra l o p io id s
■ Little systemic absorbtion
■ Decreased side effects
■ 1 .ess nausea
■ 1 .ess ileus
Ipf
■ Urinary retention +/- 
a Analgesia for days to
■ With catheters
■ With automated pumps
■ Can be used at home for 
patients
L ocoreg ion al o p io id s
p. .st* tpcrativc analgesia (Candid* > 
Kl),Winnie \l\Ghalcl) Ml, 
haftouh MW, I'ranco (Cl): Reg 
\nesth Pain Med. 2002 Mar ‘ 
Apr;27(2): 162-7
sufentanil. Bazin JL, Massom C, 
Bruclle P, l enies Y, (iroslicr 1), 
Schoettlcr P: Anaesthesia. 1997 
Scp;52(9):858-62
Fentanyl transderm al p atch es
\ p p lie d  to  shaved, c leaned  
areas
liv e n  th o ug h  a p o te n t  fo rm  o f  
n a rco t ic , o n e  o l  the  po o res t 
deliver)- m e th o d s
■ Provides “ background” 
analgesia
■ Needs to he supplemented
■ I expensive
■ Variable ahsorhtion
■ Duration
5
Z / 1 4 / Z U 1 1
Opioids in continuous 
rate infusions
■ Best pain relievers for R c m in fc n ta n ii acute severe pain
■ Titrability key factor
■ l entanyl and remifentanil 
of great benefit for 
ICU/CCU patients
■ Often combined as part 
of mixed analgesic 
infusions (ex. MIX or 
MX)
■ Caution with metabolites, 
potency, accumulation
T ran sm u cosa l b u p ren ex  in  cats
R obertson SA, et.al. 2002 
Alkalinity o f  saliva 
Systemic uptake o f  
bupreiK irphine after buccal 
adm inistration 
■ C o m p a ra b le  to  IN' 
a d m in is t ra t io n  
Pharmacokinetic data 
suggests 100" i. 
bioavailability 
Thermal threshold 
increased
I :xlcinlal-l\c/‘,iH' I jfxisni)/,il ( ipioidsJor I nulling Pain in Dog*
2 0 0 5
L e s le y  J .  S m it h ,  D V M ,  D A C V A  
D e p t  o f  S u r g ic a l  S e rv  ic e s ,  S V M ,  U n iv e r s i t y  o f  W is c o n s in ,  2015 L in d e n  
D r . ,  M a d is o n ,  W I  53706
PLO transdermal gels and cremes 
with opioids
■ C o m p o u n d e d  rcgu la rl\
■ I vase o f  u se  t< >r an im a ls  w ith  
lim ite d  o ra l in ta ke
■ S id e  e f fe c ts  lessened
■ D a n g e r  w ith  h um a n  ahs< irh tio n
■ T he rape u t ic  bl< >od c< >ncentrali< m s 
ra re ly  m e t at s im ila r  pa ren te ra l 
d o ses
■ S ub je c t iv e  o w n e r  asse ssm en t 
v a r ia b le
■ G o o d  to very good fo r selected 
agents
■ I Usually requires a h igher dose vs. 
oral dosing
Suppository op io id s
■ P h a r m a c o k in e t ic s ,  
p h a n n a c o d y n a m ic s ,  a n d  
a n a lg e s ic  e f fe c t s  o f  m o r p h in e  
a f t e r  r e c ta l,  in t r a m u s c u la r ,  a n d  
in t r a v e n o u s  a d m in is t r a t io n  in  
d o g s .
■ I L tm lia r t  M D . J l u b b e l l  J A . M u i r  
W A Y , S a m s  K A . P e d n a r s k i K M .
D e p a rtm e n t  o f  V e te r in a ry  C lin ic a l 
Sciences, C o l le g e  o f  V e te r in a ry  
M e d ic in e , T h e  C )h io  State 
U n iv e rs ity
C o lu m b u s  43210 , U S A
■bioavailability no t much im proved 
com pared to ora l use
6
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Oral op io id s
■ Tramadol l-3mg/kg po del to 3-5mg/kg po rid
■ Not that effective 
a Not for cats
■ Codeine 0.1-lmg/kg po bid
■ Constipation in dogs
■ Combined with tylenol usually
■ Hydrocodone 0.05-0.2mg/kg po bid
■ Oxycodone O.lmg/kgpo sid-tid
■ ER morphine 0.1 mg/kg po sid
M ethadone
■ Mu agonist opioid
■ NM1)A antagonist
■ Added benefit
■ Similar to morphine
■ More panting
■ 1 a ss  nausea and vomiting 
a I .ess dysphoria
■ Used extensively in 
I •‘.iirope
J-eibefscder I X  A  com parison o f  epidural and 
IV  methadone on  in traop is o f and postop analg 
requirements in dogs Y A A  2oo6
K o h rc r lllc y  ( Q im pa risnn  o f  perioperative 
raeemic methadone, levonurhadone, and 
dextromoram ided in  cats Y A A  2(Mt|
O p io id  hypertherm ia in  cats
O fte n  seen w ith  h yd ro m o rp h o n c  
use
■ Repetitive dosing 
C a n  h e  seen w ith  
m o rp h in e  use
C o m m o n  w h e n  o p io id s  co m b in e d  
w ith  o th e r  d ru g s  
m ketamine 
W h a t  to  d o ?
■ Stop op io id
■ fluids
■ Phcnothiazincs
■ Environm ental methods
■ Tincture o f  time (3-6 hours)
O p io id  hypera lgesia
Increasing pain in patients 
that have been “well 
c< >ntr<tiled” <>n < »pit >ids 
hirst sign o f  tolerance 
Proposed mechanisms
■ Imbalance between anti and 
pri mociccprion
■ Toxic effects o f metabolites
■ Activation o f NM DA 
receptors via glutamate
Most likely seen with
■ Morphine
■ Hydromorphonc
A n g s t  M S , C la rk  J D  O p io id  In d u ced  
H yp e ra lg e s ia . A n e s th e s io lo g y  2006
D iag no s is : in c rease  dose o f  op io id s  
and  see in c re a se d  p a in
O p ioid  h istam in e release
■ I a aiMliim of liixt.tniinc kIcmc during conntant ran- infiiaion of mnqrlriiu- in dog*.
■ ( iin il«-> A< i. Ilndr 111*. Itnlcr MA
■ IX |■.■Him in "I Vi Unn.li) t.lmu al Suh.t, < "ILgi ol Viirrinaiy Mxluim , I'mvi inly "I Mm 
.Yiinl I’jIII. UN
()ll|l ( ll\ I*: To rvaliialr liiklanimc nli-au anil krlrrlrd nhykuilogir Vaiuldik during ..'iiklanl lair ,1,Ilium, ff.KI) ol iimrnluni- ui dogk. ,\MM MS: In, lii.illlu, i-oouimi*. uil.icl I. null Hog*.M Ml KIM ANIJ Ml I IK'DS: I -.mg a I aim uinarc. rrprair.l nr.wNi. .1, ugn. *!•■>;. oiidomly 
amgiiid in dux' irrntinnil grnupk in im ivr a 4 linui < KI ol mIiiic (SAl.j, im j loading ilma ol ■ iioiiiI■■ a' .11 (Omg fgf I) (fM). ol lift mgkgf I) (JIM). I'nllou.'il by an iiilimum ol II I ingkg( I) lmm( 
I) (1 Ml ami 11.34 ion I g( I) linuif I) (I IM) n k|urlivrly. IX .gk n x ivr.l i-uHi ol llu- llm • In almoin al utl.rvalk of al It an . day*. I’launa liiklaminr .oiuvmraliun. dan limbing. id.ina and wliralk, I unit lair 
and riiydini and non uiuuii ailni.il blood prrkklirr vvi rr u> amitil Ivlmr llic loading dou and ul I, 2, 
S. (3. kt.Mf, tyi. IWIand’driiiimiil.k.lurmail.rf K», ■< :<l ll« ihitrvl Ill M l IV Jl„I .ailing dou uulmxl llu Inglu -.1 liol.uiimi o l.au in llu I IM gnmp lumg ul.ilu.li. ally lugju i llian dir 
SAl. gnmp. llu llltlainuu 1.1, au olilamid in llu- I M group all. i llu loading dou- did not dilli i loan S \l 1 Xirmg llu Iiifiition. pl.nuna linlaimn. Ivu l> u. n niuiu r>• ally I>«K>u i in llu I \l gi""p 13co.nl. « on. 
dog dial <1. vi-lojurl liypntrnkum loi 2 mu mil k alt.r llu loading dou in llu I IM group and mu dog dial 
dinwxl ocr.miHial v. ulnxilar pnni-ilui. .nnli.u-lioin fhiring bull, inornlimi lolosimo, . aulmvauailar vaiiabl.o wru kmular an mug du ll uvv lit itmnil groiipn. (.(i-NCI I SIONS WI3 (.1INK-AI.Ul l r.YANCIi: Uol|, il'iui of moqilimr mdiu . d i arialdr Imlainuu 1.1, ax- willi inmiiii.il atlvriw 
. aidio'amilar i llr.n in llu k ronkrumk, lualdiy dngk IIir plasma liiklaminr li v. I. olilaiiud may lu aktmrialrd will) ki^ iifuwul li.mndynaiuu* rliaiigrt. m paiirulk ualli linulril ranliovawiilai Iifcrivi and 
aymftallu lM' priTOin hum-.
O pio id  im m u n osu p p ression
Activation o f  CNS opioid 
receptors
■ Activates 1IA  axis 
In h if io n  o f  N K  ce lls
■ P A G  area
■ Sympathetic ou tflow  implications 
Endogenous opioids
■ Jm rease production  o f  ’Jl)2
■ Inh ib it macrophage cytokine l l . - f
■ 11.-12 necessary fo r 111 1
production 
E x o g e n o u s  o p io id s
■ Inhib its production  o f  l l . - lu  and 
IJ.-12
7
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T h e  b eau ty  o f d ex m ed e to m id in e  
for ch ro n ic  p a in  con tro l
■ Can be given mucosallv
■ Works excellent in cats and exotics, moderately w ell 
in dogs
■ Provides stress relief, relaxation, sedation
■ 1 hings the opioids don’t provide
■ Provides rotation from opioids
a Given opposite to opioids 
b Problems: human absorbtion from mm, injectable only 
avail, cardiac output decrease (is this a problem???)
A lpha tw o ag o n is t s ide  effects
a Decreased cardiac output
■ Bradycardia
■ Initial hypertension followed by 
hyp< >tcnsi< m
■ Unlike the opioids, alpha two 
agents are not “cardiac
a Mild gastrointestinal effects
A lpha two ag o n is t ag en ts  in  ve t 
oncology p a in  therapy
Dexmedetomidine
■ Provides analgesia and 
s l r c s s / a n x i c l v  n  l i e f ' 1 M
■ Potent cardiovascular sideeffects at ev en mini dose ■ J
■ I sed for moderate to severe
■ Reversible r 
b Not controlled
■ Usually given as part of a balanced regimen
■ Relative and absolute contraindications
■ Micro or mini dose employed
C lon id ine
■ N n tih yp crtcn s ive  agent
■ U se d  in  h um a n  ca rd io v a scu la r  an d  
p a in  m anagem en t
•  oral, epidural, local and 
transdcm ial fo rm s
■ S ig n if ic a n t  ca rd io v a scu la r  e ffe c ts  
p o ss ib le
■ ?p robable
■ D ose related
■ C ) ften  u sed  in  c o m b in a t io n  w ith  
o th e r  agents
■ l.p idura ls
■ la ica l b lock cremes
■ Patch
N S A ID s in  vet onco logy  p a in  therapy
NS A1 D=nonste roidal an ti - inflammatory drug
■ Antipyretic
■ Anti-inflammatory
■ Analgesic
■ Anti thrombotic
■ Used for mild to moderate pain
■ Not regulated or controlled
■ Oral and injectable forms available
■ Relative and absolute contraindications
8
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NSAID side effects are due to “good” 
C O X  &  L O X  enzyme inhibition
Interference with PC I o f  normal nastjrc homeostasis
■ Increases ga s tr ic  a c id  \ .
■ Decrease 's g a s tr ic  m u co u s  p ro d u c t io n
Interference with PC I o f  renal blood flow Gastric ulceration
■ R ed u ced  renal m ed u lla ry  M o o d  t lo u  ---------------- ► R e n a l  i s c l l C l T l i a
■ R ena l p a p illa ry  n ec ro s is  ~  ,
■ C o n tro v e rs ia l w h e the r to  use p r e o p e r a t iv e ly ^ x ' '  >pafh\
Inhibition o f  platelet function
■ In h ib its  p late le t p lu g  b y  in h ib it in g  th ro m b o xa n e
■ \ s p ir in  a ffe c ts  are pe rm a n e n t ( life  o f  p latelet)
U se o f  N SA ID S as p a r t  o f 
can ce r therapy
■ Many NSAIDs possess 
antiangit tgenic pr< iperties
■ C( )X-2 is expressed in many 
cancers
■ e p ith e lia l in  o r ig in  tum o rs
■ In  s tro m a l t issues su r ro u n d in g  
tum o rs
■ In vitro work shows 
enhanced activity o f  chem o 
and radiation rx with cox -2  
inhibitors
■ NSAIDs seem able to protect 
and prevent against gastric 
and esophageal tum ors
Colon Cnncef
C lasses o f  N S A ID S  (term inology)
Inhibit COX 1 and COX-2, 
but less COX-1 
I a . Carprofen, meloxicam
Inhibit COX-2 only 
1 .x. Deracoxib, firocoxib
A cetam in op h en
N ot an anti inflammatory!
■ ( I r< »uped with NS A11)S 
G ood analgesic in dog 
I Excellent antipyretic in dog 
Will not cause ( i l  ulceration, 
renal disease or platelet 
dysfunction
Inhibits (X)X 3 o r (X)X 
variant
Inhibits N O  synthetase 
I lepatic function (glutathione) 
must be adequate
■ N O N s d c c tiv c  N S A ID S  
Inhibit both COX-1 and 
COX-2
l .x. Aspirin, Munixin
C on tra ind ica tions for use  o f N SA ID S
A v o id  use im
■ Renal failure
■ Dehydration, hypovolemia, 
hemorrhage
■ Severe liver dysfunction
■ I lis to ry o f gastric ulceration
■ Coagulopathy
■ Pregnancy
■ Neonatal patients
■ Renal insufficiency
■ Impaired liver function
■ Asthmatic patients
CO X-3 iso form
■ Simmons D, et.al. Proc N at Acad Sci 2002
■ COX-1 variant o r isoform  expressed in high am ounts in brain and 
heart
■ Constituitively and pathologically
■ A cetaminophen (mechanism o f  action)
■ Poorly inhibits COX-1 and COX-2
■ Greatly inhibits COX-3
■ May be a Partial COX-1 o r COX-1 pre-protein
■ abundant in canine brain
9
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C ats an d  no n ste ro id a ls
■ Generally use lower doses than in other species
■ Consider specific need (antithrombotic vs. anti­
inflammatory vs. antipyretic) and modify dose
■ Use longer dosing intervals (2-7 days) with chronic use
■ Assess for subclinical renal impairment
■ Provide fluid support perioperatively
■ DC) NOT USC ACI '.TAMINOPIII'N in cats!!!!
Q
N S A ID  tran sd erm al p a tch e s
i vjnwy i.l uniir mil r|in.iur pjlti .-.milium?,, ili.-'u .»■- may l„- j,,oi mi«I .villi .. n,..n -y.'i «•j.lvcm-i-llwit, paitu ol.nly j’.olfoinii..iiiiy| dimi.li.ra In .it.ln in minimi.'* ill.- niuil.li.i- ..I ly-.l.inii' rvimi. ri-ltilrd in nn-li aynil., lopirjl N.-MDi lin e been , I,. .-I. .p. .I I onn .il u? Ml)., jppln-,1 if p.ili, rrnmt m ipfay.. p.-in-tun- ilir .km. •uliruluiimna I'nty lir.n. JII.1 mimic in am--uni. ilul an- .illlitanil in pxi-h .1 ili..|ii|wniii. nl'twi nil ]n-n|.1 n .al ni.l mural llinlianiani* in llu- alimm nl liipli plji.tli roneiiilijl|.in> Data in.liraii-iliai inpiral Ml). .ni-.-lli . livn al l.lli-vmy pain m a ninn|i..r n| arim- an.I. Iinnnr pain m.lit-jlinna '1111« n-i-i.-u- .ini.-li- ilii.'ii.fe* III.- pliiniurokmt-li... .-lli.-a.-y an,I lol.-iul.iliiy „f a m-w fnimnlalum nl ki-loprol... avail.iblea. a inpiral pai.1i Tl.r inpi.-al pal.1i, onuiiiini- l.i-ioproien l.Himp aa llu* a<-iivi- puiinplr11 a * Ix-i-n drvHo|wd lump a nm-rt .l.-lm-iy aynnn llial Ji.|m-ii«-i llimipi-nlK il"»"-» ol •!■•- .Imp ilu.Hly in llic Pill- nl injury Iliannarokin.-lic .lata mriirair llial allli.-nt-Ji plalilia li-vnl. ..I ki i.ipiniin an- lup.liM a Inn llu- .Imp 11 adiiuni.i.-ii-d a. a pai. li vvniu a ini. die inial .y.lnnir In.-ava.laliilny ..I krloprolen Kill nip J-11111111 -It-rn.l via a pan-li ip ihi more ilian II. .-I dial i.-pnn.-.l lor knopnilm 1.10 mp edmmi.iernl orally Bn-ama die paid, lanlnai.-i lep.pml'm drtivi-iy omr a -4 li.nii prnnd, llu- .Imp remain* vi.iiiniiully pii-.i-ni 111 dip iimiio :ub|i,'.-nl n> die nlr ,.| application I l'P)i liaanr Imi low pla.ma kl-.-pmlrn ronrnilialii.ni m. an dial wluli- iiiiih- rowwnl ration* arc Inpli moupli 10 rxrn a ilinrapviiiir a-lln-i plaima r.iil. nllrali.iiu innain Inu rnnnpli 10 mil rr-uli in <yn.1t.1r advitnervnm rau.nl lay rl.-valrd ar.uiii N: All) Irvrl* ll.atr III rluucal inal. in palinni willi nnn articular dii-iunaiiini anil (ranilialit: pamlnl inti n.inr miiin.-l ilniwrd dial llu- inpiral krlnprnli-ii pairli u ai ■ipnillraillly mnrr rlln-iivr llian plarrlin al n-dnrinp pain dunnp daily arnnix-i and ip.inianMiui pain aiu-i " dayi' ni-aiiimil Miitnimr. llic mpiral kilnpnifon panli waa will loleralul advene avanli u.-rr pninanly iiuannnu in naiiifi* and ormnrd in a mhiiI.ii nninU-i nl ki-tnprul'rn and placebo ui ipn-nii iiippniinp dial llirar t-venrr urn- ra-lalrd 10 dir palrh 11’<11 railiri ilian dir arm-r nlprnlinn llu- inmlmrr n|‘ paifrniniriiiiial advorir rvmi* u-ai Inu- < 8' , nl all pahmli , and nmirn-d ill a iiinilar pmpnmi.n oi paiirnu rnm-inp knopnilm and plara-bo Ttnu. dir inpiral kriopmlm pairli amman 10 lir a mnplr. riinuve and ialr ihrraprunr oplimi |ur i|n- lii-almnil ollnral painful
N S A ID  tran sd erm al c rem es
■ 1° 1. diclofenac in a liposomal 
creme
■ Shown to improve lameness 
scores in horses
■ Reduces systemic side effects
■ M ust be applied with gloves
■ Studies perform ed in canine 
patients
■ H u d s b c rg S C , L y n n  RC 
u n p u b lis h e d  re su lts  in  do g s
■ N 'o  s ta tis t ica l d iffe re n ce  in  fo rce  
p la te  ana lysis
■ Sub je c t ive  d iffe re n ce  n o ted  by  
o w ne rs  fo r  do g s  u s in g  c rem e
N O V E L  A G E N T S  F O R  C A N C E R  
P A IN  R E L IE F
Gabapentin
Anti-convulsant drug 
G A BA analog 
Used to  manage 
peripheral and central 
neuropathic and chronic 
pain
Recommended in chronic 
pain th a t is unresponsive 
to  N S A ID s
P reg ab a lin = ly rica
R5SS3R -□ Another anticonvulsant 
■ Calcium channel modulator
Nil, COjII |
r  I• > .1 .i ■
■ Similar to gabapentin except... 
■ 1 ,ess side effects
■ 1 aower effective dosage 0.1 -0.2mg/kg po bid
■ “opioid” like effect 
a ('ontrolled
■ Kxpensive
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■ I nhibit (>stc< >clast activity
■ A lte re d  m o rp h o lo g y
■ \ 'ia  c lin g in g  (tightly) to  ca lc iu m  
p h o sp h a te  c ry sta ls  in  b o n e
■ Best arc administered IV 
over a 2  hour period monthly 
(patnidronate)
■ Animal needs g< >od renal 
function o r  diuresis to 
receive
■ Also used to  treat 
hypercalcemia o f  malignancy
littir//ww\v,pxlK.vjniZpiiitL^/factis/(>/.uitia>,litii
Bisphosphonates for vet oncology
pain therapy
L ong  term  L ocoreg ional b lockade  
for ve t onco logy  p a in  therapy
■ Neurostimulation 
location
■ Ultrasound location
■ Catheter placement
■ Surgical blockade
■ Palliative blockade
■ Neurolytic blockade
c
v  „•.
i f !
L ong  te rm  o r neuro ly tic  b lockade  
c o n stitu en ts
1 ,i >cal anesthetics
■ hutamhen
a  1 jdoca inc 2 and 5 " 
• DiJpiwrainc 
Sa lin e  
M ic ro d o se
■ alpha two agonist
■ steroid
■ N M D  A  antagonist
\lc< ih o l/p h e n c  »l 
( i ly c c r o l
Amm< >nium salts 
Sa rap in
R ad io frequency  b lockade  for 
ana lgesia
N M D A  b lo ck ad e  for vet oncology 
p a in  therapy
N M D A  re cep to r ^
■ ( )nc o f  m ain excitatory paritways  ^ ‘ a
fo r n in e  transmission
■ Via glutamate activation 'I
a Via calcium influx _ 'jpN*"* tfSSfS
1-u n c t io n  T "  >
■ Passage o f  calcium, sodium , and \
potassium t i& M S H H B H f lH H H t a i i f l
■ Calcium influx cause* central
N M D A  an tag on is ts  h e lp  to  redu ce  / /
c h ro n ic  p a in  A . : '  *»*«•' •
■ Ketam ine, Amantadine, **********jtotai i  • • • • • • • • • • •
Mem antinc I
a  Noncom petitive b lockade . . . • • • • • • • • • • • • •  I *••••*•••••••
■ Reduces calcium  in flux  „  7r.‘" “ , '*‘ I —
■ Originally used for disk 
related pain
■ Destruction o f  nerves that 
transm it o r  perpetuate pain 
should relieve pain
■ Compared with direct current
■ Uniform lesioning
■ Predictable icsioning
m N o t  co m p lic a te d  b y  gas o f  
e le ctro ly s is
■ Useful for Well defined 
localized area o f  pain
■ May be associated with 
m otor deficits
In fu s io n  system s for indw elling  
ep idu ra l, sp in a l a n d  nerve ca the te rs
11
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N M D A  blockade for vet oncology
pain therapy
Amantadine
A n ti-v ira l d ru9 
N on-co m pe tit iv e ly  b locks 
N M D A  re cep to rs  
Block s am p lifica tion  o f 
pain  signals ond p reven ts  
w ind-up (cen tra l 
h yp e rscn s ifco tio n )  
T rea tm ent o f  pain  o f 
ncuropo th ic  origin
N M D A  blockade for vet oncology pain 
therapy
■ D extrom ethorphan
■ l- 2 t s p  p e r  d o g T I D
■ 1 -2  m g / k g  T I D - Q I D  ca ts  and 
do g s
■ + / - guaifenesin
■ Weinbrt>um A A ( 'anccr 2()()2
■ 75  pa t ie n ts  w ith  b o n e  a n d  so ft  
t is su e  m a lign anc ie s
■ 3 g ro u p s
■ D e x tro m e th o rp h a n  g ro u p s
■ 50-8(1% less sub pain
■ 50-70" i>lcss P C  morphine
■ 70%  less sedation
■ Sodium channel
■ I T X r  sub type
■ T  I N  s sub type
■ Blockade via
■ P re ve n t a >n < ) f  upstrc >ke o f  axe >n 
a c t io n  p o te n t ia l
■ Peripheral and central activity
■ \n t i- in f la m m a to ry  a c t io n  as 
w e ll
■ Na channel blockade results 
in analgesia
•  N e u ro p a th ic  an d  n o c ic e p t ive  
p a in
S odium  c h a n n e l b lo ck ad e  in  vet 
onco logy  p a in  therapy
L id oca in e  in fu sion  fof chron ic  
pain
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Dr. Anjuin S Khun |oad, Dr. |yoli liurud.Dr. C.liaru Melila
llic effectiveness mid duration of pain relief willi a conlmuoin ligiiocaine infusion was observed in 10 
cancer patients. All llie to
palienli were luffering from pain of neuropathic origin, having two or more of the symptoms: 
burning, aching, allodynia, reduced
sensitivity to touch or pain, hyperaeslhesia, nightly exacerbation and sleep disluHiancc. lhe 
patients received intravenous lignocaiuc
in a dose of Singkg-1 in lmlkg-1 of normal saline over 60 minutes Significant relief in pain (t 
value> I al 001), dysaeslhelic
sensations, paraeslhesias and nightly exacerbations w ere seen in the majority of patients upto 14 
days. Statistical analysis were
perfonned using lhe unpaired V  lest and analysis of v ariance (through application of x2 lest). 
Keywords : l.ignocaine infusion, Neuropaihic pain, Cancer pain.
L id oca in e  p a tch es
■ 5" n lid< >cainc patches
■ Applied to intact skin
■ Used in humans for 
treatment of postherpetic 
neuralgia and shingles
■ Studies show little systemic 
uptake in dogs, cats, and 
horses
■ Depth of penetration limited
■ Used extensively for 
musculoskeletal and trigger point therapy
L id oca in e  in fu sio n  for chron ic  
p ain
l.fficucv of S-d.iv continuous luloc.iuu- infusion for die treatment of refractor) complex regional pain 
syndrome.
Pain Mi d Maich 2IKW;I0(2):4H1 12.
Rola rtJ VI,u III, ,nun. Mnnu Paicl, John K (■rntlinacn, tjiiillcnno M Alexander
Chrome regional pain syndrome ((.Ill’S) is a severe pain condition llial usually results from an injury oi suigical 
procedure. llic pain in (.Ill’S often spreads from llic tile of injury, and with liflK heroines refractory lo 
convcitlional lln rapy. llic present study was undertaken lo rvaluate the efli-cts of 5 day eondturout intravenous 
lul-•• inii in aliiicnt in palienlt allliiled willi CRI’S. Ml .ll l(IDS: Intravenous lidocaine was iidininisirrcd in an 
i seal iimg dose schedule In 40 severely uflei'tid CHI’S patients in a monitor id selling ovrr 3 days. I'valuation of 
pam parameters and oilier signs and syinplonu of CRI’S were obtained during lhe infusion niitl al 1, 3, and 6 
utniillit lollnwitig lln rapy. RI.SI I IS: llu majorily of patients deinonstraled a sigiulieaul dci'reate in pain 
patatnelers and oilier symptoms laid signs ol"CRI’S. 'file pain reduction lasted an average of 3 months. I.idneaiur 
may In particularly elfiative for thermal and mechanical allodynia. D-ss clinically significant effects were 
documented on the niotur aspntts ol die syndrome. DISCUSSION: Intravenous lidocaine administration titrated lo 
3 mg I demonstrated: I) a significant deriease in meehanieal and tlnnn.il allodynia lot tliri-e uiouilis, 2) lessrTied 
associated inflammatory components of < Ill’S, and 3) only minimal side effects and no seven- complications.
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C alcium  c h an n e l b lo ck ad e  in  vet 
oncology p a in  therapy
(Calcium channels expressed 
on dorsal horn neurons
■ I’ /(,) an d  1. type  ( l.\ ch anne ls
■ N  type  C a  ch anne ls  
Neurotoxins which block the 
N Ca channel
■ / . ic o n o f id e  (snail)
■ I lu w e n to x in  (ch inese  b ird  
sp ide r)
O ther receptors decrease Ca 
flow through N channels
■ G  \ B A  v ia  vagal n eu ro n s
■ \ M 1 ) . \  re cep to rs
■ R c s in ite ra to x in
■ I derivative o f  cactus I a iphorb ia
■ 1 o n g  lasting (permanent?) 
b lockade
■ C a p sa ic in
■ Active com ponent to c lu li peppers
■ T R P Y 1  re cep to r agon ists
■ Peripheral 
> D R G
■ ganglia
■ Ind u ce  ca lc iu m  cy to to x ic ity
■ B lo c k s  in f la m m a to ry  hypera lges ia  
and  n e u ro g e n ic  in f la m m a t io n
R e s i n i f e r a t o x i n  a n d  c a p s a i c in  i n  v e t  
o n c o l o g y  p a i n  t h e r a p y
TC A s, SSRIs in  vet oncology 
p a in  therapy
■ Analgesic effects 
independent o f  anti 
depressant effects
■ Analgesia occurs at lower 
doses than expected for rx o f  
depression
■ Analgesia occurs due to
■ B lo c k a d e  o f  N l i  and  se ro to n in  
reup take
■ 1 Enhanced descending 
inhibition
■ In te ra c t io n  o f  o th e r  ty pes o f  
re cep to rs  ( ion  ch anne l,
N M D A ,  h is tam ine , 
c h o lin e rg ic)
S ero ton in  syndrom e
■ Comm on Mechanisms o f  
serotonin toxicity 
= “syndrome”
■ Stress o r  am phe tam ine  lik e  
d ru g s  in crease  se ro to n in  
release
■ In h ib it io n  o f  s e ro to n in  
m e ta b o lism  b y  m ao  in h ib ito r s
■ I ,-tryptc jphan  o r  I .-try p to p h an  
p re cu rso rs  increases 5 111 
p ro d u c t io n
■ Increases in  synap tic  5-1 I T  v ia  
reup take  in h ib it io n
MU M  * nmmmc+m * 141 ■>
G e p p e tt i P, T reves an i M  B r  J  P h a rm a co  141, 2004
Tramadol
Analgesic and antitussive  
W eak mu partial agonist 
In h ib its  5 -H T  and NE reuptake
Alpha-two agonist-like 
effect
M etabo lite  (M l)  is 
prim arily responsible fo r  
analgesic e ffe c ts .
Partially reversible w ith  
naloxone or yohimbine 
N o t a scheduled drug as 
compared to o ther opioids
Palliative  rad ia tio n  for vet 
onco logy  p a in  therapy
■ Mechanisms of relief for osseous 
pain
■ N ot well known 
> Cell kill?
■ T um or shrinkage?
■ Inhibition o f  prostanoid secreting 
cells within m icroenvironm ent
■ Induction o f  TGI* B
■ Basic approaches
■ M oderate dose regimen protracted
■ 1 /  >w dose single shot
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H o sp ice
■ Mobility
■ Appetite
■ Bowel and bladder function/control
■ Vomiting/ nausea/regurgitation
■ Skin care and cleanliness
■ Bleeding
■ Sleep cycles
■ Neurologic state
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